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Abstract
The activation of inflammatory responses, while critical for host defense,
contributes to hepatic injury in numerous acute and chronic liver disease states as well
as drug-induced liver injury (DILI). The interactions that mediate susceptibility to liver
injury and disease, however, are still poorly understood, underscored by the complexity
of immune interactions and the diverse cellular composition and functions of the liver.
Using Citrobacter rodentium, a well characterized rodent-specific enteric pathogen as a
source of extrahepatic inflammatory stress; host liver responses, metabolic
dysregulation, and susceptibility to injury in C57BL/6 mice were investigated. For the
first time, we show altered liver pathology during the early course of C. rodentium
infection, characterized by periportal necrosis indicative of thrombic ischemic injury,
correlating with distinct circulating and tissue specific cytokine/chemokine profiles.
Using Acetaminophen (APAP), a widely used analgesic and well-characterized
hepatotoxin, we evaluated liver responses in isolation and in the context of host
inflammation to gain insight into the role of live bacterial infection in altering liver
metabolism and susceptibility to DILI. We combined systemic and tissue-specific
cytokine/chemokine levels, clinical serum chemistries, and histopathological
assessments of hepatic and enteric inflammation and necrosis to measure molecular-
level responses to treatment and their physiological effect. Using principal components
analysis (PCA), clustering, partial least squares regression (PLSR), and a combination
mutual-information-correlation network, enabled detection and visualization of both
linear and nonlinear dependencies between molecules and physiological states across
tissues and timepoints.
C. rodentium-induced inflammatory stress was finally investigated for its
potential in altering drug pharmacokinetics (PK) of substrates varying in their
metabolic biotransformation and clearance mechanisms. Infection resulted in
increased systemic oral exposure (AUC) of clinically relevant xenobiotics such as
verapamil, propranolol, and digoxin. Functionally, these changes were not found
dependent on CYP-mediated biotransformation of parent compounds; rather, they
appear driven more by proposed gut barrier compromise.
In conclusion, gastrointestinal infection with C. rodentium alters systemic and
hepatocytes specific responses, not previously appreciated from this enteric pathogen,
making it a useful model for studying host-pathogen interactions under acute hepatic
inflammatory stress and injury.
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Chapter 1: Introduction
Stress Response and Inflammation
Acute stress primes immune functions by stimulating cell trafficking from lymphoid
organs into systemic circulation and sites of infection. In humans, exposure to even
short term stress, like public speaking, results in increased numbers of certain
populations of circulating lymphocytes and briefly increase natural-killer-cell
activity [1]. Innate immune cells mediate early cytokine release (IL-1, TNF-a, IL-6)
promoting the acute phase response, which is critical to appropriately deal with
infection and trauma. As an essential response to harmful stimuli such as chemical
injury and microbial pathogens, however, inflammatory activation must be tightly
coupled with regulatory mechanisms that bring about its own resolution [2]. A
failure to properly regulate inflammatory processes can result in sustained
collateral damage to healthy cells and tissues (cytokine storms, septic shock), as
demonstrated by numerous knockout (KO) models as well as disease states with
both genetic and environmental components. Indeed, persistent and aberrant
inflammation plays a key role in many, if not most, serious human diseases
including atherosclerosis, autoimmune disorders, inflammatory bowel disease,
neurodegenerative disease, obesity/diabetes, chronic infection, and cancer [3, 4].
Recently, research groups have begun to address the role of various stressors on
liver responses (apoptosis/necrosis) and metabolic function. Such stressors include
endotoxin-induced inflammation (lipopolysaccharide (LPS)) [5, 6], pathogenic
bacterial infection [7, 8], caging stress [9], temperature [10], electric foot shock [11],
and various other 'generic' stress conditions. Infection with pathogenic bacteria is
one stress that can lead to inflammation, resulting in the stimulation and
recruitment of immune regulators and release of various cytokines and chemokines
at local and systemic levels with concomitant release of bacterial antigens that can
activate innate and adaptive immune responses.
Innate Immune System in Stress and Inflammation
Pattern recognition receptors (PRRs), and their recognition of highly conserved
pathogen-associated molecular patterns (PAMPs), as well as endogenous stress
signals termed damage-associated molecular pattern molecules (DAMPs), allow the
innate immune system to discriminate a variety of potential pathogens and injuries,
furthermore, to coordinate appropriate responses [12]. PRRs include toll-like
receptors (TLRs), NOD-like receptors (NLRs), C-type lectin receptors (CLRs), and
several others, which contribute to immune activation in response to diverse
stimuli, including infection and tissue injury. PRR expression can include the cell
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surface, cytoplasm, and endosomal compartments, with levels and expression of
receptors varying by cell type. Interestingly, despite a variety of TLR ligands,
signaling converges to activation of nuclear factor-kappa B (NF-KB), mitogen-
activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), p38,
and c-Jun N-terminal kinase (JNK). Adapter molecules are also critical in mediating
effector function, and of the TLR adaptor proteins identified (MyD88, Mal, TRIF,
TRAM, and SARM), MyD88 is utilized by most TLRs (and some NLRs) to regulate
cytokine and major histocompatibility (MHC) molecule production through NF-KB
[13]. Repressors of MyD88 signaling have also been discovered, specifically IRAK-
M, expressed only in monocytes and macrophages, has been implicated in LPS
tolerance in sepsis, and can suppress innate immunity mechanistically due to
dampened Nf-KB activation [14, 15].
Recently, NLR proteins (NALPs, IPAF) have been reported to form caspase-1-
activating complexes called inflammasomes, the process of which has recently been
reviewed in depth [16]. Inflammasomes appear to play a critical role in leading to
the activation of pro IL-1 and IL-18, key early mediators in inflammation and cell
responses. It has also been proposed that NALP inflammasomes may also
contribute to antimicrobial defense by inducing the apoptosis of infected cells [17].
In macrophages, IL-1p production requires double stimulation with TLR ligands,
which induce gene transcription, and NLR agonists (such as ATP or muramyl
dipeptide (MDP)) that activate the inflammasome and subsequently activate pro-IL-
1j. Interestingly, monocytes can release active IL-1 upon stimulation with TLR
ligands alone [18]. Conceptually, it has been proposed that TLR signaling in the
absence of NLRs may result in a 'yellow' alert, indicating for example gut barrier
compromise, and in conjunction with activation of inflammasome NLRs, may trigger
a 'red alert', indicating exposure to more virulent pathogens [19]. This signal
processing is complicated further by an emerging number of molecules known as
DAMPs, a group naturally expressed in the cytosol or nucleus, and currently
includes S100 proteins, heat-shock proteins (HSPs) and HMGB1, and when released
extracellularly, induce signals to the host of tissue damage [20, 21]. HMGB1 is of
particular interest, as its release can be active, secreted by macrophages and
monocytes (as well as NK cells [22]) in response to exogenous and endogenous
inflammatory stimuli (LPS, TNF-a, IL-1, and IFN-y), or passive during necrosis, in
both cases mediates innate and adaptive inflammatory responses to infection and
injury. Recently, a reactive oxygen species (ROS), hydrogen peroxide (H202), was
shown to induce both active (at low dose) and passive (high dose) HMGB1 release
from macrophages and monocytes, a mechanism abrogated by JNK and MEK
inhibition [23]. While there is clear diversity in PRRs, PAMPs, and DAMPs,
downstream signaling through conserved signaling nodes indicates that the
network state might be resolved by interrogating a select number of downstream
effectors (ex Nf-KB, JNK, MAPK, JAK-STAT) and gain insight by correlating these
states to cellular responses as well as pathophysiological outcomes.
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Liver Structure and Function
Functionally complex, the liver plays critical roles in metabolism, lipid and protein
synthesis, as well as detoxifying functions. The liver is unique in its anatomical
proximity affording it continuous blood flow through the sinusoids from the
gastrointestinal tract, and diverse in cellular composition; host to metabolically
active hepatocytes, non-parenchymal cells (biliary, Kupffer, sinusoidal endothelial,
and stellate cells) and various innate and adaptive immune cell populations
(neutrophils (PMN), monocytes, dendritic cells (DCs), and lymphocytes (T, B, NK,
and NKT cells) that can enter via hepatic arteries or the portal vein [24]. Within this
heterogeneous tissue, cytokines and chemokines, small molecular-weight
messengers that act in autocrine, paracrine, and endocrine fashion, are critical in
mediating effector functions of resident and distal immune cells, as well as
intracellular hepatic signaling responses that modulate liver homeostasis [25].
While indispensable in its metabolic function, the liver is also a key "immunological"
organ, underscored by its constant perfusion of blood from the gastrointestinal tract
which is highly enriched with potential antigens, providing an early line of defense
against microbes and toxins crossing the intestinal barrier [26]. The immune cells
mentioned above have the potential in initiate both innate and adaptive immune
responses, as in the case of infection in response to high levels of systemic LPS or
bacterial superantigens, while balancing immunological tolerance in the case of low
levels of LPS and innocuous antigens.
Inflammation and Liver Diseases
The activation of the inflammatory response, while critical for pathogen defense,
contributes to hepatic injury in numerous cases of liver diseases including alcoholic
liver disease (ALD), non-alcoholic fatty liver disease (NAFLD), ischemia/reperfusion
(I/R) injury, autoimmune hepatitis and viral hepatitis. Generally it is accepted that
acute injury is driven primarily by a Th1 cytokine response, among these tumor
necrosis factor-a (TNF-a), in combination with additional pathophysiological
factors, seems to play a central role in liver damage by induction of hepatocyte
apoptosis, although oncotic necrosis, typically a consequence of acute metabolic
perturbation characterized by ATP depletion and mitochondrial dysfunction, can
also predominate [27]. Indeed, pure apoptosis or necrosis might just represent
extremes in the spectrum of so called "necrapoptotic" responses, and that the more
typical response of liver cells to injury might be a mixture of events associated with
apoptosis, necrotic cell death, and inflammation. Recently, necrotic mechanisms
have been described, indicating a process more regulated than originally thought
[28]. It has also become evident that hepatocyte responses to TNF-a are context-
dependent, promoting pleitropic cell responses such as apoptosis, proliferation, or
survival [29]. Such seemingly disparate outcomes demonstrate dependence on
autocrine loops, and sustained intracellular signaling (ex Nf-xB, JNK activation).
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Decision processes of cell fate in tissues are also likely intricately linked to the
presence and coordinated signaling of PAMPS, DAMPS, and local and systemic
cytokine levels. HMGB1, for example engages its receptor RAGE, and results in
cooperation with TLR2/4 in inducing inflammatory responses. The role of TLR4
dependent signaling in resident cell types has gained considerable attention, and
while it has been generally accepted that Kupffer cells, a TLR4 expressing cell, are
critical mediators of liver inflammation, recent findings demonstrate that hepatic
stellate cells also express TLR4, and furthermore, are the predominant target
through which TLR4 ligands promote fibrosis [30].
Drug-induced Liver Injury (DILI)
Drug induced liver injury (DILI) is a major pharmaceutical and clinical concern that
can result in last stage discontinuation of drug development, limit the use and
distribution of effective therapeutics, and even lead to market withdrawal [31]. DILI
is the leading cause of acute liver failure (ALF) in the United States, accounting for
about half of all cases [32]. Drugs that cause severe DILI in humans do not show
clear hepatotoxicity in currently used animal models, generally lack dose-related
toxicity, and typically demonstrate low rates of severe injury in humans (1 in 5,000
to 10,000 or less). In the US alone, DILI accounts for more than 50% of cases of ALF,
with -39% due to acetaminophen and -13% resulting from idiosyncratic drug
reactions (IDRs) [32]. Such IDRs could be a reflection on host factors and individual
susceptibility, as the majority of patients do not demonstrate adverse drug reactions
to these agents[33]. Whether they are the result of genetic or acquired differences
has not yet been established, and to date no genetic, metabolic, or other
characteristic has been found to predict severe DILI in an individual.
While inflammation is intricately associated with numerous liver diseases, its
importance is also appreciated in DILI: proposed mechanisms include the Hapten
and Danger hypotheses as a model for allergic reactions observed with some drugs
(ex penicillin) [34]. Others hypothesize that variable host factors such as endotoxin
leakage from the gut, for example during pathogenic infection or gut barrier
compromise (alcohol ingestion), or underlying inflammatory conditions (ex
hepatitis, arthritis) can promote increased basal levels of local or systemic
inflammatory cytokine, chemokines, or other soluble factors that predispose the
liver to injury[6, 35, 36]. The role of bacteria and cytokines on the regulation of
hepatic metabolic enzyme activity, such as cytochrome P450s and more recently
drug transporters have been demonstrated and recently well reviewed [37]. These
changes are believed to be regulated by altering nuclear receptor activities (PXR,
CAR, FXR, RXR, LXR) which drive expression of phase I, II, and III metabolic
enzymes. While critical for biotransformation and clearance, the changes in
metabolic enzymes do not fully explain idiosyncratic effects observed in
humans[33].
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Acetaminophen-Induced Liver Injury
Acetaminophen (APAP) is the worlds most commonly used analgesic and
antipyretic, responsible for approximately a third of cases related to DILI [38].
Under normal liver conditions, -90% of APAP is metabolized to non-toxic
conjugated metabolites APAP-glucuronide and APAP-sulfate and -10% of APAP
metabolism occurs via cytochrome P450 oxidation (CYP 2E1, 3A4, and to a lesser
extent 1A2) to form N-acetyl-p-benzoquinoemine (NAPQI), a highly reactive
electrophilic metabolic intermediate [39]. Detoxification of NAPQI normally
proceeds by conjugation with intracellular glutathione, either spontaneously or
catalyzed by glutathione-s-transferase (GST), the majority of which is excreted into
bile via multidrug resistance-associated protein 2 (Mrp2) [40]. When doses exceed
glutathione stores, free NAPQI can covalently modify thiol (SH) groups on cellular
proteins (summarized in Figure 1-1). While long thought that covalent protein
adducts are the cause of liver injury [41], it has been recently suggested that adduct
formation is a necessary initiating factor in cell death but not sufficient, requiring
amplification through intracellular signaling [42]. In this regard there is a central
role for sustained JNK activation [43], a serine/threonine kinase important in
responding to environmental stresses, growth factors, and cytokines [44].
Important intracellular activators of JNK are ROS such as H20 2 generated from
mitochondria and other sources [45, 46]. Indeed APAP-induced ROS from
mitochondria is a necessary requirement for APAP induced toxicity, demonstrated
by upstream knockout of ASK1, JNK knockout, and INK specific inhibitors [42, 47].
Altering the host's ability to properly balance both protoxicant and hepatoprotective
processes has also been shown to alter susceptibility to APAP-induced injury.
Germline KO for IL-13 [48], IL-10 [49], IL-6 [50], cyclooxygenase-2 (COX-2) [51], C-C
chemokines receptor 2 (CCR2: receptor for MCP-1), and Nrf2 all demonstrate
increased susceptibility to APAP-induced liver injury, while CX-chemokine receptor
2 (CXCR2: receptor for KC and MIP-2) KO is protective [52]. Furthermore, the
importance of innate immune cells in mediating injury as demonstrated by Kupffer
cell depletion using liposomal chlorondate treatment, which confers protection at
early time points after APAP treatment [53], but can lead to more severe injury at
later time points [54]. While mechanistically not completely understood, depletion
dramatically reduced transcript levels of IL-10 and IL-6, corroborating their
importance demonstrated in KO studies. Functionally, IL-10 limits inducible nitric
oxide synthase (iNOS) expression [49, 55] and peroxynitrite-induced liver injury
after APAP overdose, while IL-6 promotes regeneration. Others have found that
APAP toxicity results in liver infiltration of a macrophage (IM) population derived
from circulating monocytes, distinct from resident Kupffer cells. The IMs exhibit a
phenotype consistent with that of alternatively activated macrophages, with ability
to phagocytize apoptotic cells and induce apoptosis of neutrophils. Furthermore, in
the absence of the IMs, the resolution of hepatic damage following APAP-induced
hepatotoxicity was delayed in CCR2 KO mice at 48 and 72 hours [56], however,
necrosis and circulating ALT were comparable at earlier time points (10 and 24 hrs
post dose). These animals demonstrated reductions in infiltrating macrophages.
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These findings implicate IMs in the processes of tissue repair, including dampening
inflammation and promoting angiogenesis.
The role of PRRs has also been examined, and TLR4 is involved in APAP-induced
hepatotoxicty, as C3H/HeN (TLR4+/+) mice demonstrated more severe histological
lesions, significantly higher ALT, and higher liver and plasma TNF-a levels than
C3H/HeJ (TLR4-/-) [57]. Interestingly, endotoxin pretreatment of male C3H/OuJ
mice 24hr prior to APAP treatment (400mg/kg) afforded protection but not in male
C3H/HeJ, furthermore, protection was mimicked with pretreatment with IL-la
alone in both strains [58]. LPS binding protein (LPB) KO mice also show protection
to APAP-induced liver injury, and a recently used LPB inhibitory peptide
demonstrated protection against APAP-induced hepatotoxicity in C57BL/6 mice
[59, 60]. LPB is known to assist binding of LPS to receptors CD14 [61] and
TLR4/MD2, promoting inflammatory cytokine production. Furthermore, while the
effect of LPS delivery 24 prior to APAP has been shown protective, potentially via
suppression of CYPs associated with APAP bioactivation, a distinctly different local
and systemic cytokine profile than may be experienced with APAP delivery 2 hrs-
post LPS [62], where LPS pretreatment moved the dose response curve to the left,
sensitizing animals to injury. Collectively, this indicates a complex role for LPS
signaling and predisposition to injury may be context or time dependent.
More recently, C57BL/6 mice deficient in TLR9, a key receptor for bacterial DNA, as
well as modified mammalian DNA, demonstrated protection to APAP-induced
hepatotoxicity [63]. Mammalian DNA in cells undergoing apoptosis can be modified
by caspase-activated DNase-mediated (CAD-mediated) cleavage [64], as well as
methylation [65], and oxidative damage [66], modifications shown to increase its
ability to activate TLR9 [67]. Downstream targets of TLR9, including components of
the inflammasome (Nalp3, apoptosis-associated speck-like protein containing a
CARD (ASC), and caspase-1) when knocked out, decreased susceptibility to APAP-
induced liver injury and mortality to a normally toxic dose. Mechanistically, it was
demonstrated that activation of TLR9 and subsequent caspase-1 activation via
inflammasome components, resulted in processing of pro-IL-1 and pro-IL-18 to
their respective active forms. APAP appeared to have a 2-signal requirement (TLR9
and Nalp3 inflammasome) mediating toxicity, analogous to the 'red' alert hypothesis
of innate immune activation. Although not mentioned by the authors, JNK activation
is downstream of TLR4, TLR9, and IL-1R [43], a key mediator of APAP toxicity
downstream of metabolic activation.
Animal Models of Liver Injury
LPS is found in the outer membrane of gram-negative bacteria. It contains Lipid A, a
hydrophobic anchoring protein also known as endotoxin, a potent PAMP known to
activate TLR4. LPS is commonly used to induce an inflammatory state to interrogate
the role of host factors to explain the susceptibility of certain individuals to
idiosyncratic drug reactions[36]. Specifically, numerous papers from Roth et al.
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demonstrate that drugs such as Ranitidine and Trovafloxacin, which result in
idiosyncratic injury in humans, synergize with a subtoxic iv dose of LPS resulting in
hepatotoxicity in rats and mice, while innocuous when treated with either drug or
LPS alone [68, 69]. Mechanistically, subsequent studies demonstrated critical roles
for TNF-ca [70, 71], neutrophils [72], and the coagulation pathway [73], in mediating
the toxic response. Although, it has been noted that levels of LPS in this model are
not physiologically relevant to what would be observed in clinical patients [33], and
the profile of toxicity in these studies is similar to high dose LPS treatment alone.
While the use of LPS has helped greatly in the understanding of cytochrome P450
regulation under inflammatory conditions, it may not accurately predict enzyme
regulation and cell responses under live bacterial infections, which results in
complex pathogen host interactions, and release of diverse PAMPs other than LPS.
Moreover, a bolus injection of LPS is unlikely to be physiologically relevant.
Citrobacter rodentium
Citrobacter rodentium is an enteric bacterial pathogen that results in varying
degrees of intestinal inflammation, acute colitis, hyperplasia, and edema in
numerous strains of inbred and outbred laboratory mice [74, 75]. Sharing
numerous virulence factors with the human infecting enteropathogenic Escherichia
coli (EPEC) and enterohemorrhagic E. coli (EHEC), as well demonstrating superior
pathogenicity to the former in mice, have made C. rodentium infection a highly
utilized and robust model for studying the pathogenesis of attaching and effacing
(A/E) lesion forming pathogens. In experimentally infected mice, large numbers of
bacteria colonize the distal colon and are observed adhering to the epithelial surface.
Although highly dependent on mouse strain, peak colonization and hyperplasia can
be seen as early as 4 days post inoculation (DPI), with maximal colonic thickening
observed between 10 and 12 dpi. In adult C57BL/6, disease recovery and full
clearance of C. rodentium occurs by 4 weeks post infection (WPI) and full resolution
of colonic lesions by 6 wpi [74, 76].
Recent work by Richardson et al demonstrates that C. rodentium infection alters
mRNA levels of phase I (cytochrome P450s) and phase II (UGTs) metabolic enzymes
in liver and kidney, as well as hepatic cytokine levels [7, 8]; a time course of
regulation that followed colonic inflammation and bacterial colonization, peaking at
7-10 dpi, and returning to normal by 15-24 dpi. Interestingly, when the role of toll-
like-receptor 4 (TLR4) was examined in the regulation of hepatic and renal mRNA
changes using C3H/HeJ (TLR4-/-) and C3H/HeN (TLR4+/+) mice, the majority of
transcriptional changes were TLR4 independent. Subsequent study comparing IV
versus oral infection with C. rodentium resulted in both quantitatively and
qualitatively different responses in regulation of P450 enzymes [77]. What remains
unclear, is the role of potential cross-talk from other TLR receptors, as well as NLRs
on regulating hepatic transcriptional changes in this model, furthermore, if cytokine
and chemokine secretion due to pathogenic bacterial detection in the gut and
subsequent transport to liver via portal blood flow is primarily driving these
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changes, and not bacterial antigens leaking from the gut. Furthermore, whether
there is a consequential change on drug exposure and clearance under infection
conditions.
Concluding Remarks:
While inflammation plays a critical role in liver homeostasis and response to
xenobiotics, clear biomarkers that predict host susceptibility factors for
hepatotoxicity are currently lacking. Its diverse cellular constituents as well as its
many functions critical for host survival underscore the complexity of the liver as a
tissue and early responder to pathogenic infection. This includes a population of
innate and adaptive immune regulators under constant flux, balancing proper
responses to deal with host stress and insult, while also mediating its resolution and
eventual homeostasis. Local responses in the liver to intestinal stimuli are a
substantial source of circulating cytokines [77], attributable to portal blood
(potentially containing bacterial components, cytokines/chemokines etc) draining
from the intestines for liver filtration prior to entering systemic circulation. A
balance between the gut and liver axis may be critical in mediating host-pathogen
equilibrium, a failure of which can result in detrimental consequences in both
intestinal, liver, and systemic health [4, 78]. It is possible that these cytokine
responses are general to the presence of bacterial products, but may also indicate a
liver response to distal infection in the gut. A combination of cytokines, PRRs,
DAMPs, and intracellular stress may all synergize to induce such hepatic injury,
however, depending on the time course of expression may also contribute to
resistance and resolution of injury via immune mechanisms. Particularly interesting
is the potential for molecular mimicry of host components (mammalian DNA) as
well as active and passive release of HMGB1 that have cross-talk with PRRs,
resulting in altered kinetics of signaling, potentially critical in understanding and
predicting toxic disposition or resolution of injury. While in vitro attempts to
understand these processes have been immensely helpful, to truly understand the
complexity may require systems-wide interrogation in vivo using a reproducible
physiological model of pathogenic inflammation using multiplex capabilities and
computational tools.
Here we have utilized C. rodentium infection, a model of EPEC and EHEC infection
and IBD in humans, to interrogate both systemic and liver-specific effects of
gastrointestinal infection in C57BL/6 mice. Using a physiologically relevant source
of systemic inflammation and acute stress, we measured liver responses at various
pathological states of infection, pathogen-host interactions under conditions of
drug-induced-liver injury, and systemic effects on drug clearance across a diverse
class of xenobiotics that vary in their biotransformation and clearance mechanisms.
Furthermore, using a computational approaches such as PCA, PLSR, affinity
propagation, and mutual information, we have attempted to build a model of
interactions that help not only visualize this interactive landscape, but show both
linear and non-linear interactions using a compilation of systemic and tissue specific
cytokine/chemokine levels, serum chemistries, histological scoring metrics.
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My first aim (reviewed in Chapter 2) focused on taking a systems-level approach in
characterizing both systemic and liver-specific changes that occur over the course of
C rodentium infection kinetics using multiplex assays and multivariate
computational modeling approaches. This resulted in the novel discovery and
characterization of an infection-induced liver necrosis in the absence of clinically
relevant colonic injury, paralleled by local and circulating cytokine and chemokine
changes indicative of a host inflammatory component to the injury. In subsequent
work, we demonstrated that C rodentium induces systemic and local changes in
liver signaling as early as 12 hours post inoculation (Appendix Chapter B). The
second aim, and focus of Chapter 3, involved superimposing drug treatment on
gastrointestinal infection in order to evaluate the potential effect of local and
systemic cytokine changes induced by C rodentium to synergize or protect animals
from drug-induced injury. Using APAP treatment at a mildly hepatotoxic dose in the
presence and absence of C rodentium-induced inflammatory stress, a compendium
of measurements were generated including systemic and local cytokine levels
(colon and liver), serum chemistries, as well as pathological assessment of
inflammation and necrosis for both liver and colonic sections. We not only
confirmed our initial findings of C rodentium induced liver lesions during early
course of infections, but determined through computational approaches such as
mutual information and partial least squares (PLS), signatures characteristics of
both infection-induced and drug-induced liver injury. In the final aim (Chapter 4),
we evaluated the effect of gastrointestinal infection on altering oral bioavailability of
clinically relevant xenobiotics. C rodentium resulted in increased systemic
exposure (AUC) to commonly used pharmaceutical agents, such as verapamil,
propranolol with paralleled increases in their metabolites. Mechanistically, it
appears that C. rodentium acts to increase intestinal absorption, perhaps through
alteration of the mucosal barrier, as a principle mode of PK alteration. In summary,
these findings are important in helping to build our understanding of the dynamic
interplay between inflammation and systemic/tissue-level homeostasis during
enteric infection. Future work focusing on neutralizing antibodies or conditional
KO's may help to confirm and expand on the importance of numerous targets
implicated.
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Figure 1-1. Acetaminophen Metabolism and Elimination.
Acetaminophen biotransformation proceeds by phase II glucuronidation or sulphation with
subsequent elimination via renal excretion. A minor pathway (10%) involves oxidation via
cytochrome p450s (2E1, 3A4 > 1A2) to a reactive quinone imine (NAPQI), followed by
detoxification by glutathione stores and biliary elimination via Mrp2. Under conditions of
glutathione depletion or overdose, NAPQI reacts with hepatic proteins and nucleic acids
resulting in subsequent toxicity. Figure obtained from Steven R. Tannenbaum and amended
to include details of P450 activation and elimination pathways.
Table 1-1. Target modulation and susceptibility to APAP-induced toxicity in
experimental models. (Modified and updated table from Kaplowitz 2004 [7)
5. * * ' S '
GST-Pi-
CYP 2E1+--
IFN-y-/-
NALP3 --
TLR9-/-
CXCR2+ (KC and MIP-2
receptor)
NK/NKT depletion
IL-1a (24 hrs prior)
LPS binding protein
LPS delivery (24 hrs prior)
[80]
[81]
[82]
[63]
[63]
[52]
[85]
[58]
[60]
[581
IL-6-/-
IL-10+--
IL-4/IL-10 (highly sensitive)
IL-13-/-
CCR2 (MCP-1 receptor)
COX-2-/-
JNK-- (and inhibition)
MIP-2 inhibition
LPS delivery (2 hrs prior)
Ii
I.;'
II 'I
OH
[50]
[49]
[55]
[48]
[83, 84]
[51]
[43]
[86]
[62]
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2.1 Introduction
Liver responses under acute and chronic forms of inflammation have gained
considerable interest, particularly due to the role of inflammation in non-alcoholic
steatohepatitis (NASH) [87, 88] and drug induced liver injury (DILI). While genetic
manipulation and pharmacological inhibition has helped greatly in our
understanding of hepatic homeostasis under inflammatory stress conditions, there
still exist few animal models that can properly predict these pathologies in the
human case. Furthermore, understanding the host response to environmental
pathogens is critical in order to study how exposure to chemicals amplifies,
synthesizes with, or mitigates environmentally induced disease.
Citrobacter rodentium (C. rodentium) is an enteric bacterial pathogen that causes
varying degrees of intestinal inflammation, acute colitis, hyperplasia, and edema in
numerous strains of mice [74-76]. As a murine homolog of enteropathogenic
Escherichia coli (E. coli) and enterohemorarrhagic E. coli (EPEC and EHEC
respectively), C. rodentium has become a highly utilized animal model of these
human infections, providing a reproducible, robust, and physiologically relevant
model of inflammation. More recently, is has demonstrated organ-specific effects
distal to the main site of attachment and disease with alterations of phase I
(cytochrome P450s) and phase II (UGTs) metabolic enzymes in liver and kidney, as
well as increases in hepatic cytokine transcript [7, 8]; a time course of regulation
that follows colonic inflammation and bacterial colonization, peaking at 7-10 days
post inoculation (DPI), and returning to normal by 15-24 DPI. Such changes in local
and systemic cytokines could lead to metabolic dysregulation or alter susceptibility
to injury and disease. Furthermore, altered phase I and II metabolic enzymes, which
catalyze the biosynthesis and catabolism of endogenous substrates and metabolic
clearance of pharmaceuticals, could be of clinical impact for patients presenting
inflammatory bowel syndromes (IBS) or pathogenic gastrointestinal infections.
Here we examined the host response to C. rodentium at various stages in the course
of enteric infection, focusing particularly on systemic and liver-specific cytokine
protein profiles. For the first time, we show distinct liver pathology associated with
enteric infection with C. rodentium in C57BL/6 mice, characterized by periportal
necrotic lesions indicative of thrombic ischemic injury during the early course of
pathogenic infection. Histologic liver changes in inflammation and injury.correlate
with serum elevation of liver transaminases, systemic and liver resident cytokines,
as well as signal transduction changes and liver inflammation prior to peak bacterial
colonization and colonic disease. C. rodentium infection in C57BL/6 mice appears to
be a useful new model to study acute liver injury and inflammatory stress under
conditions of gastrointestinal infection analogous to pathogenic E.coli infection in
humans.
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2.2 Results
Infection kinetics and body weight changes
As previously reported, fecal shedding of C. rodentium in C57BL/6 mice reached a
maximum of -109 CFU/g feces [89], with detectable levels 3 DPI, peaking 7 DPI,
with clearance beginning as early as 10 DPI (Figure 2-1A). Although dependent on
mouse strain, bacterial load in the colon peaks at 5-14 DPI with approximately 109
colony-forming units [74]. Body weight changes were not significant over the
course of infection, although variable with some animals losing close to 20% of their
initial body weight (Figure 2-1B & C), in line with previous findings that C.
rodentium infection in adult C5713L/6 mice results in self-limiting disease with
minimal incidence of morbidity and mortality [74, 76, 90].
C. rodentium-induced histological colonic changes
Infection and disease was confirmed by colonic histological changes assessed by
H&E with sections scored by a veterinary pathologist blinded to study treatment
groups (Figure 2-2). The integrity of epithelial and goblet cells appear intact in
control animals but as early as 3 DPI, epithelial defects, colonic foci of inflammation,
edema, and hyperplasia were noted (Figure 2-2A and B) with statistically
significant increases in inflammation, edema, and epithelial defects by 7 DPI (p <
0.05, Krustkal Wallis with Dunn's post test), appearing maximal by 14 DPI (Figure
2-2C and D). Statistically significant changes in crypt atrophy and hyperplasia were
only observed at 14 DPI (Figure 2-2D) (p < 0.05 and p < 0.01 respectively).
Although highly dependent on mouse strain, peak colonization and hyperplasia can
be seen as early as 4 DPI, with maximal colonic thickening observed between 10 and
12 DPI. In adult C57BL/6, disease peaks approximately 2 weeks post inoculation
(WPI) with recovery and full clearance of C. rodentium occurs by 4 WPI and
resolution of colonic lesions by 6 WPI [74, 76, 91].
C. rodentium-induced histological liver changes
While the effect of C. rodentium infection has been well characterized with respect to
colonic changes, we decided to examine in greater detail the effect of pathogenic
enteric infection on liver homeostasis. Liver sections were formalin fixed, paraffin
embedded, and stained by H&E for pathological assessment (Figure 2-3). C.
rodentium induced statistically significant histological changes as early as 3 DPI
(lobular inflammation) in liver sections and most significant at 7 DPI (portal
inflammation, lobular inflammation, interface inflammation, # lobes with >5
inflammatory foci, and hepatitis index), with moderate improvement by 14 DPI
(Figure 2-3E). Control livers had no observable histological abnormalities,
however, at 3 DPI, the appearance of foci of inflammation indicated a pro-
inflammatory state with multifocal vascular coagulative necrosis observed in 3/6
mice (Figure 2-3A-D). Necrotic lesions presented primarily with a periportal
pattern of distribution (Figure 2-3G) and indicative of thrombic ischemic injury
with the presence of portal venular fibrin thrombi. Necrotic regions contained
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hepatocytes with eosinophillic cytoplasms, appearance of pyknotic or absent nuclei,
and loss of normal cellular structure. To confirm and measure the extent of
necrosis, serum was processed for alanine amino transferase (ALT), and aspartate
amino transferase (AST), two accepted markers of hepatic injury. Hepatic necrosis
score correlated with increased ALT at 0 vs 3 DPI = (28.60 ± 2.358 U L-1 N=5 versus
415.2 ± 250.4 U L-1 N=6). Mice presenting lesions had ALT levels 56, 16, and 13-fold
higher than average control values (ALT = 1603, 464, and 359 U L-1 respectively),
while non-lesions bearing animals at 3 DPI were comparable to controls (Figure 2-3
F). To our knowledge, this is the first reported liver lesion of this kind reported as a
result of C rodentium infection and have been repeated and confirmed in
subsequent studies (Chapter 3).
Further characterization of necrotic livers by immunohistological staining for
activated caspase 3 and Ki-67 revealed labeling index in periportal areas of injury
for both markers indicating heterogeneous cell death and active proliferation
(Figure 2-4). Livers harboring lesions at 3 DPI contained a higher incidence of
positively stained cells for Ki-67, as compared to controls and non-lesions bearing
mice at 3 DPI, indicating a proliferative state in these livers with a comparable
increase in labeling index at 7 and 14 DPI Figure 2-5A and B). Animals at 7 and 14
DPI did not harbor obvious necrotic lesions, however, the presence of large
hepatocytes and areas of necro-granulomatous inflammation indicate prior lesions
in these animals may have resolved via inflammatory and proliferative mechanisms.
Serum cytokine and chemistry changes due to C rodentium infection
C rodentium has been shown to induce numerous immune regulators at both
systemic and local levels, and generally associated with a mucosal TH1/Th17-
mediated response in C57BL/6 mice ([92, 93]). Recently, serum and colon matched
cytokines were analyzed in C rodentium infected C57BL/6 mice at peak colonic
disease (14 DPI), demonstrating correlations of colon and systemic levels associated
with disease severity [94]. Here we decided to measure both serum specific changes
in cytokines/chemokines (23-PLEX Luminex bead-based ELISA) as well as serum
chemistries in multiplex at early, peak, and resolving timepoints of bacterial
clearance (Supplementary Figures 2-1 and 2-2). We determined numerous
circulating cytokines and chemokines to be significantly induced at 3, 7, and 14 DPI.
Findings at 3 DPI are particularly interesting as they correlate with our histological
findings in the liver and precede peak colonic bacterial colonization and disease.
Circulating cytokines were significantly elevated for IL-2, G-CSF, GM-CSF, MCP-1,
MIP-1b, and RANTES at 3 DPI as a group (p < 0.05, by one way ANOVA with Tukey's
multiple comparison test). Elevations in IL-10 and KC were noted but missed
significance. For the majority of targets measured, mice at 7 DPI appeared to have
the highest circulating cytokines and chemokines, correlating with peak bacterial
burden as assessed by fecal shedding (Supplementary 2-1), which included
elevations in pro-inflammatory (ILib, IL-6, and TNF-a), immunomodulatory (IL-2,
IL-12p70, IL-17), TH2 (IL-4, INF-gamma), and macrophage chemotaxis/activation
(GM-CSF, MIP-1b) (p<0.001 as compared to controls).
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Serum cholesterol levels also increased significantly at 3 DPI and continued to rise
until 14 DPI. It has been shown that C. rodentium can alter the transcriptional levels
of certain phase I (cytochrome P450s) and phase II metabolic enzymes in both liver
and kidney, key in metabolism of endogenous and pharmaceutical substrates [7, 8].
Cholesterols clearance from circulations is partially mediated by oxidation via CYP
7A1, and we have shown decreases in CYP7a1 in liver infected with C. rodentium
(Appendix Chapter B). LPS has also been shown to induce expression of ATP-
binding cassette transporter Al (ABCA1), a transporter known to promote
apolipoprotein-dependent cholesterol efflux from cells, with cholesterol
participating in the removal of an immunostimulatory bacterial lipid,
lipopolysaccharide (LPS)[95]. Others have also shown that acute phase proteins
such as serum amyloid A are loaded into HDL vesicles for transport, indicating a
mechanisms for cholesterol in host defense that have previously not been
appreciated. Cholesterol homeostasis is complex, and while interesting in this
model, would require considerable follow-up to understand the mechanism for its
increased serum levels in this infection model. Other serum chemistries and
electrolytes, including albumin and glucose, were normal and did not vary
significantly across times monitored (Supplementary Figure 2-1).
Liver cytokine and signaling changes due to C. rodentium infection
To determine if systemic cytokine and chemokine profiles correlated with local
levels in the liver, we analyzed lysates using the 23-plex cytokine/chemokine panels
and discovered numerous targets increased in serum demonstrated similar up-
regulation in livers at 3 DPI (Supplemental Figure 2-3). Liver levels of IL-1 (L), G-
CSF (L), KC (L), MCP-1 (L), MIP-la (L), and RANTES (L) showed upregulation at
3DPI. Cytokines are known signaling molecules in signal transduction pathways, so
we also measured signal transduction in liver lysates using multiplex phospho-kits
monitoring both total and phosphorylated forms of JNK, AKT, ERK1/2, p38, IKBa,
and STAT3 (phosphorylated only). STAT3 showed increases in livers harboring
necrotic lesions as confirmed by western analysis, with lower but sustained
activation at 7 and 14 DPI (Figure 2-7). Akt activation as assessed by the ratio of
phosphorylated/total Akt was statistically significantly upregulated at 14 DPI,
although levels were comparably elevated at 3 and 7 DPI but missed significance
(Figure 2-7). Phosphorylation of IKBa, which results in proteasome-mediated
degradation and subsequent activation of Nf-KB, was increased in animals bearing
necrotic lesions, indicating potential activation of pro-inflammatory and tissue
repair mechanisms associated with this transcription factor.
Multivatiate analysis uncovers serum and tissue cytokines and chemokines
discriminate necrosis
Analyzing data based on averages in representative groups can cause an
investigator to miss important correlations on an individual animal basis. Based on
this, we decided to take a multivariate computational approach in determining
features that covary best in our data compendium leveraging its multiplex nature.
PLS-DA (Partial Least Squares Projection to Latent Structures - Discriminant
2-30
Analysis) and OPLS (Orthogonormalized Partial Least Squares Regression) were
used to determine variables with the highest discriminatory power for lesion
bearing animals at 3DPI, furthermore, to determine features that correlate best with
serum ALT, a known biomarkers of liver necrosis. We developed non-invasive
models (serum targets only), tissue level model (liver targets only), and a combined
model using both types of features. The serum PLS-DA model resulted in good
separation of lesion bearing vs non-lesion bearing animals (Figure 2-8A), with
dummy variables (Y) based on this classification covarying with serum targets that
make up the principal components plane (Figure 2-8B). Their relative importance
as discriminators was assessed by their variables in projection (VIPs) score for the
principle component 1, where values >1 are have positive influence in
discriminating between classes and VIP <1 are less influential (Figure 2-8C and D).
Similarly using OPLS regression, which reduces dimensions on the basis of their
covariance with a specified dependent variable (Y, serum ALT) (principal
component 1 - predictive), while ignoring targets orthogonal to this vector
(principal component 2 - orthogonal) also resulted in clear separation of animals
based on this classifier (Figure 2-9). PLS-DA serum models uncover ALT, AST,
immune modulators (IL-6, IL-10), monocytes chemokines/activators (MIP-la, MCP-
1), neutrophil chemokines/activators (G-CSF, KC), and t-cell activation (RANTES) as
enriched in lesion bearing animals (Figure 2-8 C-D).
This method was repeated for tissue markers (Liver PLS-DA Figures 2-10, and
OPLS Figure 2-11) and resulted in a large overlap with the serum specific targets;
immune modulators (IL-1a (L), IL-6 (L), IL-12p40 (L)), monocytes
chemokines/activators (MIP-1a (L), MIP-1b (L), MCP-1 (L)), neutrophil
chemokines/activators (G-CSF (L), KC (L)), and t-cell activation (RANTES (L)) as
enriched in lesion bearing animals resulting in enrichment of liver PLS-DA and OPLS
models generated using serum targets, liver targets, and combined targets are
summarized (Table 2-1). Overall, both serum and tissue models were highly
effective at discriminating both necrosis state prediction of necrosis severity. The
tissue models were slightly better independently than the serum models, and the
combine (serum + tissue) gave the highest R2Y (cumulative) and Q2 (cumulative)
with the least number of components. The less non-invasive method of serum
cytokine detection makes this a more attractive method even with a modest lost in
model prediction.
2-31
2.3 Discussion
In the present study we have characterized the systemic and liver effects of C.
rodentium infection in female C57BL/6 mice at early, peak, and resolving timepoints
of bacterial clearance. We demonstrated systemic targets (cytokines/chemokines
and serum chemistry markers) that differentiated animals by PLS-DA. Systemic
elevations in ALT, AST, with an upregulation of immune modulators (IL-6, IL-10),
monocytes chemokines/activators (MIP-la, MCP-1), neutrophil
chemokines/activators (G-CSF, KC), and t-cell activation (RANTES) at 3PDI
correlated with coagulative liver necrosis, lesions predominantly periportal in
nature and associated with fibrin thrombi. Mice harboring lesions also
demonstrated induction of STAT3 and IKBa phosphorylation, coupled with liver
specific protein elevations of IL-1p (L), IL-6 (L) G-CSF (L), KC (L), IL-12p40 (L),
MCP-1 (L), MIP-1a (L), and RANTES (L).
C. rodentium-induced histological liver changes
Pathological assessment of livers discovered that 50% of mice at 3 DPI harbored
periportal necrotic lesions that have not been observed and/or reported to our
knowledge in this murine model of enteric infection and colonic hyperplasia. This
may due in part to the fact that 3 DPI is early in disease pathogenesis coupled by our
interest in investigating an organ distal to the primary site of disease pathology and
bacterial colonization. Bacterial translocation due to inflammation or overgrowth of
commensal bacteria has been shown to occur, with translocation of luminal bacteria
to other organs [96, 97], in some cases resulting in sepsis and the subsequent death.
Furthermore, C. rodentium has demonstrated translocation to MLNs during infection
course [98]. We did not plate liver tissues to determine C. rodentium liver load but
follow-up experiments staining liver sections using a C. rodentium specific antibody
could confirm this. C. rodentium has been associated with disruption of tight
junctions and barrier function in intestinal epithelial cells in vitro and in vivo ([99,
100]). As liver lesions were predominantly periportal in their pattern of
distribution, and indicative of thrombic ischemic injury with portal vein thrombi
present, it is possible that bacterial components, or C. rodentium (live or dead) at the
early stages of bacterial colonization, translocated from the gut lumen via portal
blood to the liver inducing a systemic and local inflammatory response. LPS, for
example, through interaction with LPS-binding protein has been demonstrated to
induce fibrin clots in tissues. Others have proposed that the liver may act to trap
LPS, along with other bacterial components as a protective mechanism to prevent
systemic spread of bacteria. As a regenerative organ, minimal necrosis via
coagulative mechanisms could me manageable. The presence of necro-
granulomatous inflammation at later timepoints indicates perhaps of residual
effects of clearance mechanisms of prior injury in these animals. The lack of
circulating ALT indicates that active necrosis was likely not occurring.
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Cytokine/chemokines correlations with necrotic lesions
Using PLS-DA and OPLS modeling, we demonstrate an upregulation of targets
associated with necrosis at 3 DPI (for total list see Figure 2-12). G-CSF (S/L), MCP-
1 (S), KC (S/L), IL-6 (S/L), IL-10 (S), and RANTES (S/L) were highly predictive for
animals harboring liver lesions and demonstrated high covariation with ALT.
Neutrophil activation is commonly observed at the sight of tissue injury. Indeed, G-
CSF, a chemokine known for neutrophil recruitment and activation, was elevated in
serum and liver homogentates. G-CSF is also known to promote the survival,
proliferation, differentiation, and function of both precursor and mature
neutrophils. The increased levels of G-CSF may also account for the induction of
STAT3 and Akt levels found in the liver. Interestingly, IL-6 can inhibit the
inflammatory induced by neutrophil-activating chemokines by facilitating
neutrophils apoptotic clearance [101, 102]. Mechanistically, this has been
demonstrated a result of STAT-3 activation in a model of acute peritoneal infection
[103]. Deregulation of gp130 (IL-6 receptor) signaling in this model did not affect
the initial CXCL1/KC-driven neutrophil recruitment, indicating early induction of
these chemokines is IL-6 independent. IL-10 (S) was also elevated in necrotic
bearing mice in our model, a cytokine with known hepatoprotective affects in drug-
induced liver injury. IL-10 can regulate KC levels in vivo attributable to modulation
of STAT 1 and STAT3 (non- gp130 mediated) signaling [104], as well as iNOS levels
in an APAP-induced model of liver injury [49, 55).
C. rodentium also induced cytokines MCP-1 and MIP-la in necrosis-bearing mice,
targets implicated in the process of hepatic inflammation, known to recruit
monocytes and lymphocytes during liver injury. MCP-1 is primarily secreted by
monocytes, macrophages, and dendritic cells and demonstrates activation for
macrophages and chemotactic activity for monocytes [105] and basophils but not
for neutrophils or eosinophils. MCP-1 is also associated with numerous models of
fibrosis, and shown to activate hepatic stellate cells, which play a major role in
hepatic fibrosis. Here the occurrence of portal vein thrombi in liver lesion-bearing
animals parallel increases in serum and liver MCP-1 and PLS-DA analysis at 3 DPI
also showed covariation with P-IKBa; a known regulator of Nf-KB transcription. It
has also shown to work in an autocrine loop with RANTES, and demonstrates high
correlation with MCP-1 (R2 = 0.84) in our study (Supplemental Figure 2-4
comparing 3 and 7 DPI networks). Collectively, the regulatory control by both STAT
and Nf-KB mediated transcription deserve further exploration in precise roles in
mediating the responses to early infection and liver inflammation/injury in this
model.
It is interesting that liver responses detected in animals at 3 DPI overlapped many of
the targets associated with acute colitis and disease severity such as chemokines
MCP-1, MIP-1a, MIP-1b, RANTES, and KC and neutrophil/Th17-related targets such
as KC, IL- 1b, IL-6, IL-12/23p40, G-CSF. Local responses in the liver to intestinal
stimuli are a substantial source of circulating cytokines [77], attributable to portal
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blood (potentially containing bacterial components, cytokines/chemokines etc)
draining from the intestines for liver filtration prior to entering systemic circulation
[78]. It is possible that these cytokine responses are general to the presence of
bacterial products, but may also indicate a liver response to distal infection in the
gut. While indispensable as a metabolic organ, the liver is also a key
"immunological" organ, underscored by its constant perfusion of blood from the
gastrointestinal tract which is highly enriched with potential antigens, providing an
early line of defense against microbes and toxins crossing the intestinal barrier [26].
Whatever the source or stimuli for these local and systemic changes, they clearly
correlate with observed pathologies determined by PLS modeling in a complex data
set, but also predictive for known biomarkers of injury such as serum ALT for liver
necrosis.
Future analysis would hope to confirm the phenotype of liver injury at early
timepoints of C. rodentium infection. Indeed, subsequent work from our lab has
confirmed it as reproducible in work to be published (Chapter 3). Specifically, the
incidence of necrotic injury at 3 DPI was increased in our hands to 5/6 animals with
an overnight fast prior to necropsy, with lesion resolution again by 7 DPI. To better
understand the temporal kinetics of injury, collecting serial bleeds from animals
preceding, during, and under conditions of resolving liver injury could be extremely
helpful in understating the kinetics of cytokine release and whether such targets are
precursors to injury or simply a consequence. Furthermore, use of neutralizing
antibodies or conditional knockout studies may also help to elucidate the
importance of these markers in the predisposition and severity of injury.
In conclusion, we show for the first time, to our knowledge, distinct liver pathology
associated with enteric infection with C. rodentium in C57BL/6 mice, characterized
increased inflammation and hepatitis index as well as periportal necrotic lesions
indicative of thrombic ischemic injury during the early course of pathogenic
infection. Histologic changes correlate with serum elevation of liver transaminases,
systemic and local cytokine and chemokine changes, as well as signal transduction
changes prior to peak bacterial colonization and colonic disease. C. rodentium
infection in C57BL/6 mice appears to be a useful new model to study acute liver
injury and inflammatory stress under conditions of gastrointestinal infection
analogous to pathogenic E. coli infection in humans.
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2.4 Selected methods
Mouse Infections
24 female 8-10 week-old, specific pathogen free C57BL/6 mice were (The Jackson
Laboratory, Bar Harbor, ME) were housed and maintained as described in Appendix
A (General Methods). Infectious colitis was induced by intragastric inoculation with
~1 x 109 CFU of DBS120 in 3% sodium bicarbonate (in PBS, pH 7.4) using a 1OOuL
volume. Control animals (0 DPI) were sacrificed within 1hr of inoculation while the
3, 7, and 14 DPI animals were monitored for fecal shedding (3,7,10,14 DPI) and
body weight changes as indicated and euthanized and necropsied at their respective
timepoints as described in Appendix A.
Histopathology
Tissues were processed as described in Appendix A. Colons and livers were
sectioned and stained by H&E for histological assessment by a veterinary
pathologist blinded to study treatment groups. Disease severity of colonic sections
was based on an existent method assessing inflammation, edema, epithelial defects,
crypt atrophy, hyperplasia, and dysplasia and graded on a scale from 0 to 4. Livers
were assessed for both inflammatory and necrotic parameters. Degree of hepatic
inflammation was graded on a scale from 0 to 4 based on region (lobular, portal, and
interface), and the number of lobes with greater than 5 inflammatory foci was
noted. The summation of these categorical inflammatory scores resulted in a
hepatitis index; mice with a score > 4 were defined as having hepatitis.
A modified scoring criterion was developed to define the extent, degree, and pattern
of liver necrosis. The degree of necrosis was scored from 0 to 4 and the pattern of
injury was evaluated as centrilobular, midzonal, or periportal in nature (# = low, ##
= medium, ### = high). The distribution of necrosis was evaluated as follows: 0-
none, 1 - focal, 2 - multifocal, 3 - translobular, 4 - submassive, involving multiple
lobules or entire lobe.
Immunohistochemistry
Formalin-fixed paraffin-embedded livers and intestinal sections were stained to
assess the degree of proliferation (Ki-67) and apoptosis (activated caspase 3). Anti-
activated caspase 3 (Cell Signaling Technologies, Inc., Beverly, MA) and anti-Ki-67
antibodies were used as specified by the manufacturer. Antibodies were detected
with biotinylated goat anti-rabbit IgG (Sigma-Aldrich, St. Louis, MO) and sections
visualized with diaminobenzidine and hematoxylin counterstained.
Clinical Chemistries
Serum samples were thawed on ice and diluted 1:4 in water and processed on an
Olympus AU 400e serum chemistry analyzer (Beckman Coulter, Inc., Brea, CA) for
18 serum chemistry targets. All samples were run against internal standards and
machine calibrated prior to use as specified by the manufacturer.
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Multiplex Detection of Serum Cytokines and Chemokines:
Mouse serum collected at necropsy was processed using mouse 23-plex cytokine
panels (Bio-Rad, Hercules, CA) as specified by the manufacturer. Briefly, serum was
diluted in species-specific sample diluent (1:4) and 50uL of sample or premixed
standards were incubated with pre-washed target capture antibody-conjugated
microspheres provided and incubated for 30 minutes with orbital shaking (300
rpm) in a 96-well plate. Upon washing, beads were incubated with detection
antibody (30 min), washed, and subsequently incubated with streptavidin-PE (10
min). Beads were washed and resuspended with 125uL assay buffer and read on
the Luminex 200 suspension array system using the low RP1 target setting (High
PMT) for maximum sensitivity. Data analysis was carried out with the Bio-Plex
ManagerTM 5.0 software and cytokine or chemokine concentrations calculated
against an 8 point standard curve generated by either 4PL or 5PL curve fitting.
Multiplex Detection of Liver Cytokines, Chemokines, and Phospho-Signaling
Colon and livers were thawed on ice and -30-50 mg of liver was briefly washed
with 500uL ice-cold cell wash buffer (Bio-Rad, Hercules, CA). Livers were then
transferred to a clean pre-weighed eppendorf tube and resuspended 12X the tissue
weight with cell lysis buffer (Bio-Rad, Hercules, CA). Tissues were homogenized on
ice for 1 minute with a Tissue TearorT ' and subsequently frozen to -80*C overnight.
Tissues were then thawed on ice and sonicated on level 5 with 5 short (-3 sec)
bursts. Upon sonication, lysates were centrifuged for 10 minutes (5,000 rpm, 4*C).
Resultant supernatant was carefully removed, protein quantified by BCA protein
assay (Thermo Scientific, Rockford, IL), and adjusted to lug/uL with 1X PBS + 0.5%
BSA (w/v). 5OuL of adjusted lysate was subsequently loaded on to a Mouse Group I:
23-Plex panel (Bio-Rad, Hercules, CA) and standards resuspended in the
appropriate matrix. Samples were subsequently processed as specified above for
serum cytokines and chemokines analysis using the Bio-Plex array system and
software manager.
Immunoblot of Phospho-proteins:
Tissues were thawed on ice, suspended in Bio-Rad cell lysis buffer with provided
phosphatase and protease inhibitors, and homogenized with a Tissue Tearor" for 1
minute. Upon freeze thawing (-80*C), samples were sonicated on level 5 for three
10 second bursts, incubated on ice for 20 minutes, and centrifuged at 4*C at 5000
rpm for 15 minutes to precipitate insolubles. Supernatants were protein quantified
by BCA (Thermo Scientific, Rockford, IL) and adjusted to 2ug/uL with Bio-Rad lysis
buffer. Equal volumes of 2X SDS loading buffer was added and 20uL loaded
(20ug/well) onto 10% SDS Tris-glycine gels (Invitrogen, Carlsbad, BA). Upon
transfer to immobolin PQ PVDF membranes, blots were incubated with antibodies
(1:2000 P-STAT-3, 1:2000 anti-rabbit monoclonal, Cell Signaling Technologies) in
TBST-5%BSA, incubated with Santa Cruz luminal reagent, exposed by Kodak MR
film, and quantified by NIH imageJ.
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Statistical Analysis:
Statistical significance in body weight change, bacterial load, disease indices,
cytokine changes, clinical chemistries, and mRNA expression levels was determined
by comparing control or experimental groups by either student's T-test or by two-
way analysis of variance (ANOVA) followed by Tukey's post tests. Data that
demonstrated no-normal distributions or categorical in nature were assessed by
Kruskal-Wallis non-parametric test with Dunn's multiple comparison test against
controls unless otherwise indicated. If only two groups were analyzed, Mann
Whitney was utilized. All analyses were done using GraphPad Prism software,
version 4.0 and P values of <0.05 were considered significant.
PCA and PLSR Analysis
The data was mean centered, variance scaled, logio transformed, and analyzed by
multivariate analysis using SIMCA-P 11.5 software (Umetrics Inc., Kinnelon, New
Jersey). PCA analysis was used to reduce the dimensionality of the data set and to
assess the covariation of variance across measured targets. PLS-DA analysis was
used to determine the features that best differentiated between selected groups of
animals designated as classes (ex. mice harboring necrosis vs non-harboring mice).
OPLS analysis was used to determine the features that best correlated with a
desired Y variable, such as ALT levels or degree of necrosis/hepatitis, resulting in
variable importance in the projection (VIP). VIPs greater >1 were considered
significant in their contribution to the model predicting the dependent variable (Y)
of interest. Model quality was assessed and reported using the following
parameters: R2 Y, the fraction of the sum of squares of all Y variables explained by
the component of the model, and R2 Y cumulative, the cumulative sum of squares of
all Y variables explained by all components of the model. Q2 is the fraction of the
total variation in Y variables that can be predicted by the component, and Q2
cumulative is the cumulative Q2 of the Y variables for all components in the model.
An R2 cumulative and Q2 cumulative of 1 indicate a perfect fit, with 100% of the
relationship between X variables and Y variables explained.
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2.5 Figures and Tables
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Figure 2-1. Infection kinetics and body weight changes in C57BL/6 mice infected with
C. rodentium.
C. rodentium bacterial burden (A) was detectable by 3DPI and maximal around 7 dpi with
clearance beginning by 10 dpi. Monitoring of body weights (B) demonstrated no
statistically significant weight loss over the coarse of infection, however % body weight loss
(C) was variable across animals with some approaching 20% loss of their initial weight.
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Figure 2-2. C. rodentium-induced colonic effects in C57BL/6 mice.
(A) Mock inoculated animals at 0 DPI with normal colonic architecture where epithelial
integrity and goblet cells appear intact. (B) Colon at 3DPI showing epithelial defects at the
top of the crypt. (C) Colon at 14 DPI demonstrating hyperplastic crypts and depletion of
goblet cells. (D) C. rodentium induced statistically significant histological changes as early as
7 DPI (inflammation, edema, epithelial defects) in colonic sections and found to be most
dramatic at 14 DPI. Crypt atrophy and dysplasia were only noticeable at 14 DPI. There
were observed changes in inflammation, edema, epithelial defects, and hyperplasia as early
as 3 DPI but did not reach statistical significance (Kruskal Wallis non-parametric test with
Dunn's multiple comparison test: * p <0.05, ** p<0.01, *** p<0.001). Symbols indicate
individual animals and lines indicate group means.
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Figure 2-3. C. rodentium-induced necrosis and histological liver changes in C57BL/6
mice.
(A) Control livers appeared normal with no observable histology. (B) At 3 DPI the
appearance of small injury of inflammation indicating a pro-inflammatory state (indicated
by #). (C) Multifocal vascular coagulative necrosis (indicated by *) was observed at 3 DPI
demonstrating periportal injury to hepatocytes indicative of thrombic eschemic injury (D)
400X view of necrotic injury containing hepatocytes with eosinophilic cytoplasm,
appearance of pyknotic or absence of hepatic nuclei, and loss of normal cellular structure.
(E) C. rodentium induced statistically significant histological changes as early as 3 DPI
(lobular inflammation) in liver sections and most significant at 7 DPI (portal, lobular,
interface inflammation, # lobes with >5 inflammatory foci, and hepatitis index score), with
moderate improvement by 14 DPI. (F) The degree of necrosis determined by pathological
assessment as well as serum ALT measurements (G) The pattern of necrosis was assessed
as centrilobular, midzonal, or periportal in distribution. (Kruskal-Wallis with Dunn's post
test compared to controls: * p <0.05, ** p<0.01, *** p<0.001). Symbols indicate individual
animals and lines indicate group means.
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Figure 2-4. Activated caspase 3 and KI-67 in C. rodentium-induced liver lesions
Control livers showed minimal staining for the apoptotic marker activated caspase 3, and
proliferative marker KI-67 (far left panels), while lesion-bearing livers at 3 DPI stained
positively for both markers with a periportal pattern of distribution (middle (10OX) and far
right (200X)). Pictured is an indicative liver section sliced twice and stained independently
for each cell marker.
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Figure 2-5. C rodentium significantly increases Ki-67+ labeling index in livers(A) Top panels are 200X and lower panels are 400X views of the same frame. A brown-
colored pigment indicates positively stained cells for KI-67. (B) Average number of KI-67+
cells/mm 2 liver determined in 15 fields (magnification, x400, 3 fields/lobe) per mouse (n =
3 for 0, 7, and 14 DPI; n = 2 for 3 DPI (NEC); n=1 for 3 DPI (No NEC)). Data is represented as
box-whisker plots, where boxes represent the first to third quartile and a horizontal line
indicates the median. Bars represent ranges. (One-way ANOVA with Tukey's multiple
comparison test: *** p<0.001)
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Figure 2-6. Signal transduction changes in liver due to C. rodentium infection.
The phosphorylated/total mean fluorescence units (MFI) ratios were determined for liver
lysates (5ug total protein) harvested from animals over the course of C. rodentium infection.
Average Akt activation was significantly increased at 14 DPI with comparable elevations at
3 and 7 DPI missing statistical significance. Elevations were observed in IKBa
phosphorylation, particularly in liver lesion-bearing mice, demonstrating statistical
significance as a group versus 14 DPI livers. ERK1/2 and p38 failed to demonstrate changes
over the course of C. rodentium infection in livers (One-way ANOVA with Tukey's multiple
comparison test: * p <0.05, ** p<0.01, *** p<0.001). Data presented are mean ± SEM.
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Figure 2-7. STAT3 activation in livers of C. rodentium inoculated C57BL/6 mice.(A) P-STA3 levels were detected by Bio-Rad phospho panel and expressed as a fold changes
of mean fluorescence intensity (MFI) relative to control animals. STAT3 was statistically
significantly activated in livers of mice inoculated with C. rodentium at 3 and 7 DPI (Kuskal-
Wallis test with Dunn's multiple comparisons test: *p <0.05, ** p<0.01). (B) Western
detecting P-STAT3 levels in liver lysate (20ug/lane) from one animal per time point. Mouse
08-5648 (3DPI) is shown and presented the most severe necrotic injury and highest ALT
levels, correlating with largest P-STAT3 MFI fold-change (5.3-fold). Data presented are
mean ± SEM.
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Figure 2-8. Serum specific PLS-DA analysis of C rodentium infected C57BL/6 mice at 3
DPI
(A) Partial least squares discriminate analysis (PLS-DA) showing separation of lesion and
non-lesion bearing mice using the first two principal components (B) Cytokine covariation
based on class discrimination using cytokine targets as independent variables (X) and
pathological states (presence of absence of necrotic lesions) as the dependent dummy
variables (Y). (C) Variables in projection (VIPs) for the principle component 1, where
values >1 are have positive influence in discriminating between classes and VIP <1 have less
influence (D) Table representing the serum specific VIPs and their respective scores that
best discriminate necrotic from non-necrotic mice at 3 DPI
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Figure 2-9. Serum specific OPLS analysis of C rodentium infected animals at 3 DPI
OPLS analysis of C rodentium infected animals at 3 DPI using serum cytokines and
chemistries (X) for prediction of ALT levels (Y) (A) Mice segregated well in the
predictive component (Principle component 1) with an R2X (1) = 0.35, indicating
this component captured --35% of the variance present in the X variables. (B) The
predictive weight and covariation of serum targets (black triangles) in relation to
serum ALT (red square). (C) The variables that best separate the two pathological
states in relation to the predictive component (D) Variables in projection (VIPs) for
the predictive component where values >1 are have positive influence in
determining ALT levels, and VIP <1 have less predictive influence (E) Observed vs
predicted plot for ALT resulted in a R2= 0.989 2 indicating a highly predictive model
based on serum cytokines. (F) Table representing the VIPs for the predictive
component for serum ALT.
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Figure 2-10. Liver specific PLS-DA analysis of C. rodentium infected C57BL/6 mice at 3
DPI
(A) Partial least squares discriminate analysis (PLS-DA) showing separation of lesion and
non-lesion bearing mice using the first two principal components (B) Cytokine covariation
based on class discrimination using cytokine targets as independent variables (X) and
pathological states (presence of absence of necrotic lesions) as the dependent dummy
variables (Y). (C) Variables in projection (VIPs) for the principle component 1, where
values >1 are have positive influence in discriminating between classes and VIP <1 have less
influence (D) Table representing the serum specific VIPs and their respective scores that
best discriminate necrotic from non-necrotic mice at 3 DPI. The contribution of both
components was listed in this model.
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Figure 2-11. Liver specific OPLS analysis of C. rodentium infected animals at 3 DPI
OPLS analysis of C rodentium infected animals at 3 DPI using serum cytokines and
chemistries (X) for prediction of ALT levels (Y) (A) Mice segregated well in the predictive
component (Principle component 1) with an R2X (1) = 0.35, indicating this component
captured -35% of the variance present in the X variables. (B) The predictive weight and
covariation of serum targets (black triangles) in relation to serum ALT (red square). (C)
The variables that best separate the two pathological states in relation to the predictive
component (D) Variables in projection (VIPs) for the predictive component where values >1
are have positive influence in determining ALT levels, and VIP <1 have less predictive
influence (E) Observed vs predicted plot for ALT resulted in a R2 = 0.9892 indicating a
highly predictive model based on serum cytokines. (F) Table representing the VIPs for the
predictive component for serum ALT.
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Table 2-1. PLS-DA and OPLS component contributions to discrimination (R2 Y) and
variance (Q2) of necrosis at 3 DPI.
Both PLS-DA and OPLS models were utilized to interrogate serum features that best
discriminate between lesion-bearing and non-lesion bearing mice at 3 DPI. Model results
are indicated based on using serum or tissue targets s well as the combined models using
the top variables from each independent model.
R2 Y (cumulative)
0.789
0.957
0.987
0.842
0.923
0.980
0.441
-0.336
0.343
0.547
0.137
0.198
Q2 (cumulative)
0.441
0.385
0.596
0.547
0.684
0.882
PLS-DA: 3DPI
OPLS: 3DPI (ALT)
SModel Tp
R2Y R2 Y (cumulative) Q2 W (cumulative)
1 (P)
2(0)
3(0)
Combined
Component
1+2 (27 targets)
1+2 (13 targets)
P+(O) (26 Targets)
0.735
0.248
0.0154
0.783
0.208
0.0065
RaY
0.983
0.994
0.996
0.735
0.984
0.999
0.783
0.990
0.997
R2 Y (cumulative)
0.983
0.994
0.996
0.492
0.656
0.86
0.522
0.234
0.132
Q2
0.987
0.976
0.96
0.492
0.825
0.976
0.522
0.756
0.888
Q2 (cumulative)
0.917
0.976
0.96
PLS-DA: 3DPI
OPLS: 3DPI (ALT)
Model Type
PLS-DA: 3 DPI
PLS-DA: 3DPI
OPLS: 3 DPI (ALT)
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Serum Model
Component
1
2
3
1 (P)
2(0)
3(0)
R2Y
0.789
0.168
0.0299
0.842
0.0809
0.0563
Liver Model
Component
FM-odel Type
PLS-DA :3 DPI (necrosis)
Serum and Liver Combined
MIP-1a (L)
RANTES (S)
G-CSF (L)
G-CSF (S)
RANTES (L)
MIP-la S)
IL-6 (L)
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Figure 2-12. Most influential variables in serum and liver for PLS-DA (necrosis versus
no necrosis) and OPLS (ALT) models ranked by Variable in Projection (VIP) values.
Targets highlighted in white are those that were found influential in both serum and liver.
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Supplemental Figure 2-1. Serum chemistry changes in C57BL/6 mice inoculated with
C. rodentium.
Systemic parameters assessing liver function (ALT, AST, ALP, total bilirubin), kidney
function (creatinine, BUN, CPK) and electrolytes (Ca, Cl, Na, K) were measured at 0, 3, 7, and
14 DPI. (One-way ANOVA with Tukey's multiple comparison test: * p <0.05, ** p<0.01, *
p<0.001). Lines indicate group means.
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Supplemental Figure 2-2. Systemic cytokine and chemokine changes induced by C.
rodentium infection in C57BL/6 mice
Serum cytokines and chemokines were measured by quantitative multiplex analysis using
Luminex technology. (One-way ANOVA with Tukey's multiple comparison test: * p <0.05, **
p<0.01, *** p<0.001). Lines indicate group means (n= 5 to 6 animals per timepoint).
2-53
11111
11100-
1140
Says post Inoculation
9L-1a (L)I
Day, P222kOa. i2222
L-12 (PTO) (L)
Dy. P . c..o
IFN-g (L)
Days PON noculton
on". Pow k"Cu"Ma
is1
U:
on PotI-WM
L14 (L) ILA (4
f :VM
is2 , 2
2& .P. . : 0# 2ot L I
1L-13 (L)
Dj2 .P.22n
KC (L)
Days P.4t 42nocu1a2on
IL-17 (L)
D...1'nclain
MCP-, (L)
IL-1b (L) It-2 (L)
MIP-1a (L)
1
I- -:-
I I
2 2 22 2 2 22 22
DaySPOE 2.2.4*122. Day. P4*222o.1a24*n
* 3 7 14
Day Post inoe.an"
IL-10 (L)
DOys Po"2 k"Nloetn
"-C$F (LI
DVA
Day. POW* bww"~a
RAllIES (L)
am
31.
TIOF-. IL)
ft PamI4* tmo
Supplemental Figure 2-3. Liver cytokine and chemokine changes induced by C.
rodentium infection in C57BL/6 mice
Liver cytokines and chemokines were measured by quantitative multiplex analysis using
Luminex technology. Statistically significant changes as a group were only found for IL-1p
(L), MCP-1 (L), MIP-1a (L), and RANTES (L) (One-way ANOVA with Dunnett's multiple
comparison test comparing all columns to controls: * p <0.05, ** p<0.01, *** p<0.001). Lines
indicate group means (n=6 animal livers per timepoint).
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Supplemental Figure 2-4. PLS-DA analysis of 3 and 7 DPI animals.
Animals were assigned one of three classes; 1) 3DPI (no necrosis), 3 DPI (necrosis), and 7
DPI. Animal separation based on the first two principal components (A). Target
covariation using all serum target, liver targets, and histological scores (B).
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3.1 Introduction
Drug induced liver injury (DILI) is the leading cause of acute liver failure (AFL) in
the United States, characterized by low incidence, mechanisms independent of
therapeutic target, and is poorly predicted for in animal models. From a
pharmaceutical and clinical perspective, DILI is a major concern that can result in
last stage discontinuation of drug development, limit the use and distribution of
effective therapeutics, and even lead to market withdrawal [31]. Inflammation is
one host susceptibility factor contributing to DILI, evidenced by numerous knockout
studies and endotoxin-induced inflammation (LPS), demonstrating increased
predisposition to injury under immune dysregulation and inflammatory stress [6,
34, 71]. Immune mediators such as cytokines and chemokines are recognized pro-
and anti-inflammatory players involved in the progression and regression of DILI
and critical in mediating liver homeostasis and repair.
Acetaminophen (N-acetyl-para-aminophenol (APAP)) is a well-studied hepatotoxin,
responsible for approximately a third of cases related to DILI [38]. Toxicity is
dependent on cytochrome P450 bioactivation of parent molecule to a highly reactive
quinone imine (NAPQI), which under high doses depletes hepatic glutathione
resulting in protein adducts, with subsequent mitochondrial dysfunction, formation
of reactive oxygen species (ROS) and peroxynitrite, and eventual liver necrosis. This
process shows dependence on intracellular signal transduction of JNK, with
sustained activation promoting APAP-induced injury [106]. More recently, pattern
recognition receptors (PPR's) TLR9 and components of the inflammasome
(Nalp3)[63] implicate damage associated molecular patterns (DAMPs) such as
mitochondrial DNA from necrotic cells, as playing a role in APAP injury, with
potential for cross talk with Toll-like receptors (TLRs) and pattern associated
molecular patterns (PAMPs) such as LPS, which can also modulate susceptibility to
APAP [58, 62]. Furthermore, both innate [85, 107] and adaptive immune responses
can alter the susceptibility of APAP injury; moreover, APAP treatment alone can
induce levels of inflammatory mediators (ie cytokines and chemokines) both locally
and systemically [108]. Collectively, this all points to the importance of
inflammatory state in mitigating responses associated with APAP-induced liver
injury.
Citrobacter rodentium (C. rodentium) is an enteric bacterial pathogen that results in
varying degrees of intestinal inflammation, acute colitis, hyperplasia, and edema in
numerous strains of mice [74, 75]. As a human homolog of enteropathogenic
Escherichia coli (E. coli) and enterohemorarrhagic E. coli (EPEC and EHEC
respectively), C. rodentium has become a highly utilized animal model of these
human infections, providing a reproducible, robust, and physiologically relevant
model of inflammation. More recently, is has demonstrated organ specific effects
distal to the site of attachment and disease with alterations of phase I (cytochrome
P450s) and phase II (UGTs) metabolic enzymes in liver and kidney, as well as
increases in hepatic cytokine transcript [7, 8]; a time course of regulation that
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follows colonic inflammation and bacterial colonization, peaking at 7-10 days post
inoculation (DPI), and returning to normal by 15-24 DPI.
Previously, we observed C. rodentium-induced coagulative liver necrosis at 3 DPI,
paralleled by increased ALT and both serum and liver cytokine changes associated
with monocytes and neutrophils chemotaxis/activation as well a Th1 predominant
cytokine environment. Whereas, at 7 DPI, infection results in maximal systemic
cytokine induction and hepatic inflammation, correlating with peak bacterial load
with induction of Th17 environment characterized by serum IL-17, IL-6 and IL-1p(Chapter 2). As host inflammation and disease state have been implicated as a
susceptibility factors for DILI, we evaluated APAP-induced liver injury (200 mg/kg
IP) during early and peak stages of C. rodentium-induced inflammatory stress (3 and
7 DPI). Furthermore, we took a systems-level approach in determining the role of
pathogenic enteric infection on altering the response of DILI induced by APAP using
both linear (PLS-based) and non-linear dependent (mutual information)
computational approaches. These methods were applied to a multi-parameter data
compendium that included tissue-resident and circulating cytokine/chemokine
targets measured in multiplex, clinical serum chemistries, and pathological liver and
colonic assessments of inflammation and necrosis. Specifically, we evaluated
potential biomarkers and inflammatory signatures that correlate with the type(sterile (APAP) vs microbially-induced (C. rodentium)) and extent of liver damage
induced under inflammatory and drug-induced scenarios, furthermore, compared
them to standard biomarkers for hepatic injury such as serum ALT/AST.
Here, we demonstrate distinct signatures associated with both types of injury,
furthermore, modulation of inflammatory patterns when treatments were
superimposed. While moderate APAP protection was demonstrated at early stages
of C. rodentium infection (3 DPI), statistically significant increases in circulating ALT
and additive serum and tissue markers were observed at later time points
associated with an increased inflammatory state (7 DPI). This demonstrates a
dynamic interplay between sterile and microbial-induced injury and inflammation
with implications in understanding liver homeostasis under acute inflammatory
stress.
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3.2 Results
Experimental design
Based on previous studies, we evaluated APAP-induced liver injury during early and
peak stages of C. rodentium-induced inflammatory stress (3 and 7 DPI), timepoints
based on liver and serum cytokine and chemokine changes in this model. For the
remainder of the chapter we will use C. rodentium and Citro interchangeably when
describing study groups. The experimental design is presented in Figure 3-1.
Briefly, at day 0, 8-10 week old female C57BL/6 mice were infected with either C.
rodentium (~OA9 ) or sodium bicarbonate (vehicle control) by intragastric
inoculation. At 2 DPI, animals were fasted 14-16 hrs to uniformly deplete hepatic
glutathione stores, and delivered either vehicle (0.9% saline solution) or 200mg/kg
APAP solution delivered via intraperitoneal injection (IP) at an infusion volume of
lOOmL/kg. 24hrs after IP injection, animals were sacrificed and blood/tissues
harvested and processed for H&E (pathological assessment), serum and tissue
cytokines quantification using multiplex panels, serum chemistry analysis, and liver
total glutathione and serum total bile salts. The process was repeated for animals at
6 DPI. The resulting data compendium included over 4,500 data points and is
detailed in Table 3-1.
Histopathology of Citro, APAP, and APAP+Citro-induced liver inflammation
and injury
Upon examination of liver sections by H&E at 3 DPI, we observed C. rodentium-
infected animals (5/6) with periportal multi-focal coagulative necrosis,
accompanied with thrombi of injury primarily in the portal vein (Figure 3-2A,C)
(degree of necrosis, p-value = 0.026, Mann-Whitney compared to vehicle controls).
Necrotic regions contained hepatocytes with eosinophillic cytoplasms, appearance
of pyknotic or absent nuclei, and loss of normal cellular structure. C. rodentium
treatment alone resulted in a statistically significant increase in portal inflammation
(p<0.01), with a pattern of necrosis predominantly midzonal/periportal in
distribution (Figure 3-2B,D). We first reported this novel pathological finding in a
prospective study examining systemic and liver effects of C. rodentium in C57BL/6
mice at various stages of infection course. The incidence of necrotic liver lesions in
that study was 50% (Chapter 2). Although speculative, it is possible that fasting
may have increased the incidence in the current study. APAP treatment alone at 3
DPI resulted in liver necrosis with characteristic centrilobular injury, coupled with
elevations in lobular inflammation and significant increases in interface
inflammation, # of foci of inflammation, and hepatitis index (p<0.05, p<0.01, p<0.05
respectively) (Figure 3-2 A, B, and D). APAP+Citro livers at 3DPI, as least grossly,
appeared similar to APAP treatment alone and were comparable in inflammatory
categories scored (Figure 3-2 A-D), except for a decreased trend in periportal
inflammation.
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The degree of liver necrosis was corroborated by paralleled increases in the serum
liver transaminases alanine aminotransferase (ALT) (control = 34 ± 5.92, Citro =
178 ± 110, APAP = 5391 ± 6700, APAP+Citro = 1193 ± 1372 (mean (U/L) ± SD))
(Figure 3-2C). Surprisingly, at 3 DPI, superimposing a hepatotoxic dose of APAP on
Citro-induced liver injury and moderate hepatic inflammation did not result in an
additive or synergistic outcome, rather, demonstrated decreased levels of necrosis
and serum ALT, albeit just missing significance as a group (p = 0.083 for ALT, APAP
vs APAP+Citro (one-way ANOVA with Bonferroni post test)). When we
superimposed drug treatment at 7 DPI, however, we found a statistically significant
increase in circulating ALT levels (p<0.01, ANOVA with Tukey multiple comparison
test) with comparable degree of necrosis by pathological assessment between APAP
and APAP+Citro groups (Figure 3-4C). Pathological scores for categories of liver
inflammation were similar between APAP and APAP+Citro groups and comparable
to 3DPI, but due to the larger samples size at 7 DPI (n = 10-12 per group) reached
higher levels of statistical stringency (Figure 3-4B). Citro treatment alone at 7 DPI
did not induce serum ALT (control = 33.33 ± 6.08 vs Citro = 22.30 ± 4.67 (mean
(U/L) ± SD)) as it did at 3 DPI, however, there was a significant increase in portal
inflammation (p<0.01), hepatitis index (p<0.05), and increased regions of
inflammatory infiltrates (Figure 34A and B).
Multivariate analysis of serum and tissue markers associated with APAP and
Citro-induced liver injury and inflammation
As mentioned in our previous evaluation of C. rodentium induced liver changes
(Chapter 2), we found robust changes in both serum and liver cytokines at 3 and
7DPI in C57BL/6 mice, and using computational tools, determined variables highly
discriminatory for both liver pathological state (necrosis and inflammation) and
markers correlative for serum ALT. Analyzing data based on average responses can
result in an investigator missing important variables driving inter-animal
differences. Based on this, we decided to again take a multivariate computational
approach in determining features that covary best in our data compendium
leveraging its multiplex nature. PLS-DA (Partial Least Squares Discriminant
Analysis) was used to determine features with highest discriminatory power for
lesion-bearing animals and treatment conditions at 3 and 7 DPI, furthermore, to
distinguish features most strongly associated with microbial-induced (Citro) and
drug-induced (APAP) liver injury. Using OPLS (Orthogonormalized Partial Least
Squares Regression), we determine features that correlate best with serum ALT
(dependent variable (Y)), an established serum biomarker of liver necrosis, with
serum and tissue measurements (independent variables (X)). As serum is the most
easily accessible compartment for biomarker evaluation, we developed non-
invasive models (serum targets) and combined models (tissue & serum targets).
PLS-DA analysis at 3 and 7 DPI:
The effect of underlying C. rodentium infection on APAP-induced circulating ALT
varied at 3 and 7 DPI, furthermore, liver pathology associated with C. rodentium
infection is distinct at these two timepoints, prompting us to initially evaluate 3 and
7 DPI groups independently. Using PLA-DA, we used all tissue and serum targets in
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model generation, but paid particular attention to serum targets as they represent
the most accessible compartment for biomarker use. PLS-DA at 3 DPI resulted in an
expected separation of treatment groups with moderate overlap of animals in the
Citro and APAP+Citro groups (Figure 3-3 A). This could be attributable to certain
animals presenting a more dominant C. rodentium than APAP signature. The first
principle component (PC1, 27% of variance) was dominated by features that
separated best APAP-only treated animals and Citro infected groups, while the
second principal component (PC2, 11% of variance) appeared to capture best the
differences between Citro and APAP+Citro cohorts. The representative scores plot
shows covariation of targets responsible for class discrimination (Figure 3-3 B).
By highlighting animals in representative groups, we were able to generate
weighted score plots of the features driving class separation in the principal
component plane (Figure 3-3 C and D). Examining APAP vs Citro at 3 DPI (Figure
3-3 C), we find that APAP treated animals are dominant for IL-4 (L, S), IL-6 (L, S),
MCP-1 (L), TNF-cc (L), AST, and ALT levels, while Citro animals were discriminated
best by targets such as IL-1a (L, S), IL-1 (L), IL-10 (S), IL-12p40 (L), G-CSF (S), MIP-
la (L), and RANTES (L, S), IL-17 (CO), KC (CO). We repeated the analysis for APAP
vs APAP+Citro (Figure 3-3 D). Interesting, while ALT/AST, IL-4 (S) and IL-4 (L)
MCP-1 (L), were highly discriminate for APAP alone, they did not have much
importance in APAP+Citro; if these target were equally important between groups
its weighted score would be close to zero. The variable weight, however, did drop in
intensity, indicating potential attenuation under infection conditions. Indeed,
examining those targets independently by one-way ANOVA showed a significant
suppression of IL-4 in both liver and serum under conditions of Citro infection at
both timepoints (Figure 3-8 C) (APAP vs APAP+Citro (3DPI) = p<0.05, APAP vs
APAP+Citro (7 DPI) = p<0.001). These changes are in the context of observed
changes in ALT/AST with Citro infection (Figure 3-2 C). Furthermore, the
importance of IL-6 (S) was larger for APAP rather than APAP+Citro, and its relative
contribution compared to MCP-1 changed greatly at 3 DPI (Figure 3-3 C and D).
We also analyzed animals at 7 DPI by PLS-DA and obtained clear separation of
treatment groups and resultant scores plot for the principal component plane
(Figure 3-5 A and B). We obtained a similar pattern for IL-4, however this time, IL-
6 (L, S), MCP-1 (L), ALT and AST were better at discriminating APAP+Citro animals,
confirming our ANOVA results where animals treated with APAP under Citro
infection at 7 DPI had significantly elevated ALT levels (Figure 3-4 C). We also
noticed increased weight for targets IL-10 (L), IL-13 (L), and IFN- y (L) in APAP
treatment alone over APAP+Citro at 7 DPI, indicating that those cytokines were
down-regulated in the latter cohort (Figure 3-4 D). This demonstrates that both
APAP and Citro can induce cytokine and chemokine changes in numerous
compartments (liver, serum, colon), furthermore, that superimposition of APAP and
Citro results in cytokine changes that coincide with ALT changes.
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OPLS for ALT: Citro versus APAP-induced necrosis:
APAP-induced liver necrosis
We were curious if the features that predict serum ALT elevations were different
between drug-induced and pathogen-induced injury and utilized OPLS using serum
and tissue targets as independent (X) variables and ALT, a surrogate for liver
necrosis, as our dependent (Y) variable. OPLS analysis using all normal and APAP-
only treated animals at both timepoints (3 and 7 DPI) resulted in good separation of
animals in the predictive component and a strong R2 = 0.9611 for ALT (Figure 3-6 A
& E). Some of the targets that correlate best with ALT were total serum bile acids,
pathologically scored degree of necrosis, MCP-1 (L, S), IL-4 (L, S), and KC (L, S) and
glucose. These features had some of the highest VIPs (>1) listed for both liver and
serum-specific targets (Figure 3-6 D). MCP-1 is one cytokine that has consistently
demonstrates high correlation with severity of APAP injury clinically [109]. Hepatic
levels of MCP-1 are greatly increased during acute liver inflammation, and CCR2/
(MCP-1 receptor) mice are markedly more sensitive to the hepatotoxic effects of
APAP [84]. MCP-1 has also been associated with late monocytes recruitment in
APAP injury [56, 83].
Citro-induced liver necrosis
As ALT increases were only detectable in C. rodentium treated animals at 3 DPI, we
developed an OPLS model to determine features that correlate best with circulating
ALT at this time point, providing correlates of microbial-mediated liver injury. OPLS
analysis resulted in separation along the predictive axis with cytokines
superimposed on the predictive plane, generating a model with an R2 = 0.7446 using
the predictive component and one orthogonormalized rotation (Figure 3-7 A, B,
and E). Variables with the highest VIP include targets associated with neutrophils
chemotaxis and activation (G-CSF (L, S) and KC (L, S)), monocytes /macrophage
activation and chemotaxis (MCP-1 (L, S), MIP-1b (L, S)), Th1 cytokines (IL-la/3 (L),
IL-12p40 (L), RANTES (L)), and immunomodulatory targets (IL-10 (S)). This is in
line and confirms previous target associations with Citro-induced liver injury
(Chapter 2). While there is clear overlap of targets between APAP and Citro-
induced liver injury, differences are apparent. Mainly, total bile acids, MCP-1, and
KC are correlated with ALT in both types of injury, indicating potentially a shared
response to necrosis or liver injury in general. For APAP-alone, however, IL-4
appears to play a much larger role in predicting ALT than in Citro-induced liver
injury, where RANTES, G-CSF, IL-la/s, and IL-10 are more dominant. Furthermore,
relative to APAP treatment, the induction of ALT was minor in Citro treated animals
at 3 DPI, however, the induction of G-CSF and IL-10, and MCP-1 was far more robust
in comparison, with G-CSF (S) and IL-10 (S) showing higher correlation for ALT in
Citro-induced than APAP-induced necrosis (Figure 3-8 A and B).
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Affinity Propagation, Network Diagrams, and Mutual Information
While PLS-based modeling is a powerful tool for determining linear relationships in
large datasets, occasionally, biological targets are not linear in their behavior due to
negative feedback and context-dependent responses. Furthermore, our data set
contains numerous values below the range of our standard curve, especially for
control animals, as well as groups that may show no variance (such as some
pathological scores) for certain treatment conditions. PLS accommodates such
cases by excluding or interpolating their contribution and importance to the model.
PLS is also sensitive to outliers (common with animals data), and VIP-score-based
model reduction is not maximally insightful; resulting in numerous PLS planes to
digest where target redundancy is difficult to determine.
Mutual information uses a general framework of variable dependence. The method
involves initially discretizing data into optimal levels of separation (quantile
discretization), converting continuous data into discrete counterparts. This helps
accommodate measurement values below the detectable range to be set as the
lowest discretization level while values above the detectable range are set to the
highest (See methods for detailed description). Unlike PLS-based modeling,
mutual information makes no assumptions about linear variable dependence,
thereby allowing more diverse detection of functional relationship [110],
furthermore, is amenable to missing or out of range data and outliers, and provides
calculated dependence between categorical labels (ie pathology) and numerical
values (ie. cytokine target) using permutation methods to determine statistical
significance. For our dataset, we discretized our measurements into optimal levels
for comparison between treatment classes. The one caveat with mutual information
is that class membership must be set a priori in developing the model. In our case,
we determined 6 discrete classes based on pathological endpoints and treatment
groups; 1) Control, 2) APAP only (3 and 7 dpi combined) 3) Citro 3 DPI (necrotic
lesions+ALT elevations) 4) APAP+Citro 3 DPI, 5) Citro 7 DPI (no obvious lesions or
ALT elevations), and 6) APAP+Citro 7 DPI.
Given the size of the current data set, we wanted to generate visualizations that best
represent the architecture of interactions and dependencies in our data
compendium. We first generated a correlation-based matrix using affinity
propagation, a robust clustering algorithms that minimizes the error involved in
cluster generation compared to other methods. We determined measurement vs
measurement correlations as well as measurement vs animal correlations for the
purpose of visualizing the overall structure of our dataset (Supplemental Figures
3-1 and 3-2). This resulted in clear clusters of treatment conditions as and targets
associated with scored pathological endpoints (APAP treatment). For the purpose
of visualizing connectivity, we next generated network interaction diagrams using
mutual information and ANOVA correlations (p-value 0.001) for both 3 DPI and
7DPI timepoints based on our 6 treatment classes (Supplemental Figures 3-4 and
3-5). Navigating such a complex web of interactions can be difficult, furthermore, if
one is interested in a specific target and its interaction partners, we encoded the
ability to highlight target sub-networks using MatLab (Example highlighting IL-1p
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(L) interactions at 3 DPI, Supplemental Figure 3-6). Deciphering causality from
such visualizations is not necessarily possible due to the nature of our data set;
however, affinity propagation and network diagrams help present features of our
data that covary with one another, as well as specific treatment groups and
pathologies making our data amenable to inferring relationships. Furthermore,
such visualizations and network diagrams provide associations across the data
compendium at a quick glance; which is not easily obtained using PLS-based
methods, where digesting multiple principal component planes is necessary.
Mutual information with Liver Pathologies
We first harnessed mutual information to show dependence of our quantitative
measurements (tissue and serum cytokines, chemistries etc) with pathological
endpoints for liver inflammation and necrosis, but also wanted to find targets able
to differentiate between our 6 classes of treatment conditions. Using permutation
testing, we incorporated a statistical test to determine those features most
significant in their ability to predict pathological states and treatment class from our
multivariate dataset. The targets that resulted are presented in a heatmap based on
their correlation with the specified treatment class and a subset evaluated by one-
way ANOVA (Figure 3-9 A and B). We then used these targets and generated a
correlation based heat map for liver pathologies, as well as a mutual information
heat map colored by Logio p-value for each target association (Figure 3-10 A and
B). Targets that demonstrate very high mutual information for general degree of
necrosis include ALT, AST, IL-4 (S, L), total cholesterol, and MCP-1 (L), MIP-1b (S),
and all of these also demonstrate high correlation for degree of necrosis except for
IL-4 (S, L). If we examine the pathological manifestations of portal vein thrombi,
some of the targets that demonstrate high mutual information and correlation
include MCP-1 (S, L), a target that correlated well with both APAP-induced and
Citro-induced liver injury by OPLS. MCP-1 is a major target involved in monocyte
chemotaxis and activation; furthermore, monocytes are a major source of tissue
factor (TF), a key component in thrombin formation. Others have also correlated TF
and MCP-1 with liver necrosis and markers of graft rejection [111].
One key advantage of this approach is that targets that demonstrate little to no
correlation but have high mutual information for a particular pathology indicate a
potential non-linear relationship. This is exemplified by liver and serum IL-4 levels,
which show extremely high mutual information for degree of necrosis, but very little
correlation for liver necrosis across the data set (Figure 3-10 A and B). Indeed, IL-
4 levels were highly induced in animals treated with APAP alone, and paralleled
levels of ALT, however, at 7DPI, APAP+Citro animals had significantly elevated ALT
elevated compared to APAP alone, but IL-4 levels were attenuated greatly (Figure
3-9 A and B). This could indicate that IL-4's potential role in hepatic injury may be
dependent on the cytokine environment. Indeed IL-4 has been implicated as both
protective and deleterious with respect to hepatic inflammation and injury in
various models. For example, IL-4 promotes hepatitis after concanavalin-A (ConA)
treatment, but is protective against damage associated with ischemia/reperfusion
(I/R) [112, 113]. One could imagine that under an already induce inflammatory
3-65
state, associated with neutrophils accumulation and activation (ex high KC, G-CSF),
that additional IL-4 could further augment both of these processes, resulting in
undesirable collateral damage. Furthermore, IL-4 has been associated with DILI in
the case of dicloxicillin-induced hepatic injury, where neutralization of IL-4 in mice
was hepatoprotective [114]. And more recently, duel roles for IL-4 have been
proposed in the pathogenesis of immune-mediated DILI; including 1) suppressing
auto-antigen-induced regulatory responses and 2) promoting hapten-induced pro-
inflammatory responses [115]. Clearly, continued study into the role of IL-4 in DILI
is warranted, particularly in its role in both innate and adaptive function in liver
homeostasis.
Fibrosis associated signature with C. rodentium (3DPI):
Affinity propagation demonstrated strong correlation with the occurrence of portal
vein thrombi in animals expressing elevated IL-la (L), IL-13 (L), IL-12(p40) (L),
RANTES (L), and MIP-1a (L) at 3DPI (Supplemental Figure 3-1). These animals
also presented with coagulative necrosis resulting from C. rodentium infection at
this early time point based on observed ALT increases and pathological assessment.
Three of these targets demonstrated high mutual information for liver pathology
and correlated highly with Citro 3 DPI. Under conditions of APAP treatment at this
timepoint, however, these targets (RANTES (L), IL-1a (L), IL-12p40 (L))
demonstrate down-regulation (Figure 3-9 A and B). While IL-1 (L) missed
statistical significance based on mutual information, it can still be evaluated in its
ANOVA-based sub-network and shows correlation in this pathological finding
(Supplemental Figure 3-4 A and B). These targets are associated with Th1-
mediated response, whereas IL-4 is a prototypical Th2 cytokine. Based on this,
there appears to be a neutralization of these two T helper cell polarizing cytokine
subtypes in the APAP+Citro case at 3 DPI.
C. rodentium infection at 7 DPI aggravates APAP-induced liver injury
Based on the mutual information heat map, there also appeared targets associated
with APAP+Citro treatment (7 DPI) that had dependences for liver pathology and
discriminatory across all treatment classes. Such targets appeared to be down-
regulated (MCP-1 (S), IL-4 (L, S) or up-regulated in this treatment group (KC (L), G-
CSF (S, L), and IL-17 (CO), bile acids, and cholesterol) compared to APAP alone or
APAP+Citro at 3 DPI. Peak bacterial colonization and infection with C. rodentium is
associated with a characteristic Th17 response, characterized by elevations in
colonic and systemic IL-17 [94]. The role of IL-17 has been recently examined in the
context in liver injury and in a ConA model of hepatitis; IL-17 plays a role in
modifying Nf-KB mediated responses in a STAT3 dependent manner [116]. Using
mutiplex assays for colonic cytokines, we found robust induction of IL-13, IL-6, KC,
IL-17, G-CSF, targets that show high covariation and cluster by affinity propagation
(Supplemental Figures 3-2 and 3-2). KC in particular appeared to demonstrate
synergy at 7 DPI as Citro alone was unable to induce levels, but APAP+Citro resulted
in robust responses that resulted in statistical significance when APAP treatment
alone did not (Figure 3-9 B).
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3.3 Discussion
Most animal models of DILI involve exposure to extremely high levels of chemical
stress with subsequent expression changes of cytokines such as TNFa, HMGB-1, IL-
6, IL-10 and IL-10, potentially misrepresentative of the majority of cases of liver
injury observed clinically [117-119]. Here we investigated moderately hepatotoxic
doses of APAP in the presence and absence of physiological acute stress induced by
gastrointestinal infection with C. rodentium in C57BL/6 mice, an animal model of E.
coli infection and IBD in humans. Using computational approaches such as PLS
based modeling and mutual information, we present unique cytokine signatures
associated with APAP-induced and microbially-induced liver necrosis, furthermore,
altered cytokine patterns under superimposition of drug treatment and enteric
infection.
C. rodentium infection at 3DPI was moderately protective against APAP-induced
liver injury, correlating with decreased serum and liver cytokines (IL-4, IL-6), liver
transaminases (ALT, AST), and histological disease scores as well as elevations in
MCP-1 (S), MIP-1b (L), G-CSF (L, S), and IL-10 (S). At 7 DPI, however, superimposing
pathogenic enteric infection augmented APAP-induced liver injury characterized by
elevated ALT, correlating with decreased IL-4 (L, S), IL-6, and increased levels of G-
CSF (L, S) and KC (L, S), and IL-17 (S, CO). It is important to note that despite the
association between greatly elevated ALT levels and hepatocellular diseases, the
absolute height of the ALT elevation does not necessarily correlate with the extent
of liver cell damage [118]. Thus altered ALT levels under infection conditions could
also be attributable to altered kinetics of injury potentially slowing or accelerating
progression or recovery. Future work following individual animals over time prior
to and after 24hrs-post APAP treatment seems warranted in this regard.
The role of anti-inflammatory cytokines has been investigated in fasted transgenic
C57BL/6 mice lacking targets such as IL-4, IL-6, IL-10, IL-13, and MIF, dosed with a
comparable levels of APAP (200-300 mg/kg, IP), and demonstrate increased
susceptibility to APAP-induced liver injury [48-50, 55]. These data suggest a
hepatoprotective role for anti-inflammatory mediators and that the balance
between the Th1 and Th2 responses is an important determinant for APAP-induced
liver injury. Indeed, here we demonstrate an induction of circulating IL-1a/@, IL-4,
IL-6, IL-10, RANTES, IL-12(p40), G-CSF, KC, MCP-1, in animals harboring C.
rodentium-induced necrotic lesions at 3DPI, indicating that microbially-induced
hepatic injury 'primed' the liver, making it less susceptible to injury with APAP
treatment. It is also possible that up-regulating protective factors prior to APAP
administration allowed for faster resolution of APAP-induced necrosis, possibly
altering the signaling landscape and attenuating the extent of liver necrosis. Follow
up study measuring liver signaling states would help support this. C. rodentium is
known to activate Thl/Th17 responses in various strains of mice, potentially
skewing the systemic balance of cytokines and altering the extent of APAP damage.
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Indeed, strain susceptibility has been investigated; demonstrating C57B/6 mice are
more sensitive to APAP-induced liver injury than BALB/c mice, which are
characteristically Th2 in their response to treatment compared to their C57BL/6
counterpart [120]. However, the study in question did not examine the role of an
already activated and Thl/Thl7-skewed environment prior to dosing as
investigated here. Furthermore, we evaluated this cytokine environment at early
and late stages of enteric infection, under conditions of moderate liver injury and
inflammation. Our findings, however, do agree with proposed protection of a Th2
response at late stages of C. rodentium infection, but not at earlier timepoints where
the already induced liver injury (Th1 cytokines, neutrophils, monocytes, and T-cell
related cytokines and chemokines) appeared to tolerate or prime the liver to
subsequent insult with APAP and seemed to play a more important role than the
Th2 response initiated by APAP treatment alone.
Sterile inflammation with APAP
Inflammatory responses are critical for eradication of pathogens, but also necessary
for tissue and wound repair. Like microbially-induced inflammation, sterile
inflammation is characterized by neutrophil and macrophage recruitment coupled
with production of pro-inflammatory cytokines and chemokines (Recently reviewed
[21]. If in excess or unchecked, however, inflammatory responses can aggravate
existing injury. For example, exaggerated neutrophil recruitment and activation in
response to sterile inflammatory stimuli contributes to the immunopathology of
numerous diseases, such as autoimmunity, DILI, ischemia-reperfusion (I/R), trauma,
and others [63, 107, 121-123]. APAP treatment alone resulted in significant
elevations in IL-4 (L, S), IL-6 (L, S), KC (L, S), and MCP-1 (L, S) (Figures 3-3, 3-5, 3-
9). Interestingly, some of the most highly specific targets up-regulated by APAP
treatment include IL-4 and IL-5, Th2 cytokines involved in allergic responses and
eosinophil activation. Indeed, APAP treatment has gained increased attention for
potentially predisposing individuals to allergic responses, especially children [124].
At both 3 and 7 DPI, C. rodentium significantly down-regulated IL-4 (L, S) levels
induced by APAP (Figure 3-8 C, Figure 3-9 A and B). IL-4 is key in cytokine
involved in differentiation of naive helper T-cells (ThO) into Th2 cells. Some of IL-
4's other functions include eosinophil activation, neutrophils migration and
activation, as well as class switching in B-cells and inducing MHC-II production. The
presence of circulating IL-10 and G-CSF were paralleled with lower levels of IL-4 in
livers and serum at 3 DPI and 7 DPI, indicating that the cytokine environment
induced by C. rodentium may have affected the signaling network, attenuating
secretion of IL-4. This is in line with evidence that IL-10 inhibits the secretion of IL-
4 in peripheral blood monocytes and neutrophils [125]. IL-4 secretion in
neutrophils has also been demonstrated in APAP-induced liver injury, and IL-4 has
been shown to induce leukocyte migration (monocytes and neutrophils) to sites of
inflammation in other disease models, preceded by inflammatory cytokines such as
MCP-1 [126]. Indeed, IL-4 and MCP-1 expression in APAP treatment alone was
highly correlated but was lost under conditions of C. rodentium infection (APAP: R2=
0.75; APAP+Citro 3 DPI: R2= 0.17, APAP+Citro 7 DPI: R2 = 012) (Figure 3-8 D).
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Others have shown that MCP-1 can directly enhance synthesis of IL-4 by T cells
[127, 128]. More recently, IL-4 was also shown to up-regulate MCP-1 production in
vascular endothelium through NADPH-oxidase-mediated ROS production [129,
130]. Regardless of the direct relationship, MCP-1 is also critical in mediating Th2
polarization and proper trafficking of T-cells in addition to its role as a monocyte
chemoattractant. Hepatic levels of MCP-1 are also greatly increased during acute
liver inflammation, and CCR2+ (MCP-1 receptor) mice are markedly more sensitive
to hepatotoxic effects of APAP compared to WT mice [84]. MCP-1 has also been
associated with late monocytes recruitment in APAP injury [56, 83], and, clinically,
MCP-1 is highly associated with APAP injury, especially at levels >1000 IU/L [109].
Functionally, the elevated levels of IL-10 and moderate protection observed at 3DPI
as a result of Citro infection, is in line with IL-10's established hepatoprotective role
in APAP-induced injury. IL-10 limits inducible nitric oxide synthase (iNOS)
expression and peroxynitrite-induced liver injury after APAP overdose and IL-10 KO
animals are more sensitive to APAP [49]. Based on the KO studies it appears that IL-
10 in conjunction with IL-4 is required for proper balance of IL-6 responses. This
was demonstrated in IL-10+/IL-4 / double knockout mice, which are extremely
sensitivity to APAP, attributable to unchecked levels of IL-6 [55]. In APAP-induced
liver injury (300 mg/kg i.p), IL-6 knockout results in sustained serum AST
elevations at 48 hrs, and did not normalize until 72 hrs; findings coupled with
higher levels of MCP-1 and MIP-2 in the liver [131]. Collectively, it appears that IL-4,
in conjunction with IL-10, plays a critical role in mediating proper expression of IL-6
and MCP-1, necessary for proper resolution of APAP-induced injury.
Microbially-induced liver injury with C. rodentium
Pathogens of the gastrointestinal tract can have hepatic manifestations, as we have
demonstrated in Chapter 2, but the mechanisms involved in establishing hepatic
injury and disease secondary to enteric infection remains poorly understood.
Recently, severe necrotizing hepatitis has been observed in IL-10 KO mice infected
orally with Trichinella spiralis, an enteric parasite [132]. IL-10 in this model was
critical in mediating trafficking of intestinally derived CD4+ T-cells, and determined
the primary source of IL-4 in this model. Furthermore, sequestration of activated
neutrophils was shown dependent on IL-4, and while neutrophils depletion
alleviated necrosis, they were not required for initiation of injury. This example
demonstrates the importance of the enterohepatic cytokine balance for appropriate
hepatic immune function. Serum IL-10 is robustly induced in C. rodentium-infected
animals at 3 DPI and associated with our microbially-induced coagulative necrosis.
As a regulatory cytokine, IL-10 exerts influence on numerous immunological
activities such as antigen presentation and cytokine production, furthermore is
involved in the initiation and maintenance of inflammation [133]. Interestingly, in
this study we also confirmed a previous finding that C. rodentium-induced necrosis
induces both serum and liver RANTES, a chemokine responsible for T-cell
activation. RANTES failed to show induction in APAP-induced liver injury and
indicates a biomarker for differentiating between drug-induced (sterile) and
microbially-induced liver injury. RANTES correlates poorly with ALT levels in Citro-
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induced injury, but is a good discriminator for the presence of lesions, demonstrated
by high correlation and mutual information with lesion bearing animals and
correlation with portal inflammation (Figure 3-9 and Figure 3-10 B,
Supplemental Figures 3-1). Other targets that showed preference in Citro-induced
injury include IL-la/3 (L, S), IL-12p40 (L, S). Via TLR4, LPS has been shown to
activate type 1 (early, ie IL-la/p, RANTES) and type 2 cytokine production (late, ie
IL-4) both in vitro and in vivo in macrophages from C3H/HeJ or C3H/HeOuJ mice
[134]. IL-4 production, a prototypical type 2 cytokine, requires both MyD88 and
TRAM (adapter molecules) for its secretion 48 hrs after LPS stimulation. If LPS
mediated injury with C. rodentium at 3 DPI, it would explain the cytokine
environment, furthermore, potentially explain the neutralization of Thl/Th2
responses under conditions of APAP+Citro treatment at 3 DPI. It is possible that the
regulatory state induced by an LPS sets in place a regulatory network less capable of
inducing IL-4 secretion.
While animals at 7 DPI did not demonstrate clear pathological necrotic lesions and
failed to induce serum transaminases, their remained a state of hepatic
inflammation (see liver pathology Figure 3-4) with elevations of serum, liver, and
colonic cytokines. The contribution of significantly increased circulating levels for
IL-17 at 7 DPI implicates colon as the source, with colonic cytokine levels increasing
-10 and 228-fold (average FC at 3 and 7 DPI respectively vs. controls) in animals
treated with Citrobacter, while IL-17 levels in the liver were decreased at 7 DPI.
This hints at a potential mechanism for down-regulation of hepatic cytokine
expression under peak colonic inflammation and infection. It has also been
documented that IL-17 production in myeloid cells (ie macrophages) is induced by
IL-6 and suppressed by IL-10 [116], indicating that perhaps early IL-10 induction
with Citro infection acts to limit the response of Th17 cells. At 7 DPI, however,
circulating IL-17 levels are higher and additive with APAP treatment, correlating
with increased ALT when the two were superimposed. Others have also shown a
dependence of Th17 responses for recruitment of Th1 cells to inflamed or injured
tissues.
Altered cytokine responses under APAP+Citro superimposition
There are numerous factors that could explain the altered cytokine environment
under APAP+Citro conditions, specifically the observed neutralization of Thl/Th2
responses as well as changes in neutrophils and monocytes targets. Transcription
factors such as STAT 1, STAT3, STAT6, AP-1, and Nf-KB are key mediators of
inflammatory processes. The role of Nf-KB on APAP-induced liver injury has been
investigated, and the loss of functional p50 subunit of NF-KB is associated with
decreased ability of APAP to up-regulate TNF-a, KC, and IL-10 expression and
increased expression of IL-4 and TGF-p, however, gross changes in APAP-induced
injury were not observed [135]. This argues that Nf-iB function alone may not fully
explain changes in susceptibility to APAP-induced liver injury associated with
various inflammatory mediators, however, does not discount the potential for
susceptibility in combination with other transcriptional regulators listed above.
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Interestingly, in our study, there were significant changes in IL-10, IL-4, KC, and to
some degree TNF-a, which points to altered function of Nf-KB under Citro-induced
injury and inflammation. LPS, is a component of C. rodentium's cellular wall, and a
known inducer of Nf-KB transcriptional activity. The role of LPS in APAP-induced
liver injury has been examined. LPS pretreatment of male C3H/OuJ mice 24hr prior
to APAP treatment (400mg/kg) affords protection but not in male C3H/HeJ (TLR4
deficient), furthermore, protection was mimicked with pretreatment with IL-1a in
both strains [58], a cytokine that we see induced with C. rodentium in liver, serum
and colon (Figure 3-3 and 3-5) but failed to reach significance by mutual
information in discriminating all 6 classes but was found to have significant
correlations as presented in its total and sub-networks (Supplemental Figures 3-3,
3-4, and 3-5). IL-1a is one of the first effector pro-inflammatory cytokines released
upon exposure to LPS by various cell types. LPS binding protein (LPB) KO mice also
show protection to APAP-induced liver injury, and a recently used LPB inhibitory
peptide demonstrated protection against APAP-induced hepatotoxicity in C57BL/6
mice [59, 60]. LPB is known to assist binding of LPS to receptors CD14 [61] and
TLR4/MD2, promoting inflammatory cytokine production. While the effect of LPS
delivery 24 prior to APAP has been shown protective, potentially via suppression of
CYPs associated with APAP bioactivation, however, a distinctly different local and
systemic cytokine profile than may be experienced with APAP delivery 2 hrs-post
LPS [62], where LPS pretreatment moved the dose response curve to the left,
sensitizing animals to injury. This argues in favor of a temporal dependence of LPS,
and inflammatory regulators associated with bacterial host response, in mediating
hepatic protection of susceptibility to drug-induced injury. Similarly, at two
different timepoints of Citro-induced liver injury and of host-pathogen interactions
we have two distinct outcomes with APAP treatment in this study.
An acute viral hepatitis model recently showed protection to APAP-induced liver
injury characterized by decreased APAP-protein adducts and serum ALT. The
authors demonstrated no effect on liver total glutathione, however, attributed
protection to decreased bioactivation of APAP->NAPQI as mRNA levels of CYP2E1
and CYP1A2 were decreased 3 days post viral infection [136]. We have evaluated
the effect of Citro infection at 7 DPI on APAP drug exposure (Chapter 4) and do not
see changes in parent drug exposure due to infection; furthermore, others have
demonstrated that Citro does not alter hepatic mRNA levels of murine CYP2E1, the
primary CYP responsible for APAP bioactivation [8]. This argues that changes in ALT
levels with Citrobacter infection are likely not attributable to alterations in APAP
metabolism or clearance. What is unclear is whether early infection with C.
rodentium results in gastrointestinal damage, resulting in the release of DAMPs into
portal circulation. Future work would look to measure systemic (or portal)
concentrations of known DAMPs such HSPs, HMGB1 etc. The early necrotic lesions
may very well be a consequence of both PAMPs (LPS, bacterial products) as well as
DAMPs released during early gastrointestinal infections and resultant epithelial
damage promoting leakage into portal circulation. Furthermore, examination of
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livers at early timepoints would be insightful as to the signaling mechanisms and
temporal kinetics of injury under microbially-induced liver injury and inflammation.
Recently, a detailed demonstration of how intravascular danger signals guide
neutrophils to sites of sterile inflammation was presented [137]. While the authors
induced hepatic necrosis by means of localized thermal injury, the host response to
the injury may well translate to drug-induced necrosis seen with APAP. In their
model, adenosine triphosphate (ATP) from necrotic cells activated the Nlrp3
inflammasome generating an inflammatory microenvironment (up-regulation of
ICAM-1) alerting circulating neutrophils to adhere within liver sinusoids.
Subsequent generation of an intravascular chemokine gradient (targets such as MIP-
2 and KC) directed neutrophil migration through healthy tissue toward foci of
damage. Lastly, formyl-peptide signals released from necrotic cells guided
neutrophils through nonperfused sinusoids into the site of injury, overriding the
signals from chemokines to reach areas of sterile tissue necrosis. The authors
describe this as a potential method to avoid collateral damage of healthy tissue
during sterile inflammation. Furthermore, it has recently been demonstrated that
APAP treatment in mice results in release of DAMPs such as heat shock protein 70
(HSP70) and high mobility group box-1 (HMGB1) [138]. In our investigation, we
saw an up-regulation in numerous neutrophil and monocytes/macrophage
associated targets (KC, MCP-1, MIP-la/b). Moreover, chemokine balance appears
important in mediating APAP severity, as CCR2 KO (MCP-1 receptor) exacerbates
injury [83, 84] while CXCR2 KO (KC and MIP-2 receptor) is protective [52]. C.
rodentium infection may provide a physiologically relevant model for the
interrogating the role of PAMPs and DAMPs and cytokine/chemokine balance under
sterile inflammatory stimuli associated with APAP-treatment.
Mutual information
C. rodentium induced a characteristic signature with direct mutual information for
liver pathological states which included IL-12(p40) (L), RANTES (L), and IL-la (L) ,
which demonstrated attenuation under co-exposure with APAP at 3 PDI and
captures as significant using mutual information (Figure 3-9). IL-12p40 production
occurs via activation of inflammatory cells, which includes macrophages,
neutrophils, microglia and dendritic cells (DCs) upon stimulating by a various
inflammatory and pathogenic agents (like LPS) [139, 140]. As a homodimer (IL-
12p8O), it is known to act as a chemoattractant for macrophages [141, 142] and
more recently shown to initiate dendritic cell (DC) migration from the lung to
draining lymph nodes in mice challenged with pathogenic mycobacteria. Several
other groups have proposed a role for IL-12p40 in fibrosis. Similarly, we have both
IL-12p40 in liver and serum upregulated in animals harboring portal venular fibrin
thrombi (Affinity Heatmap, Supplemental Figure 3-2). It is interesting to note
that under APAP treatment at this timepoint, levels of these targets decreased
significantly, attributable potentially to IL-4, a Th2 cytokine that can attenuate Th1
responses (Figure 3-9). Furthermore, the occurrence of portal vein thrombi was
decreased under APAP treatment as well as portal inflammation (missed
significance). In other models, IL-4 has been associated with balancing
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inflammatory processes as well as modulating tissue factor expression and
synthesis in monocytes, a key component for thrombin formation. Given the extent
of injury under superimposition of drug and infections, it is difficult to determine
whether APAP treatment alleviated C. rodentium induced periportal necrosis,
however, there was clearly a down regulation of targets associated with such lesions
in Citro only animals and decreased ALT at 3 DPI. Modulating levels of RANTES, IL-
la/P and IL-12p40 may be useful in subsequent experiments to determine their
role in mediating microbial-induced liver injury in this model.
Mutual information also highlighted IL-17 (CO) as significantly associated with
treatment classes and liver pathology, and C. rodentium has previously been shown
to induce both circulating and colonic elevations at 14 DPI [91, 94]. Activated liver-
infiltrating IL-17- producing T helper (Th17) cells are also responsible for
neutrophil recruitment into the liver [143]. Furthermore, serum IL-17 levels are
increased and serve as a marker of the severity of acute hepatic injury [144]. Here
we noticed increased levels of IL-17 in serum and likely attributable to colonic or
circulating cells as liver lysates failed to show statistically significant increases.
Furthermore, 7DPI was elevated for serum, liver, and colonic G-CSF and KC, two
neutrophil-associated targets. While IL-17 levels in the liver were lower in Citro and
APAP+Citro treated animals at 7 DPI in this study, it is possible that the robust Th17
response in the colon (and serum) may have acted to down regulate expression in
peripheral tissues or created a systemic cytokine/chemokine environment
promoting hepatic inflammation or injury. Similarly, we also saw decreased levels
of IL-13, IFN- y, and IL-10 in liver at 7 DPI for Citro and APAP+Citro animals, targets
believed protective in APAP-induced injury and may have contributed to
significantly higher ALT levels at this timepoint. The role of IL-17 has been recently
examined in the context in liver injury and in a ConA model of hepatitis; IL-17 plays
a role in modifying Nf-KB mediated responses in a STAT3 dependent manner [116].
Furthermore, increased systemic or liver IL-4 levels (albeit attenuated under Citro
superimposition) in conjunction with circulating IL-17 may have potentiated
neutrophils accumulation and activation in livers at 7 DPI in APAP+Citro treated
mice in combination with higher G-CSF and KC levels.
Conclusions and Future Work
Inflammatory responses can be both protective and predispose the host to APAP-
induced liver injury illustrated by numerous KO models and pharmacological
inhibition of immune modulators. In our model of acute inflammatory stress, APAP
did not synergize with extrahepatic inflammation induced by C. rodentium infection,
rather demonstrated moderate protection during the early course of enteric
infection while statistically increased serum ALT levels at 7 DPI. We attribute this to
an already induced Thl/Th17 response by C. rodentium, which we have recently
documented (Chapter 2) and shown here to induce coagulative necrosis, primarily
periportal in distribution early in the infection kinetics. Under co-exposure, the
tissue and systemic cytokines levels appear to indicate Thl/Th2 neutralization, as
the usual Th2 promoting targets (IL-4 (S, L)) associated with APAP treatment and
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Th1 targets with C. rodentium (IL-12p40 (L), RANTES (L), IL-a/b (L)) demonstrated
attenuated levels as compared to single treatment alone. This can be at least in part
attributed to the induction of IL-10, with known immunomodulatory effects on T
cell polarization with C. rodentium and the anti Th1 effects of IL-4 resulting from
APAP treatment. Future work would focus on neutralizing some of the targets
obtained in this analysis such as IL-10 to address it role in Citrobacter-induced liver
injury at 3 DPI, as well as the role in mediating altered signaling states under
superimposition with APAP treatment. Cytokines are known signaling molecules in
signal transduction pathways, and we previously observed signaling alterations in
liver STAT1, STAT3 and IKBa phosphorylation under Citro infection (Chapter 2,
Appendix Chapter B), important mediators of cytokine signaling and immune
responses. Measuring a limited number of intracellular signaling states may help to
clarify mechanisms driving altered liver response and changes in T-cell polarizing
targets observed here.
We also demonstrate the utility of using multiple computational approaches for
interrogating signaling networks in large multi-parameter data sets. Specifically,
PLS based methods for correlation determination for a specific target of interest
such as ALT, with assumptions of linear dependence, which is useful towards
biomarker discovery. We also utilized affinity propagation, a specialized clustering
algorithm for visualization of correlations across the entire data set and outlier
determination. And finally, in a novel fashion used a hybrid approach harnessing
both mutual information and correlation based methods in tandem to create a
network architecture that helped us evaluate measured targets with pathological
endpoints with a specified number of classes. This method allows statistical
evaluation of correlation and dependencies, furthermore, presents data for global
and target selective interrogation of interactions using sub-networks.
In summary, we show that drug-induced and microbially-induced liver injury and
inflammation have distinct and shared features, furthermore that enterohepatic
cytokine balance is involved in mediating appropriate hepatic immune function and
responses to both drug and infection-induced insult. Altering the cytokine milieu
with Citro infection was associated with moderate protection from APAP-induced
liver injury 3 DPI, attributable to induced anti-inflammatory mediators such as IL-
10 and monocytes chemokines MCP-1 and MIP-1b, however, aggravated injury at 7
DPI correlated with significant elevations in KC and G-CSF and serum IL-17. C.
rodentium alters APAP-induced cytokine changes, attenuating a Th2 response with
demonstrated down-regulation of IL-4 at both early and late stages of infection.
Furthermore, we propose non-linear dynamics for IL-4 with respect to liver injury
response, indicating its role in hepatic homeostasis may be context dependent.
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3.4 Selected methods
Media and Bacterial Strains
Luria-Bertani (LB) agar and broth (Difco Laboratories, Detroit, MI) was used for
cultivation of bacteria. MacConkey lactose agar (Difco Laboratories) supplemented
with 40 pg/ml of kanamycin was used for quantitative monitoring of bacterial
counts in fecal samples. The kanamycin-resistant strain of C. rodentium strain,
DBS120 (pCRP1:Tn5, Kanr) [145] was used for all infections.
Animal Housing and Bacterial Infections
Female 8-10 week old C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) mice
were housed six per microisolator cage in a specific pathogen-free facility approved
by the Association for Assessment and Accreditation of Laboratory Animal Care.
Animals were maintained on pelleted rodent chow (LabDiet, Purina Mills, Inc.,
Richmond, IN) and water ad libitum and allowed to acclimate one week prior to
experimentation. Infectious colitis was induced by intragastric inoculation with -1
x 109 CFU of DBS120 in 3% sodium bicarbonate (w/v in 1X phosphate buffered
saline (PBS), pH 7.4), 1OOuL volume as described previously [145], while the
uninoculated control groups received 100uL of 3% sodium bicarbonate vehicle.
Infection kinetics was monitored by fecal shedding determined by plating serial 10
dilutions of fecal slurries (10% [w/v] in 1X PBS, pH 7.4) on LB agar with selection
for kanamycin. The Massachusetts Institute of Technology Committee on Animal
Care approved all animal experiments prior to investigation.
Fasting and Acetaminophen delivery
Animals were fasted 14-16 hrs to uniformly deplete glutathione stores prior to
delivery of either vehicle (0.9% saline solution) or 200mg/kg Acetaminophen
(APAP) (Sigma-Adrich, St. Louis, MO) solution delivered via intraperitoneal injection
(I.P.) at an infusion volume of lOOmL/kg. APAP solution was made fresh for each
experiment at 20mg/mL in 0.9% sterile saline (Pheonix Labs) and heated to 55*C in
a water bath to dissolve. Animals were sacrificed by C02 asphyxiation 24 hours post
IP injection. At necropsy, tissues were immediately flash frozen in liquid nitrogen
and stored at -80 for subsequent analysis. Blood was collected via terminal cardiac
puncture using a 30-gauge needle and transferred to serum separator tubes (Benton
Dickinson (BD), Franklin Lakes, NJ), allowed to clot for 30minutes at room
temperature, and processed by centrifugation at 8,000 rpm for 10minutes at 4*C.
Serum was transferred to a clean eppendorf tube and frozen to -80C until needed
for serum chemistry, serum cytokine/chemokine analysis, and total bile acid
determination.
Body Weights and Fecal Shedding
Animals weights were monitored every 2-3 days post inoculation with C. rodentium
or vehicle delivery and at necropsy. Animals losing >20% of initial body weight
were euthanized and excluded from subsequent analysis.
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Multiplex Detection of Serum Cytokines and Chemokines:
Mouse serum collected at necropsy was processed using mouse 23-plex cytokine
panels (Bio-Rad, Hercules, CA) as specified by the manufacturer. Briefly, serum was
diluted in species-specific sample diluent (1:4) and 50uL of sample or premixed
standards were incubated with pre-washed target capture antibody-conjugated
microspheres provided and incubated for 30 minutes with orbital shaking (300
rpm) in a 96-well plate. Upon washing, beads were incubated with detection
antibody (30 min), washed, and subsequently incubated with streptavidin-PE (10
min). Beads were washed and resuspended with 125uL assay buffer and read on
the Luminex 200 suspension array system using the low RP1 target setting (High
PMT) for maximum sensitivity. Data analysis was carried out with the Bio-Plex
ManagerTM 5.0 software and cytokine or chemokine concentrations calculated
against an 8 point standard curve generated by either 4PL or 5PL curve fitting.
Multiplex Detection of Tissue Cytokines and Chemokines
Colon and livers were thawed on ice and -30-50 mg of tissue was briefly washed
with 500uL ice-cold cell wash buffer (Bio-Rad, Hercules, CA). Tissues were then
transferred to a clean pre-weighed eppendorf tube and resuspended 12X the tissue
weight with cell lysis buffer (Bio-Rad, Hercules, CA). Tissues were homogenized on
ice for 1 minute with a Tissue TearorT ' and subsequently frozen to -80*C overnight.
Tissues were then thawed on ice and sonicated on level 5 with 5 short (-3 sec)
bursts. Upon sonication, lysates were centrifuged for 10 minutes (5,000 rpm, 4'C).
Resultant supernatant was carefully removed, protein quantified by BCA protein
assay (Thermo Scientific, Rockford, IL), and adjusted to lug/uL with 1X PBS + 0.5%
BSA (w/v). 50uL of adjusted lysate was subsequently loaded on to a Mouse Group I:
23-Plex panel (Bio-Rad, Hercules, CA) and standards resuspended in the
appropriate matrix. Samples were subsequently processed as specified above for
serum cytokines and chemokines analysis using the Bio-Plex array system and
software manager.
Clinical Chemistries
Serum samples were thawed on ice and diluted 1:4 in water and processed on an
Olympus AU 400e serum chemistry analyzer (Beckman Coulter, Inc., Brea, CA) for
18 serum chemistry targets. All samples were run against internal standards and
machine calibrated prior to use as specified by the manufacturer. Calcium levels
were adjusted to albumin using the following equation: Adjusted CA = (3.5-
Albumin) + non-adjusted CA.
Detection of Total Liver Glutathione
40-60 mg of liver was thawed on ice and transferred to a clean pre-weighed
eppendorf tube. 5% 5-Sulfosalycylic acid (in ddH20, w/v) was added at 5X the liver
wet weight and homogenized for one minute with a Tissue TearorT " (Biospec
Products, Inc., Bartlesville, OK), and lysate subsequently frozen at -80'C overnight.
Upon thawing at room temperature, lysates were cleared by centrifugation at 8,000
x g for 10 minutes and transferred to a clean eppendorf tube. Supernatant was then
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diluted 1:20 in ddH20 and analyzed for total glutathione (Dojindo Molecule
Technologies, Rockville, MD) by monitoring the absorbance of 405nm on a
spectrophotometer (Molecular Probes, Sunnyvale, CA) after 10 minutes of
incubation at room temperature as specified by the manufacturer. Total
glutathione concentration in liver samples was calculated against a glutathione 8-
point standard curve using the pseudo-endpoint method and converted to
mM/gram tissue.
Total Bile Acids Detection
Serum samples were diluted 1:4 in distilled water and processed using the total bile
acids assay kit (BioQuant, San Diego, CA) as specified by the manufacturer. Briefly,
the formation of formazan dye was monitored measuring the absorbance at 540nm
using a spectrophotometer (Molecular Probes, Sunnyvale, CA). Absorbance was
measured at time zero and after 10 minutes of incubation at 37*C. Total serum bile
acids were determined by calculating the ((AAs 40 Sample/(AAs40 Standard))*
Standard (36.1uM/L). All measurements were conducted in duplicate.
Histology and Pathology Scores
At necropsy, blood, fecal, and tissue samples were collected. Distal colon (-0.5 cm)
and the left lateral lobe of the liver were snap-frozen in liquid nitrogen and stored at
-80*C until needed for protein isolation for western blot and Luminex
cytokine/chemokine detection. The remaining colon and liver was fixed in 10%
formalin, paraffin embedded, sectioned at 5 pim, and stained with hematoxylin and
eosin (H&E), and submitted to a board-certified veterinary pathologist blinded to
experimental treatment groups. Colonic tissue sections were scored on a scale of 0
to 4 (0, no lesion; 1, minimal; 2, mild; 3, moderate; and 4, severe) for the categories
of inflammation, edema, hyperplasia, dysplasia, and epithelial defects. The sum of
all five categorical scores (maximum of 20) resulted in the histological colitis index.
Livers were assessed for both inflammatory and necrotic parameters. Degree of
hepatic inflammation was graded on a scale from 0 to 4 based on region (lobular,
portal, and interface), and the number of lobes with greater than 5 inflammatory
foci was noted. The summation of these scores resulted in a hepatitis index; mice
with a score > 4 were defined as having hepatitis. A modified scoring criterion was
developed to define the extent, degree, and pattern of liver necrosis. The degree of
necrosis was scored from 0 to 4 and the pattern of injury was evaluated as
centrilobular, midzonal, or periportal in nature (# = low, ## = medium, ### = high).
The distribution of necrosis was evaluated as follows: 0- none, 1 - focal, 2 -
multifocal, 3 - translobular, 4 - submassive, involving multiple lobules or entire lobe.
Statistical Analysis:
Statistical significance in body weight change, bacterial load, disease indices,
cytokine changes, clinical chemistries, and by comparing control or experimental
groups by either student's T-test or by two-way analysis of variance (ANOVA)
followed by Bonferroni if group sample sizes were equal or Tukey's post tests if
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sample sizes were not equal. Data that demonstrated non-normal distributions or
categorical in nature (ex. pathology scores) were assessed by Kruskal-Wallis non-
parametric test with Dunn's multiple comparison test against controls unless
otherwise indicated. If only two groups were analyzed, Mann Whitney was utilized
for non-parametric data. All analyses were done with GraphPad Prism software,
version 4.0 and P values of <0.05 were considered significant.
PCA and PLSR Analysis
Data was mean centered, variance scaled, logio transformed, and analyzed by
multivariate analysis using SIMCA-P 11.5 software (Umetrics Inc., Kinnelon, New
Jersey). Values that were out of range for the assay were set as missing values. PCA
analysis was used to reduce the dimensionality of the data set and to assess linear
covariation of variance across measured targets. PLS-DA analysis was used to
determine the features that best differentiated between selected groups of animals
designated as classes (ex. mice harboring necrosis vs non-harboring mice). OPLS
analysis was used to determine the features that best correlated with a desired Y
variable, such as ALT levels or degree of necrosis/hepatitis, resulting in variable
importance in the projection (VIP). VIPs greater >1 were considered significant in
their contribution to the model predicting the dependent variable (Y) of interest.
Model quality was assessed and reported using the following parameters: R2 Y, the
fraction of the sum of squares of all Y variables explained by the component of the
model, and R2 Y cumulative, the cumulative sum of squares of all Y variables
explained by all components of the model. Q2 is the fraction of the total variation in
Y variables that can be predicted by the component, and Q2 cumulative is the
cumulative Q2 of the Y variables for all components in the model. An R2 cumulative
and Q2 cumulative of 1 indicate a perfect fit, with 100% of the relationship between
X variables and Y variables explained.
Affinity Propagation and Heat Map Generation
In order to visualize the underlying structures in the data in a heat map, we ordered
the data by clustering in both the measurement and the mouse dimensions. Because
the dataset contained diverse measurements on incongruent scales, we first mean-
centered and variance-scaled each measurement vector. These "z-score" scaled
measurement vectors were clustered using the affinity propagation algorithm [146]
with a correlation distance metric. To further order the measurements within a
cluster, we used hierarchical clustering. Next, the data matrix was clustered in the
mouse dimension using the same approach.
Heatmap analysis enabled data quality control and outlier detection. As many of the
mice clustered by treatment group, we were able to see that measurements
discriminated treatments in an unsupervised manner. We were also able to
visualize the measurements that best defined treatment classes.
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Mutual Information to detect relationships between measurements, treatment
conditions, and pathophysiology
Mutual information is a metric that allows the detection of dependence
relationships. Unlike other measures (like PLS-based modeling), mutual information
makes no assumptions about linear variable dependence, thereby allowing more diverse
detection of functional relationship. Using 3 and 7 DPI data (7 DPI repeat was
excluded for validation), our data was discretized using quantile discretization,
resulting in optimum levels, essentially converting continuous data to a non-
parametric form based on variation between the 6 designated treatment classes.
Once the data was in non-parametric form, it was analyzed using MatLab generating
mutual information metric determining the interactions that best separated the
treatment groups with a required stringency p-value < 0.001. All measurements
were analyzed against each other as well as animals resulting in pairwise
interactions. We also generated network diagrams using ANOVA correlations with a
minimum p-value stringency of 0.001 and organized using Kamada algorithm for
optimal separation of targets.
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3.5 Figures and Tables
C. rodentium
n=6
2 3 411'Fast
APAP IP
or
saline
6 7 8
Fast
APAP IP
or
saline
APAP = 200mg/kg IP -> Mild Necrosis * Necropsy
Figure 3-1. Experimental design evaluating APAP-induced liver injury under C.
rodentium-induced inflammatory stress.
At time 0 DPI, 12 female, 8-10 week old C57BL/6 mice were delivered -109 colony forming
units of C. rodentium while 12 received 3% sodium bicarbonate (vehicle). The evening prior
to dosing, animals were fasted for 14-16 hrs depleting glutathione stores and delivered
APAP (200mg/kg, IP) or saline (vehicle). Both 3 and 7 DPI were evaluated with an n=6 for
each condition and 24 animals per timepoint. We evaluated the 7DPI timepoint in two
separate experiments, yielding an n=12 per condition at 7 DPI in some of our analysis.
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Figure 3-2. C rodentium and APAP-induced liver lesions evaluated by H&E at 3 DPI
(A) C rodentium treated animals presented periportal coagulative necrosis as previously
reported. APAP (200mg/kg) treated animals demonstrate characteristic pattern of
centrilobular necrosis. APAP+Citro treated livers look very similar to APAP alone. (B)
Pathological assessment of liver sections based on lobular inflammation, portal
inflammation, interface inflammation, and the number of lobes with greater than 5
inflammatory foci. The total score for each categorical measure of inflammation was
summed resulting in the hepatitis index. Animals with a hepatitis index greater than 4 are
considered positive for hepatitis. (C) The degree of necrosis and matched serum ALT (U/L).
(D) The pattern of necrosis was assessed as centrilobular, midzonal, or periportal in
distribution. (Kruskal-Wallis with Dunn's post test compared to controls: for all pathological
scores; One-way AN OVA with Bonferroni post tests for ALT (log transformed). * p <0.05, **
p<0.01, ** p<0.001). Symbols indicate individual animals and lines indicate group means
(n = 6 for all treatment conditions).
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Figure 3-3. PLS-DA analysis at 3 DPI:
(A) PLS-DA analysis was used to determine optimal discrimination of animals based on the
targets measured at 3 DPI. Individual mice are presented and colored based on treatment
condition. (B) Scores plot for tissue and serum targets. (C) Variable weights discriminating
APAP vs Citro treated animals at 3 DPI. Animals were highlighted and those features that
best discriminate between APAP and Citro treatment are represented by green bars, with
strength indicated by length of bar. (D) Differences between APAP and APAP+Citro
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Figure 3-4. C. rodentium and APAP-induced liver H&E and inflammation at 7 DPI
(A) Representative H&E liver sections of controls, animals treated with APAP (200mg/kg,
ip) treated animals demonstrating characteristic pattern of centrilobular necrosis, Citro
alone, and APAP+Citro at 7 DPL # indicates region of inflammatory foci (B) Pathological
assessment of liver sections based on lobular inflammation, portal inflammation, interface
inflammation, and the number of lobes with greater than 5 inflammatory foci. The total
score for each categorical measure of inflammation was summed resulting in the hepatitis
index. Animals with a hepatitis index greater than 4 are considered positive for hepatitis.
(C) The degree of necrosis and matched serum ALT (U/L). Animals treated with Citrobacter
alone did not demonstrate elevations in serum ALT, while APAP+Citro showed a statistically
significant increase at 7 DPI (D) The pattern of necrosis was assessed as centrilobular,
midzonal, or periportal in distribution. (Kruskal-Wallis with Dunn's post test compared to
controls: for all pathological scores; One-way ANOVA with Tukey post tests for ALT (log
transformed). * p<0.05, ** p<0.01, *** p<0.001; ## indicates p<0.01 compared to non-Citro
counterpart). Symbols indicate individual animals and lines indicate group means (n = 10-
12 for all treatment conditions).
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Figure 3-5. PLS-DA analysis at 7DPI
(A) PLS-DA analysis was used to determine optimal discrimination of animals based on the
targets measured at 7 DPI. Individual mice are presented and colored based on treatment
condition. (B) Scores plot for tissue and serum targets (C) Variable weights discriminating
APAP vs Citro treated animals at 7DPI. Animals were highlighted and those features that
best discriminate between APAP and Citro treatment are represented by green bars. (D)
Differences between APAP and APAP+Citro. For 7 DPI, animals were pooled for analysis
resulting in treatment groups of 10-12 animals.
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Figure 3-6. OPLS results for prediction of ALT levels for all APAP treated mice.
OPLS analysis of APAP (200mg/kg, ip) treated animals using serum/liver cytokines and
chemistries (X) for prediction of ALT levels (Y) (A) Mice segregated well in the predictive
component (Principle component 1) with an R2X (1) = 0.28, indicating this component
captured -28% of the variance present in the X variables. (B) The predictive weight and
covariation of serum and liver targets (black triangles) in relation to serum ALT (red
square). (C) Variables in projection (VIPs) for the predictive component where values >1
are have positive influence in determining ALT levels, and VIP <1 are less predictive. Serum
targets were separated from the combined models for ease of viewing (D) Table
representing the VIPs for the predictive component for serum ALT. (E) Observed vs
predicted plot for ALT resulted in a R2 = 0.9611 with only one predictive and one
orthogonal rotation indicating a highly predictive model based on serum and liver targets.
3-86
A.
.GLUC
- -- Control,
4 Citro
2
.0 I .1110 106 lS 1
.09;WA 0S
-12 -10 4 4 A. 4- 0 2 4 6 1 10 12
C Printipad opnn lrdeie
k' Nal 1 .1 
E
Control
Citro
.lu']%) .100 I G(W t
-K900 .4. OL) a
4.1 0.0 01 0.2
w ct1)P
Tissue & Serum
1.61072
1.55464
1.50951
1.47421
1.47384
1.46602
1.42881
1.42704
NEI
1.40483
1.35231
1.33784
1.28142
1.22744
1.21454
1.167
1.18329
1.17253
1.16106
1.09892
1.07288
1.0638
1I04523
Serum
1.55464
1.50959
1.47427
1.35231
1. 3378
1.28142
1.22744
1.1873
1.18329
1. 6109
1.0 98921.07285
1.06382
1.04129
100 200 300
Prediaed AL T (5.0t)
Figure 3-7. OPLS model for prediction of ALT levels for Citro (3DPI) treated mice
OPLS analysis of Citro (3 DPI) treated animals using serum/liver cytokines and chemistries
(X) for prediction of ALT levels (Y) (A) Mice segregated well in the predictive component
(Principle component 1) with an R2X (1) = 0.35, indicating this component captured -35%
of the variance present in the X variables. (B) The predictive weight and covariation of
serum and liver targets (black triangles) in relation to serum ALT (red square). (C)
Variables in projection (VIPs) for the predictive component where values >1 are have
positive influence in determining ALT levels, and VIP <1 are less predictive. Serum targets
were separated from the combined models for ease of viewing (D) Table representing the
VIPs for the predictive component for serum ALT. (E) Observed vs predicted plot for ALT
resulted in a R2 = 0.7446 with only one predictive and one orthogonal rotation.
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Figure 3-8. Cytokine changes at 3 and 7 DPI with high ALT correlation for Citro or
APAP alone.
(A) Cytokine changes at for G-CSF (S) and IL-10 (S), two targets demonstrating higher VIP
for Citro-induced necrosis at 3 DPI than APAP treatment alone. (B) G-CSF and IL-10 both
demonstrate high correlation for ALT and associated with higher circulations at a given
level of ALT (C) Serum and Liver IL-4 levels demonstrate down-regulation under conditions
of Citro infection. (D) IL-4 is highly correlated with MCP-1 in both liver and serum;
however, association is lost under conditions of Citro infection at both 3 and 7 DI.
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Figure 3-9. Correlations and Mutual information of targets for liver pathologies.
(A) Correlation and mutual information heatmap for targets able to discriminate
across our 4 treatment/pathological classes with significance p-value of 50.001.
Dark red indicates high positive correlation with specific treatment condition, dark
blue indicated negative correlation, and white indicates neutral (B) Individual
animals plotted across 6 determined treatment classes. Significance determined by
one-way ANOVA with Tukey's post test (* p <0.05, ** p<0.01, *** p<0.001 compared
to controls; # p<0.05, ## p<0.01 compared to non-Citro or timepoint counterpart).
Lines indicate group means.
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Figure 3-10. Mutual information and correlation maps for liver inflammation and
necrosis.
(A) Targets able to discriminate between treatment classes were further analyzed to
determine their mutual information for liver pathologies across multiple
inflammatory and necrotic parameters. White = high mutual information, black = no
mutual information (B) The same targets were analyzed for their respective
correlation for liver inflammation and necrosis where white indicates strong
positive correlation and black indicates strong negative correlation.
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Table 3-1. Data compendium including animal numbers and measurements
collected.
Animals were excluded from analysis for the following reasons:
1 animals (Citro 7 DPI) was morbid and sacrificed prior to necropsy, while another had lost
-20% of its initial body weight and was excluded from analysis. For the purpose of
classification using Mutual Information, 3 APAP-only animals were excluded as they
demonstrated less that 2-fold induction of ALT or AST and failed to induce pathological
scores in necrosis. Targets were removed from analysis if they were not detectable in at
least 5 or more animals or if they failed all three of the following statistical tests: 1) 6-way
ANOVA for variance across classification groups with Benjamini-Hochberg multiple
hypothesis correction 2) 2-Tailed T-test (unequal varience) between Control and all
treatments combined 3) Homogeneity of variance between control and treatments.
CONTROL 6 6 4 Serum Cytokines 22 Quantitative
Liver Cytokines 20 Quantitative
APAP 6 4 5
Colon Cytokines 17 Quantitative
CITRO 6 6 4 Serum Chemistries 13 Quantitative
Other Liver Markers 2 QuantitativeAPAP+CITRO 6 6 6 (Bile Acids, GSH)
Liver Necrosis 7 Pathology
TOTAL 24 22 19 Non-parametric
ANIMALS Liver Inflammation 5 Pathology
Non-Parametric
Colon Inflammation 6 Pathology
65 (animals) X 76 (targets) =Non-Parametric
Cecum Inflammation 6 Pathology
Non-Parametric4,940 data points TOTALTARGETS 76
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Supplemental Figure 3-1. Affinity propagation clustering of all measurements
All targets measured were analyzed by affinity propagation clustering algorithm, a
correlation based technique. High target correlation is indicated by dark red where 1 =
perfect positive correlation. Dark blue indicates negative correlation where -1 equals
perfect negative correlations between two targets. Clusters indicate target covariation with
inferred association with pathologies such as colitis induction with C. rodentium infection
(ie, cluster of colon specific targets in middle of figure indicate Citro-induced Th17 response
with covariation of targets such IL-17 (CO), IL-6 (CO), IL-10 (CO), and neutrophils-related
targets such as KC (CO) and G-CSF (CO).
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Supplemental Figure 3-2. Animals and measurements clustered by affinity
propagation using Z-score values.
All targets and animals were clustered by affinity propagation clustering algorithm using z-
score (correlation distance). This allows viewing the weight of the measurement for that
particular animal across all targets measured in relation to other animals. High correlation
distance (Red) indicated a z-score of >2=indicating high expression compared to the rest of
animal measurements. Negative z-scores (Blue) indicate expression levels below the
average of all animal measurements. (Con = control, A = APAP, C = Citro, AC = APAP+Citro, r
= repeat, and 3 and 7 DPI are indicated).
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Supplemental Figure 3-3. Mutual information and correlation network at 3 DPI.
A target interaction network (3 DPI interactions) based on mutual information and ANOVA
correlations is presented using the Kamada plane for optimal separation. We assumed 6
discrete classes of treatments/pathological states in generating target selection for this
network. Green lines indicate significant positive correlation whereas red lines indicate
significant negative correlation between targets, solid purple lines indicate significant
ANOVA correlations for treatment class, and dotted purple lines indicate significant mutual
information between targets.
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Supplemental Figure 3-4. Mutual information and correlation network at 7 DPI.
A target interaction network (7 DPI interactions) based on mutual information and ANOVA
correlations is presented using the Kamada plane for optimal separation. We assumed 6
discrete classes of treatments/pathological states in generating target selection for this
network. Green lines indicate positive correlation whereas red lines indicate significant
negative correlation between targets, solid purple lines indicate significant ANOVA
correlations for all six treatment class, and dotted purple lines indicate significant mutual
information between targets.
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Supplemental Figure 3-5. Sub-network diagram highlighting interactions for liver IL-
10.
(A) In the sub-network, IL-1 (L) demonstrates significant positive correlation to
the presence and number or portal vein thrombi, IL-1a (L), IL-12p40 (S, L), MIP-la
(L), MIP-1b (S, L), (ANOVA correlation, green lines), and has significant mutual
information with G-CSF (L), MCP-1 (CO), RANTES (L) and colonic inflammation
(dotted purple line) but does not significantly discriminate for treatment class.
Mutual information does not capture the relationship (seen by ANOVA) between
treatment class and IL-1p (L) and demonstrates the utility of using both techniques
in evaluating complex data interactions and architecture. (B) Sub-network
interactions graphed for correlation coefficient for IL-10 (L) vs IL-12p40 (L) (top)
and IL-10 (L) vs MIP-1b (L) for APAP treatment alone, Citro 3DPI and Citro 7DPI as
examples. Citro at 3 DPI had the highest correlation at a timepoint/condition where
portal vein thrombi were most prevalent and associated with coagulative periportal
necrosis.
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4.1 Introduction
Drug induced liver injury (DILI) is the leading cause of acute liver failure (ALF) in
the United States, characterized by low incidence, mechanisms independent of
therapeutic target, and is poorly predicted for in currently available animal models.
From a pharmaceutical and clinical perspective, DILI is a major concern as it can
result in last stage discontinuation of drug development, limit use and distribution
of effective therapeutics, or even lead to marketplace withdrawal [31].
Inflammation is one host susceptibility factor contributing to idiosyncratic liver
injury[36], as evidenced by numerous knockout studies and endotoxin-induced
inflammation (LPS), demonstrating predisposition to injury under immune
dysregulation and inflammatory stress [6, 34].
One contributing factor for DILI may be alterations in drug pharmacokinetics (PK)
and metabolite profile under inflammatory conditions. Alterations in drug
clearance and exposure levels have recently been attributed to LPS [147] and
inflammatory disease states such as arthritis. Indeed, a rat animal model of
adjuvant arthritis (AA) is currently used in the industrial setting as a proxy for
human drug clearance alterations in the rheumatoid arthritis (RA) disease setting
[148]. Inflammation and GI infection with Citrobacter rodentium, a murine-specific
enteric pathogen analogous to Escherichia coli (E. coli) infection in humans, has been
shown to alter the expression of numerous phase I/I metabolic enzymes, necessary
for biotransformation and clearance of xenobiotics [7, 8]. The effect of C. rodentium
on altering cytochrome p450s (CYPs) specifically has been shown to be independent
of TLR4 engagement, with C. rodentium's profile of hepatic mRNA CYP450 regulation
distinct from those found with the LPS model [8, 77], with cytokine dependent
changes associated with both IL-6 and IFN-y knockout (KO) animals in this infection
model [149].
Functional studies, however, have not been conducted demonstrating altered PK
and metabolic drug profile under the disease setting of gastrointestinal infection. C.
rodentium infection in mice provides a reproducible, robust, and physiologically
relevant model of inflammation [74] amenable to investigating potential xenobiotic
biotransformation and PK differences under human disease settings such as
inflammatory bowel disease (IBD), infectious colitis, and pathogenic gastrointestinal
infections. Here we evaluated the effect of non-toxic doses of drugs varying in
degree of biotransformation and mode of elimination using C. rodentium as a source
of systemic inflammation. We evaluated propranolol (Inderal@) (high clearance
substrate), digoxin (P-glycoprotein (Ppg) substrate), fexofenadine (Allegra@)
(organic-anion transporting polypeptide (OATP) substrate, minimal metabolism),
acetaminophen (2E1 substrate, Tylenol®), which demonstrates moderate
cytochrome p450 mediated clearance, verapamil (3A4 and Pgp substrate) by oral
delivery (PO) delivery at 7 days post infection (DPI).
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4.2 Results
Acetaminophen and fexofenadine exposure is unchanged by infection with C.
rodentium
Acetaminophen (APAP) is a commonly used antipyretic and analgesic that
demonstrates relatively low clearance in human and mice. Under normal liver
conditions, -90% of APAP is metabolized to non-toxic conjugated metabolites
APAP-glucuronide and APAP-sulfate with -10% metabolized by cytochrome P450
oxidation (CYP 2E1, 3A4, and to a lesser extent 1A2) to form N-acetyl-p-
benzoquinoemine (NAPQI), a highly reactive intermediate [39]. Detoxification of
NAPQI normally proceeds by conjugation with intracellular glutathione, either
spontaneously or catalyzed by glutathione-s-transferase (GST), the majority of
which is excreted into bile via multidrug resistance-associated protein (Mrp2) [40].
APAP was delivered PO at 5mg/kg in the presence and absence of C. rodentium
infection at 7DPI and plasma processed by LC/MS/MS for detection of parent drug
levels (Figure 4-1). Both control and C. rodentium infected animals demonstrated
similar Tmax, Cmax, and area under the curve (AUC) (Table 4-1), indicating no
difference in oral exposure of APAP under conditions of enteric bacterial infection.
This is in line with findings by Richardson et al, where mRNA levels of 2E1 in mouse
kidney and liver were unchanged with C. rodentium infection at both 7 and 10 DPI
[8], furthermore, neither IL-6 or IFN-y deficiency alters CYP2E1 expression under C.
rodentium infection at 7 DPI [149]. In Chapter 3 we evaluated the role of enteric
infection on APAP hepatotoxicity, and while infection at 7 DPI increased circulating
levels of ALT, this is unlikely due to changes in systemic exposure.
We also tested fexofenadine, which demonstrates minimal metabolism and
moderate clearance (-40-50% Qh). Fexofenadine is primarily excreted as parent
compound by renal clearance in humans, but biliary elimination contributes
significantly in mouse. Although fexofenadine has been identified as a Pgp substrate
in vitro using CACO-2 cells [150], MDR1 polymorphism in fexofenadine disposition
is not clearly established [151]. In mice, for example, mdrla/1b KO does not alter
biliary clearance but results in 6-fold higher plasma exposure and 3-fold higher
brain exposure [152]. Fexofenadine is also an OATP1B1/1B3/2B1 substrate, and
OATP1B1 polymorphism affects clearance and AUC, where OATP1B3 is thought to
be the main uptake transporter[153]. PO delivery of fexofenadine under conditions
of C. rodentium-induced inflammatory stress resulted in a shorter Tmax as
compared to uninfected animals (0.08 vs 0.5 hrs respectively) and a higher cMAX
(120 vs 45 ng/mL); however, AUC was comparable between infected and non-
infected groups (139 vs 132 hr*ng/mL respectively) (Figure 4-2 and Table 4-1).
Increased oral exposure for propranolol and digoxin
Propranolol demonstrates high clearance in human and mouse (>75% Qh). The
major drug metabolizing enzymes include 2D6 (4-hydroxypropranolol), 1A2 (N-
desisopropyl), and UGT; however, polymorphism has not been shown to have an
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effect on propranolol pharmacokinetics. We evaluated propranolol at 10mg/kg and
observed an approximate 1.6 and 1.65-fold increase in Cmax and AUC respectively
(Figure 4-3 B and C) under infection conditions. Our initial evaluation of
propranolol at 5mg/kg resulted in a 2.25-fold increase in AUC; however, due to
variability in a few timepoints we repeated at 10mg/kg with comparable results.
Digoxin (Lanoxin@) is a commonly used drug for congestive heart failure, and
follows first order kinetics with approximately 50-70% of the dose excreted
unchanged in urine, while 25-28% is found in feces via biliary excretion. A small
fraction of the drug is metabolized (-16%) resulting in metabolites 3-beta-
digoxingenin, 3-keto-digoxigenin and their glucuronide and sulfate conjugates, none
of which demonstrate biologically activity [154]. It is also a known Pgp
substrate[155], and MDR1 polymorphism- has been linked to altered oral
availability[156, 157]. Under conditions of C. rodentium infection, digoxin dosed at
1mg/kg demonstrated moderate increases in exposure with 1.24 and 1.36-fold
increases in Cmax and AUC respectively. While the changes are moderate, they
indicate a significant difference between control and inflammatory conditions.
Increased oral exposure of verapamil and its metabolites
Verapamil, a 3A4 substrate, was evaluated as previous work demonstrated 3A11
(homologue of human 3A4) was decreased in hepatic mRNA expression (16% of
normal levels) in mice at 7 DPI with C. rodentium [8, 77]. 3A4 is the most abundant
P450 isoform, partially due to the enzymes broad substrate specificity [158], and is
associated with biotransformation of approximately half of therapeutics drugs used
by humans today [159]. Infection with C. rodentium resulted in approximately a 2-
fold increase in oral availability of verapamil compared to vehicle controls (AUC =
657 vs 353) with a delayed Tmax (Figure 4-4). The changes found with verapamil
were the greatest of the compounds tested herein. In order to determine if the
increased levels of parent drug in plasma were the effect of altered
biotransformation (altered levels of 3A4) or other mechanisms, we decided to
monitor changes in verapamil metabolites over the timepoints measured (Figure 4-
5). Since authentic metabolites standards were not available, metabolites were
quantified based on Metabolite Area/IS Area response in LC/MS/MS and numbers
reflect AUC of these relative ratios (Figure 4-6A). All metabolites (except D-617)
showed approximately 2-fold higher plasma levels under C. rodentium infection,
with a paralleled increase to parent drug, arguing against decreased
biotransformation by cytochrome P450s as the cause of increased parent levels
(Figure 4-6B). Individual PK exposure curves for the measured metabolites with
and without infection are presented in Figure 4-7 where norverapamil, the major
metabolite and known byproduct of verapamil oxidation by 3A4 (3A11 in mice) was
found to be increased by -2.44-fold (AUC = 12.15 vs 4.98, C. rodentium vs control
respectively); comparable to changes in parent drug levels.
We conducted a similar analysis for propranolol metabolites and determined a
comparable fold-change for its metabolites when compared to parent propranolol
(Table 4-2). 1'-hydroxypropranolol (+1.7-fold), 2'-hydroxypropranolol (+2.3-fold),
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3'-hydroxypropranolol (+2.2-fold) demonstrated approximately 2-fold higher AUC
in infected animals as compared to uninfected controls, while desisopropyl-
propranolol demonstrated only a 140% increase. In humans, desisopropyl-
propranolol is generated by CYP-mediated N-dealkylation of propranolol by CYP1A2
and is the major metabolite, whereas hydroxylation byproducts are believed
generated via oxidation by CYP2D6 [160]. As expected, parent propranolol
demonstrated the highest Cmax as compared to its metabolites in plasma.
Collectively, the results indicate that biotransformation by CYPs does not appear
responsible for altering plasma levels of parent verapamil and propranolol under
conditions of gastrointestinal infection with C. rodentium.
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4.3 Discussion
Citrobacter rodentium infection in mice provides a reproducible, robust, and
physiologically relevant model of inflammation [74] and has been used as an animal
model of IBD [93], infectious colitis, and acute diarrheal illness [161]. Infection with
C. rodentium has also been proposed as a potential model of acute inflammatory
stress that alters liver homeostasis, potentially through an altered systemic and
local cytokine environment resulting from gastrointestinal infection [7, 8, 77, 149]
(Chapter 2 & 3). Transcriptional changes in both hepatic and renal phase I and
phase II metabolic enzymes demonstrate an altered metabolic state, with the
potential to alter exposure and clearance of both endogenous (ie lipids) and
exogenous (drugs) substrates form circulation or lead to local accumulation.
Metabolic changes associated with C. rodentium, furthermore, appear distinct from
those associated with LPS treatment alone. More recently, the role of IL-6 and IFN-
y, two commonly associated systemic cytokine targets associated with C. rodentium
infection were investigated [149]; demonstrating cytokine-specific alterations
hepatic CYP450 expression. Using five commonly used pharmaceuticals varying in
their degree of metabolism and mode of elimination, we investigated the functional
consequence of previously reported transcriptional changes in CYPs associated with
C. rodentium infection on oral drug exposure.
Increased plasma exposure and gut barrier compromise
Based on our examination we determined a -2-fold difference in exposure for
verapamil, 1.65-fold for propranolol (2.2-fold in initial 5 mg/kg study), and a 1.4-
fold higher exposure for digoxin under conditions of C. rodentium induced
inflammatory stress (Summarized Table 4-1). Measuring major metabolites for
verapamil and propranolol, we found a similar -2-fold elevations in plasma of most
metabolites measured (except D-617), indicating higher levels of both parent drugs
and their respective metabolites, arguing that biotransformation by CYPs was less
likely in driving elevations in parent drug exposure after PO drug delivery. If CYPs
were the primary contributor in determining increased parent drug exposure levels,
we would expect down-regulation of hepatic 3A11 (mouse analogue of human 3A4)
to result in decreased levels of metabolites compared to parent drug levels in
diseased animals. An alternative hypothesis that we propose is that exposure
differences are attributable to increased oral availability due to a leaky GI tract,
allowing for increased permeability of certain xenobiotics under conditions of
enteric infection with C. rodentium. Leaky gut barrier function has been implicated
as responsible for translocation of C. rodentium to MLNs during infection course
[98], and C. rodentium has been associated with disruption of tight junctions and
barrier function in intestinal epithelial cells in vitro and in vivo [99, 100]. Clinically,
altered epithelial permeability and tight junctions have been associated with IBD
[162], and C. rodentium infection in mice is an animal model for such disease
conditions.
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Another potential mechanism could include down-regulation of Pgp in the intestinal
tract. Strong evidence exists that Pgp plays a key role in host-bacterial interactions
in the gastrointestinal tract contributing to maintenance of intestinal homeostasis
[163, 164]. Indeed, mdrla-/- (gene encoding Pgp) mice develop spontaneous
colitis[165], and more recently, these animals were characterized as having
increased colonic expression of IFN- y and KC [166]. Furthermore, it is well
established that intestinal Pgp located at the apical membrane of enterocytes pumps
xenobiotics back into the gut lumen [167], as a mechanism of reducing oral
absorption of well established Pgp substrates such as cyclosporine and digoxin [155,
168, 169]. Thus, increased exposure observed with digoxin under C. rodentium
infection could be attributable to decreased transporter expression of Pgp, as
digoxin is not appreciably metabolized by CYPs. Recently, verapamil has also been
proposed as a Pgp substrate in rodents [170] and similarly shows increased oral
exposure under C. rodentium infection. A potential argument against this
mechanism may be that we did not see alterations in fexofenadine, however, as
mentioned above its role as a Pgp substrate is not clearly established outside of in
vitro studies. Measuring changes in Pgp protein expression in small intestine and
colon seems warranted towards investigating its functional role or contribution in
mediating bioavailability of drugs in this model.
APAP and fexofenadine do not demonstrate altered exposure
We did not see changes in exposure of either fexofenadine or acetaminophen. While
many of the CYP isoforms examined under C. rodentium infection demonstrate some
dependence on with IL-6 or IFN- y, CYP2E1, the primary CYP involved in APAP
bioactivation was unchanged in WT and IL-6 and IFN-y KOs [149]. This indicates
that CYP2E1 has a mechanism of transcriptional control unique to that of other CYPs
demonstrating alterations under conditions of C. rodentium infection. APAP has
shown increased AUC, prolonged plasma half-life, and delayed clearance in other
diseases associated with chronic inflammation such as cirrhosis, correlating
strongly with altered haemodynamic function (systolic and arterial pressures highly
associated with AUC) [171, 172]. Furthermore, in a viral hepatitis model, protection
from APAP-induced toxicity was attributed to decreased bioactivation of
APAP->NAPQI as mRNA levels of CYP2E1 and CYP1A2 were decreased 3 days post
viral infection [136]. Interestingly, under an acute inflammatory state,
characterized with hepatic inflammation (hepatitis-like state, pathological findings
Chapter 2 & 3) with C. rodentium, however, we do not observe changes in systemic
exposure after oral delivery for APAP at 7 DPI. This argues that the type of pathogen
and resultant cytokine/chemokine response may be vital in determining functional
consequences of drug exposure and metabolism for certain substrates.
As mentioned above, pathogenic enteric infection showed increases (-2-fold) of
both parent and metabolites of verapamil and propranolol, with slightly less robust
changes with digoxin (only parent drug investigated) as quantified by LC/MS/MS in
mouse plasma. The changes in exposure, albeit moderate, indicate conditions of GI
infection can increase oral bioavailability of certain clinically used therapeutics.
While for most therapeutics this is unlikely to be of major clinical impact, there may
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be certain instances, like digoxin, for example, where the therapeutic and safety
windows may be more sensitive to even modest changes in exposure. While CYP
mRNA levels have shown down-regulation under C. rodentium infection, CYP activity
was not addressed in these studies, furthermore, the contribution of other clearance
mechanisms in drug availability such as transporter expression was also not
investigated. Cytokines are known to affect the expression of numerous CYPs and
transporters, and based in the findings in Chapter 2 and Chapter 3, C. rodentium
induces a variety of inflammatory mediators at the local and systemic levels that
could impact the transcriptional control of CYPs, transporters, as well as other
metabolic enzymes required for metabolic homeostasis, particularly for endogenous
substrates and xenobiotics. In this regard, a more comprehensive examination of
these metabolic regulators in multiple tissues under conditions of C. rodentium-
induced inflammation would helpful in fully explaining the findings presented
herein.
Future work and conclusions
It has been proposed that changes in phase I/II metabolic enzymes may result in
altered exposure and clearance of pharmaceutical and endogenous substrates under
inflammatory conditions such as GI infection. Here, using C. rodentium infection in
C56B1/6 mice, we demonstrate that changes in oral drug bioavailability,
functionally, do not appear dependent on CYP-mediated biotransformation of
parent compounds. Rather, observed changes in oral exposure for verapamil,
proporanol, and digoxin appear to be driven more by proposed gut barrier
compromise. This was illustrated by verapamil, and propranolol, which
demonstrated -2-fold increased exposure under conditions of C. rodentium
infection, with mirrored changes in numerous metabolites monitored under both
infected and uninfected conditions. Interestingly, changes in oral drug availability
were only observed in a subset of drugs investigated, as APAP and fexofenadine
demonstrated similar oral exposure under normal and disease conditions.
Furthermore, examining the expression of both uptake and efflux transporters in
the small intestines and liver under conditions of pathogenic enteric infection with
C. rodentium seems warranted. Specifically, determining the role of Pgp in
mediating altered oral bioavailability seen with C. rodentium compared to the
proposed role of leaky GI. Greater understating of the role of GI infection (and
resultant systemic and local inflammation) on drug and endogenous substrate
clearance and homeostasis could have implications for patients with disease states
such as IBD and pathogenic gastrointestinal infection. Furthermore, could help in
the treatment management for patients with similar diseases characterized by
either acute or chronic inflammation.
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4.4 Selected methods
Media and Bacterial Strains
Luria-Bertani (LB) agar and broth (Difco Laboratories, Detroit, MI) was used for
routine cultivation of bacteria. MacConkey lactose agar (Difco Laboratories)
supplemented with 40 pg/ml of kanamycin was used for quantitative monitoring of
bacterial counts in fecal samples. The kanamycin-resistant strain of C. rodentium
strain, DBS120 (pCRP1::Tn5, Kanr) [145] was used for all infections.
Animal Housing and Bacterial Infections
Female 8-10 week old C57BL/6J (The Jackson Laboratory, Bar Harbor, ME) mice
were housed six per microisolator cage in a specific pathogen-free facility approved
by the Association for Assessment and Accreditation of Laboratory Animal Care.
Depending on the particular study, anywhere from 36-42 animals were used in
evaluating a particular compound. Animals were maintained on pelleted rodent
chow (LabDiet, Purina Mills, Inc., Richmond, IN) and water ad libitum and allowed to
acclimate one week prior to experimentation. Infectious colitis was induced by
intragastric inoculation with -1 x 109 CFU of DBS120 in 3% sodium bicarbonate
(w/v in 1X phosphate buffered saline (PBS), pH 7.4), 100uL volume as described
previously [145], while the uninoculated control groups received 1O0uL of 3%
sodium bicarbonate vehicle. Infection kinetics was monitored by fecal shedding
determined by plating serial 10 dilutions of fecal slurries (10% [w/v] in 1X PBS, pH
7.4) on LB agar with selection for kanamycin. The Massachusetts Institute of
Technology Committee on Animal Care approved all animal experiments prior to
investigation.
Drug Resuspension and Administration
Acetaminophen (5mg/kg in sterile ddH20), fexofenadine (5mg/kg in sterile ddH20),
digoxin (1mg/kg in ddH20 with 5% w/v cyclodextrin, pH 7.4), propranolol (5 mg
and 10 mg/kg in sterile ddH20), verapamil (5mg/kg in sterile ddH20) were all made
fresh the morning of oral delivery (PO). Compounds were dosed at 1OmL/kg using a
blunt 22g oral gavage needle. Terminal cardiac bleeds were conducted after
euthanasia by C02 asphyxiation at 5 min, 0.5, 1, 2, 4, 8, 16, or 24 hrs post delivery of
drug using 3 animals per time point (timepoints varied slightly for each drug
investigated). Plasma samples were collected (8000 rpm @ 10 minutes, 4C) and
levels of parent drug and specified metabolites monitored by LC/MS/MS at Biogen
Idec laboratories (Cambridge, MA). Total animals used for each compound under
investigation varied between 36 and 42, depending on the number of timepoints
evaluated (6-8) for pharmacokinetic analysis.
LC/MS/MS Methodology
Twenty-five to thirty microliters (uL) of plasma samples were precipitated with
1OOuL 1:1 acetontrile/methanol and lOuL of 8-cyclopently-1,3-dipropylxanthine
(CPDPX, internal standard @ 50 ng/mL). After centrifugation, the entire
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supernatant was removed 200-300uL 0.1% formic acid added. Samples were
analysed by LC/MS/MS using multiple reaction monitoring (MRM). An HPLC, fitted
with a Kinetex C18 2.6 tm (3.0 x 50mm) column (Phenomenex, Torrance, CA, USA),
was operated in gradient mode from 90% mobile phase A (water/formic acid,
100:0.1, v/v) to 95% mobile phase B (acetonitrile/formic acid, 100:0.1, v/v) over 2
minutes. The analytes along with an internal standard were analyzed on a triple
quadrupole mass spectrometer (SCIEX API 5500, Applied Biosystems, Foster City,
CA, USA) that was equipped with a Turbo Ion Spray probe and operated in either
positive or negative ion mode. In positive ion mode, scans monitored the signal for
parent-daughter transitions for verapamil (455>150), propranolol (260>116),
acetaminophen (152>110), fexofenadine (502>171) and the internal standard
(CPDPX, 305>263). In negative ion mode, scans monitored the signal for parent-
daughter transitions for the formic acid adduct of digoxin (825>779) and the
internal standard (CPDPX, 303>260). The data was collected and processed using
Analyst version 1.5.1 (Applied Biosystems). All calculations were based on peak
area ratios between analytes and the internal standard and sample concentrations
were determined from the linear range of the standard curve.
Statistical Analysis
Statistical significance was assessed by 2-way ANOVA analysis comparing three
animals per timepoint/treatment group.
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4.5 Figures and Tables
PK of Acetaminophen after 5 mg/kg PO administration to Mice +
Citro infection in GI
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Figure 4-1. Effects of C. rodentium infection on Acetaminophen (5mg/kg) exposure.
Acetaminophen was delivered PO at 5mg/kg to both control and C. rodentium infected mice
at 7 DPI. Parent drug levels were measured in plasma by LC/MS/MS at 30min, 1hr, 2 hrs,
4hrs, 8hrs, and 16hrs post delivery (n=3 for each treatment group and timepoint).
PK of Fexofenadine after 5 mg/kg PO administration to Mice +/-
Citro infection in GI
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Figure 4-2. Effects of C. rodentium infection on Fexofenadine (5mg/kg) exposure.
Fexofenadine was delivered PO at 5mg/kg to both control and C. rodentium infected mice at
7 DPI. Parent drug levels were measured in plasma by LC/MS/MS at 30min, 1hr, 2 hrs,
4hrs, 8hrs, 16hrs, and 24 hrs post delivery (n=3 for each treatment group and timepoint).
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Fexofenadine
. Citro Untreated
Time Conc SD Conc SD
hr ng.L nglmL nq/mL ng/mL
0.083 120.4 150.0 21.8 7.0
0.5 30.1 5.6 44.5 39.7
1 16.1 7.3 24.7 15.5
4 14.3 3.9 15.0 10.7
8 2.7 0.5 1.6 1.3
16 0.1 0.1 0.1 0.0
24 0.2 0.1 0.1 0.0
Dose Tmax Cmax AUClast
Compound (mpk) Treatment (hr) (ng/mL) (hr*ng/mL)
Digoxin 1 Citro 1 509 2013
1 control 0.08 410 1469
Propranolol 10 Citro 1 56.4 185
10 control 1 35.2 112
Figure 4-3. Effect of C. rodentium infection on Propranolol and Digoxin exposure.
Propranolol (10mg/kg) and digoxin (1mg/kg) were delivered PO to both control and C.
rodentium infected mice at 7 DPI. Parent drug levels were measured in plasma by
LC/MS/MS at 30min, 1hr, 2 hrs, 4hrs, 8hrs, 16hrs, and 24hrs post delivery (n=3 for each
treatment group and timepoint).
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Effect of Citrobacter Rodentium infection on oral
exposure of Digoxin at I mg/kg in C57BU mice.
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Effect of Citrobacter Rodentium infection on oral
exposure of Verapamil at 5 mg/kg in C57BU6 mice.
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Without Infection
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1
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0.01-
0 2 4 6 8 10 12 14 16
Time [hours]
Treatment Tmax Cmax AUClast CilF VzIF
(hr) (ng/mL) (hr*nglmL) (mL/min/kg) (Llkg)
Citro 2 154 657 127 16
control 0.5 134 353 236 32
Figure 4-4. Effects of C. rodentium infection on Verapamil (5mg/kg) exposure.
Verapamil was delivered PO at 5mg/kg to both control and C. rodentium infected mice at 7
DPI. Parent drug levels were measured in plasma by LC/MS/MS at 30min, 1hr, 2 hrs, 4hrs,
8hrs, and 16hrs post delivery (n=3 for each treatment group and timepoint). Increased AUC
was observed under infection conditions.
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Figure 4-5. Verapamil metabolites monitored after 5mg/kg PO dose
Representative diagram of verapamil metabolites monitored by LC/MS/MS after a PO dose
of 5mg/kg in control and C. rodentium infected mice at 7 DPI. Norverapamil, the major
verapamil metabolite is indicated.
Figure 4-6. Method description and LC/MS/MS results of Verapamil metabolite levels
In order to monitor potential changes in the metabolic profile of verapamil under
conditions of C. rodentium-induced inflammatory stress, 5 metabolites were monitored and
retention times listed (A). AUC results for verapamil metabolites with and without C.
rodentium infection at 7 DPI (B)
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Compound Retention Time Peaks monitored
455>165
Verapamil 3.62 minutes
455>260
Norverapamil 441>165
(Major) 3.57 minutes 441>289
441>260
441>260
D-702 3.13 minutes
441>291
D-703 2.98 minutes 441>165
(2 metabolites) 3.22 minutes 441>289
291>260
D-617 0.45 minutes
291>248
Analyte +I- Citro AUCIast
+Citro 0.18
D-617
-Citro 0.17
+Citro 0.2
D-702
-Citro 0.09
+Citro 1.07
D-703 Peak 1
-Citro 0.44
+Citro 2.05
D-703 Peak 2
-Citro 1.08
+Citro 12.15
Norverapamil
-Citro 4.98
+Citro 25.61
Verapamil
-Citro 14.72
H3
Effect of Citrobacter Rodentium infection on the metabolism of Verapamil
after a 5 mg/kg oral exposure in C57BL/6 mice.
-0-
-0-
-A
a
Norverapamil (+Cipro)
Norverapamil (-Cipro)
D-703(2) (+Cipro)
D-703(2) (-Cirpo)
D-703(1) (+Cipro)
0-703(1) (-Cipro)
D-702 (+Cipro)
D-702 (-Cipro)
D-617 (+Cipro)
D-617 (-Cipro)
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0 2 4 6 8 10 12 14 16
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Figure 4-7. Effect of C. rodentium on metabolites of Verapamil (5mg/kg)
Metabolites of verapamil were monitored over the course of 16 hrs with (solid line) and
without (dashed line) infection with C. rodentium. (n = 3 mice per group per timepoint).
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1e-2 -
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Table 4-1. Summary of compound exposure under C. rodentium-induced
inflammatory stress
The effect of C. rodentium-induced inflammatory stress on drug clearance was assessed in
six compounds varying in their biotransformation and mode of elimination. No change was
observed with acetaminophen (5mg/kg, PO) and fexofenadine (5mg/kg, PO). Infection
resulted in increased oral drug exposure for propranolol, verapamil, and digoxin.
Acetaminophen 5mg/kg Citrobacter
Uninfected
Tmx cmax
(hrs (ng/mt)
0.08 2017
0.08 2077
CYP
substrate
Transporter
substrate
Fexofenadine 5mg/kg Citrobacter
Uninfected
Propranolol 10mg/kg Citrobacter
Uninfected
Digoxin 1mg/kg Citrobacter
Uninfected
Verapamtl 5mg/kg Citrobacter
Uninfected
0.08 120
0.08 103
0.08 32
0.08 410
139 minimal OATP/(Pgp?)
132 "
92 2D6, 1A2
2014
1469
minimal
Pgp?
0.5 134
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CompoundInfection
Status
AUClast
(hr*ng/mt)
Table 4-2. LC/MS/MS Results of propranolol metabolites with and without C.
rodentium Infection
Propranolol and its metabolites; Desisopropyl-propranolol, 1'-hydroxypropranolol, 2'-
hydroxypropranolol, 3'-hydroxypropranolol, and parent drug were monitored by
LC/MS/MS in plasma after an initial oral dose of 10mg/kg. AUC was determined based on
both 0-8 hrs and 0-16 hrs post drug delivery based on detection limits.
Analyte TreatmentCmax AUC (0-16 AUC (0-8) Ratio-(ng/mi) (hr*ng/mL) (br*ng/ml)
Desisopropyl- Citrobacter 0.5 1.24 1.5 1.4propranolol
uninfected 0.5 1.14 1.09
1'-hydroxy Citrobacter 0.5 1.21 6.01 5.25 1.7
uninfected 0.5 1.01 3.48 3.11
2'-hydroxy Citrobacter 0.5 0.53 1.22 2.3
uninfected 0.5 0.37 0.53
3'-hydroxy Citrobacter 0.5 0.31 1.80 2.2
uninfected 0.5 0.27 0.81
propranolol Citrobacter 0.5 3.39 9.61 7.75 2.9
uninfected 0.5 2.09 3.08 2.67
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Chapter 5: Conclusions and Future Work
The use of C. rodentium in various mouse models has contributed greatly to our
understanding to pathogenic gastrointestinal infection and inflammatory bowel
disease. Here, we investigated liver responses under extrahepatic stress and
inflammation resulting from pathogenic enteric infection. While genetic
manipulation and pharmacological inhibition has helped greatly in our
understanding of hepatic homeostasis under inflammatory stress conditions, there
still exist few animal models that can properly predict these pathologies in the
human case. Furthermore, understanding the host response to environmental
pathogens is critical in order to study how exposure to chemicals amplifies,
synthesizes with, or mitigates environmentally induced disease.
Using C. rodentium, we show for the first time, to our knowledge, distinct liver
pathology associated with enteric infection in C57BL/6 mice, characterized by
increased inflammation and hepatitis index as well as periportal necrotic lesions
indicative of thrombic ischemic injury during the early course of pathogenic
infection (Chapter 2). Histologic changes correlate with serum elevation of liver
transaminases, systemic and local cytokine and chemokine changes, as well as signal
transduction changes prior to peak bacterial colonization and colonic disease.
Specifically, using computational approaches we demonstrated systemic targets
(cytokines/chemokines and serum chemistry markers) that differentiated animals
by PLS-DA. Systemic elevations in ALT, AST, with an upregulation of immune
modulators (IL-6, IL-10), monocytes chemokines/activators (MIP-la, MCP-1),
neutrophil chemokines/activators (G-CSF, KC), and t-cell activation (RANTES) at
3PDI correlated with coagulative liver necrosis. Mice harboring lesions also
demonstrated induction of STAT3 and IcBc phosphorylation, coupled with liver
specific protein elevations of IL-1p (L), IL-6 (L) G-CSF (L), KC (L), IL-12p40 (L),
MCP-1 (L), MIP-la (L), and RANTES (L). Future efforts delineating the role of these
cytokine targets as well as potential translocation of bacteria (and bacterial
products) in mediating injury are warranted.
Having characterized C rodentium infections as a platform for systemic and liver
inflammation, we investigated its role in altering susceptibility to drug-induced liver
injury (DILI) using APAP, a well-established hepatotoxin (Chapter 3). Using
computational approaches such as PCA, PLS, affinity propagation, and mutual
information, we generated interaction networks to facilitate visualizing of this
complex data landscape, but to also interrogate both linear and non-linear
dependencies between systemic and tissue specific cytokine/chemokine levels,
clinical serum chemistries, and histological scoring metrics. . In our model, APAP
did not synergize with extrahepatic inflammation induced by C. rodentium infection,
rather demonstrated moderate protection during the early course of enteric
infection and statistically increased serum ALT levels at 7 DPI. We attribute this to
an already induced Thl/Th17 response by C. rodentium. Furthermore, under co-
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exposure, the tissue and systemic cytokines levels appear to indicate a Thl/Th2
neutralization, as the usual Th2 promoting targets (IL-4 (S, L)) associated with APAP
treatment and Th1 targets with C. rodentium (IL-12p40 (L), RANTES (L), IL-a/b (L))
demonstrated attenuated levels as compared to single treatment alone. This can be
at least in part attributed to the induction of IL-10, with known immunomodulatory
effects on T cell polarization with C. rodentium and the anti Th1 effects of IL-4
resulting from APAP treatment. Future work would focus on neutralizing some of
the targets obtained in this analysis such as IL-10 to address it role in Citrobacter-
induced liver injury at 3 DPI, as well as the role in mediating altered signaling states
under superimposition with APAP treatment. Cytokines are known signaling
molecules in signal transduction pathways, and we previously observed signaling
alterations in liver STAT1, STAT3 and hcBa phosphorylation under Citro infection
(Chapter 2, Appendix Chapter B), important mediators of cytokine signaling and
immune responses. Measuring a limited number of intracellular signaling states
may help to clarify mechanisms driving altered liver response and changes in T-cell
polarizing targets observed here.
Finally, we investigated the role of C. rodentium in altering oral drug exposure
(Chapter 4). Based on our examination we determined a -2-fold systemic
exposure for verapamil, propranolol, and a 1.4-fold higher exposure for digoxin
under conditions of C. rodentium induced inflammatory stress. Upon measuring
major metabolites for verapamil and propranolol, we found similar 2-fold elevations
in plasma, indicating higher levels of both parent and metabolite indicating that
biotransformation was less likely to blame for the elevations in parent drug. We
attribute these finding to a leaky GI tract, allowing increased permeability of certain
xenobiotics under inflammatory conditions. Furthermore, examining the expression
of both uptake and efflux transporters in the small intestines and liver under
conditions of pathogenic enteric infection seems warranted. Specifically,
determining the role of Pgp in mediating altered oral bioavailability seen with C.
rodentium compared to the proposed role of leaky GI. Greater understating of the
role of GI infection (and resultant systemic and local inflammation) on drug and
endogenous substrate clearance and homeostasis could have implications for
patients with disease states such as IBD and pathogenic gastrointestinal infection.
Furthermore, could help in the treatment management for patients with similar
diseases characterized by either acute or chronic inflammation.
A greater appreciation of the liver-gut axis and its role in disease and predisposition
at both systemic and tissue specific homeostasis could be critical in developing new
therapeutic options or properly mitigating disease. Many liver disease and DILI
involve inflammation as a contributing factor to progression and severity; continued
examination using models utilizing pathophysiologically relevant sources of stress
and inflammation may help towards this understanding. In summary, these findings
are important towards helping defining connections between the dynamic interplay
of inflammation and systemic/tissue-level homeostasis during enteric infection.
Future work focusing on neutralizing antibodies or conditional KO's may help to
confirm and expand on the importance of numerous targets implicated herein.
5-116
Appendix A: General Methods
Media and Bacterial Strains
Luria-Bertani (LB) agar and broth (Difco Laboratories, Detroit, MI) was used for
routine cultivation of bacteria. MacConkey lactose agar (Difco Laboratories)
supplemented with 40 pg/ml of kanamycin was used for quantitative monitoring of
bacterial counts in fecal samples. The kanamycin-resistant strain of C. rodentium
strain, DBS120 (pCRP1::Tn5, Kanr) [145] was used for all infections.
Quantitative real-time PCR
Total RNA was prepared from frozen tissues using Trizol reagent according to
manufacturer recommendation (Invitrogen, Carlsbad, CA). cDNA was generated
from five micrograms of total RNA using SuperScript II RT (Invitrogen). One
hundred nanograms of cDNA were amplified in a 25 d reaction volume with
predesigned primers (Applied Biosystems, Branchburg, New Jersey, USA) and
probes (TaqMan Gene Expression Assays) in an ABI Prism Sequence Detection
System 7700 (Applied Biosystems, Branchburg, New Jersey, USA) using standard
TaqMan protocols: IFN- y (Mm99999071_m1), IL-17 (Mm00439619_ml), TNF-a
(Mm99999068_ml), CCL2 (Mm00441243_g1), IL-13 (Mm00434228_m1), CCL3
(Mm00441258_ml), CCL5 (Mm01302428_ml), CXCL1 (Mm00433859_ml), CXCL2
(Mm00436450_m1), and glyceraldehyde-3 -phosphate dehydrogenase (GAPDH)
(Mm99999915_gl). Transcript levels were normalized to GAPDH, and expressed as
fold change relative to averaged sodium bicarbonate (vehicle control) inoculated
group, which were set at 1, using the Comparative Ct method (Applied Biosystems,
User Bulletin no. 2). Reactions were processed in duplicate.
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Appendix B: Effect of Citrobacter rodentium on early serum
and liver responses
Arek R. Raczynskil, Katherine Schlieper', Steven R. Tannenbaum', David B.
Schauer1,2
'Department of Biological Engineering, 2Division of Comparative Medicine,
Massachusetts Institute of Technology, Cambridge, MA, USA
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B.1 Introduction
Citrobacter rodentium (C. rodentium) is a mouse specific enteric pathogen that
results in varying degrees of inflammation, colonic hyperplasia, and more recently
liver-related metabolic dysregulation. We recently found that infection with C.
rodentium at early timepoints (3-4 DPI) results in coagulative necrosis in the livers
of approximately 50% of C57BL/6 mice, correlating with systemic changes in G-CSF,
RANTES, IL-10, MCP-1, and IL-6, coupled with STAT3 activation in livers. G-CSF, IL-
10, and IL-6 are known upstream activators of STAT3 phosphorylation. In order to
better understand the kinetics of injury at this early timepoint, we investigated
serum and liver specific effects leading up to these early liver changes by examining
C. rodentium induced changes at 12,24,48,72, and 96 hrs post inoculation (HPI). We
observed a bi-phasic response in serum cytokines and clear induction of acute phase
response transcriptional changes in livers as early as 12hr post inoculation with
reactivation around 96 HPI (correlating with necrotic lesions described previously
in Chapters 2 & 3).
To further determine whether this was a C. rodentium-specific or simply a non-
specific response of the host to inoculation with -109 bacterial colonies, we
inoculated animals with either wild-type (WT) C. rodentium (DBS 120), a cloning
strain of E. coli (DBS 9), or an intimin-deficient, non-pathogenic mutant strain of C.
rodentium (DBS 255). Intimin is a virulence factor expressed on the surface of
bacterial cells and binds to its receptor Tir (translocated intimin receptor) on
colonic epithelial cells, an interaction that is critical for attaching and effacing (A/E)
lesions, central to the pathogenesis of enteropathogenic Escherichia coli (EPEC) and
enterohaemorrhagic Escherichia coli (EHEC)-mediated diseases in humans and
Citrobacter rodentium transmissible colonic hyperplasia in mice [98, 173, 174].
Systemic cytokine changes collected were monitored at 12 and 24 hrs post
inoculation (HPI). We discovered that all three bacterial strains were able to induce
an acute phase response to some degree; however, only infection with WT C.
rodentium maintains a sustained response at 24 hrs in both cytokine levels and
STAT3 phosphorylation.
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B.2 Results
C. rodentium infection results in early responses in systemic cytokine and
chemokines
Based on previous findings of liver injury at 3DPI, we decided to investigate the host
response to C. rodentium at time points preceding liver pathology. C57BL/6 mice
were infected by intragastric inoculation with -1 x 109 CFU of DBS120 (WT C.
rodentium) and monitored for serum cytokines (Luminex 23-PLEX bead based
ELISA), transcriptional changes in liver, and signal transduction in STAT3. As early
as 12hrs post inoculation with C. rodentium, there was a statistically significant
change serum levels of IL-la, IL-13, IL-5, IL-6, G-CSF, and MIP-1b (Figure B-3)
(p<0.001 for all targets but IL-1p which was significant by p<0.01, one way ANOVA
with Bonferonni post test).
Quantitative RT-PCR for acute phase and liver targets
Quantitative RT-PCR was performed on RNA isolated from liver tissue to evaluate
the expression of some key genes involved in acute phase response (Serum amyloid
A and Serpine), immunomodulatory target (CXCL1 (KC)), and metabolic enzyme
associated with cholesterol metabolism (CYP7al) (Figure B-2). C. rodentium
resulted in statistically significant increases in Serum amyloid A transcript (12, 24,
and 96 HPI) as well as KC (12 and 96 HPI). Both are associated with the acute phase
response, and mediated as least in part by cytokines such as IL-6, IL-10, and G-CSF.
Cyp7al showed decreases in expression at 12 and 96 HPI but failed to reach
significance as a group. Overall this indicates transcriptional changes in acute phase
and chemokines associated with neutrophils activation/chemotaxis.
Bacterial clearance of DBS 9, DBS 120, and DBS 255
Oral inoculation with all three strains resulted in detectable colony forming units at
both 12 and 24 HPI, with WT C. rodentium having the slowest clearance (thus
highest bacterial load) at both timepoints, followed by the intimin-deficient strain
(DBS 255), and finally E. coli (DBS 9) had the lowest colony forming units (CFUs)
detected (Figure B-4).
Sustained STAT3 Phosphorylation with DBS 120
STAT3 activity was measured by western analysis for phosphorylation at TYR-527
(Cell Signaling Technology, MA). All three strains were able to induce STAT3
activation in livers at 12 HPI, however, only WT C. rodentium (DBS 120), the fully
pathogenic strains, was able to sustain STAT3 activation at 24 HPI (Figure B-5).
Bacterial levels at 24 hrs were approximately 3-logs higher at this timepoint.
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B.3 Discussion
Here we determined to evaluate the systemic and liver specific cytokine changes
associated with C. rodentium infection at early timepoints prior to colonic disease
(12-96 HPI). Furthermore, we investigated the effect of pathogenic (WT C.
rodentium), intimin deficient, and E. coli strains in their respective abilities of
inducing a similar response at 12 and 24 HPI. We discovered that C. rodentium is
able to induce an acute phase response in mice as early as 12 HPI as indicated by
transcriptional activation of Serum amyloid and KC, as well as elevations of pro-
inflammatory cytokines IL-1a, IL-13, and IL-6, as well as inflammatory mediators
involved in neutrophils activation (G-CSF) and monocytes chemo-attraction (MIP-
1b). Furthermore, these changes at both the systemic and tissue levels correlate
with signal transduction as monitored by STAT3 activation, a key regulator in acute
phase response and tissue injury.
Interestingly, all three bacterial strains were able to induce an acute phase response
to some degree; however, only infection with WT C. rodentium maintains a
sustained response at 24 hrs in both cytokine levels and STAT3 phosphorylation.
STAT3 phosphorylation was correlated with systemic cytokine release of pro-
inflammatory cytokines (IL-la/p), as well as IL-5, IL-6, G-CSF, and MIP-1b.
Furthermore, liver specific elevations in serum amyloid A and CXCL1 (KC) were
significantly elevated as early as 12 HPI as a result of C. rodentium infection.
What remains to be determined is exactly what role these targets may play with
respect to the reproducible liver necrosis found in animals approximately 3-4 days
post oral inoculation with C. rodentium. It is possible that this early response has
evolved fairly generically in the face of stress or acute changes in gut physiology or
bacterial colonization, and may not necessarily be a predisposition to injury.
Although, activating such responses under already injured condition, for example
under chronic liver inflammation or drug-induced injury may potentially result in
an local and systemic cytokine/chemokine and signaling network with potential
synergies or protective effects at play. Indeed, in Chapter 3 we demonstrate that
the injury associated with C. rodentium does not synergize with APAP-induced liver
injury, rather appears protective. What is unknown is whether the earlier
timepoints (12/24 hrs) or even as early as 2-8 HPI would result in a very different
response to superimposition with drug-treatment. Indeed others show what
appears to be a temporal dependence or LPS to synergize with drug treatment.
Much of this could be attributable to he complex mechanism of tolerance and
resistance, key to managing and balancing host-pathogen interactions.
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B.4 Selected Methods
Mouse Infections
40 female 8-10 week-old, specific pathogen free C57BL/6 mice were (The Jackson
Laboratory, Bar Harbor, ME) were housed and maintained as described in Appendix
A (General Methods). Infectious colitis was induced by intragastric inoculation with
-1 x 109 CFU of DBS120 in 3% sodium bicarbonate (in PBS, pH 7.4) using a 1OOuL
volume. Control animals (0 DPI) were sacrificed within 1hr of inoculation while the
12, 24, 48, 72, and 96 hour post inoculation (HPI) animals were monitored for fecal
shedding and body weight changes as indicated and euthanized and necropsied at
their respective timepoints as described in Appendix A
Immunoblot of Phospho-proteins:
Tissues were thawed on ice, suspended in Bio-Rad cell lysis buffer with provided
phosphatase and protease inhibitors, and homogenized with a Tissue TearorT " for 1
minute. Upon freeze thawing (-80*C), samples were sonicated on level 5 for three
10 second bursts, incubated on ice for 20 minutes, and centrifuged at 4*C at 5000
rpm for 15 minutes to precipitate insolubles. Supernatants were protein quantified
by BCA (Thermo Scientific, Rockford, IL) and adjusted to 2ug/uL with Bio-Rad lysis
buffer. Equal volumes of 2X SDS loading buffer was added and 20uL loaded
(20ug/well) onto 10% SDS Tris-glycine gels (Invitrogen, Carlsbad, CA). Upon
transfer to immobolin PQ PVDF membranes, blots were incubated with antibodies
(1:2000 P-STAT-3, 1:2000 anti-rabbit monoclonal, P-38 and ERK1/2, Cell Signaling
Technologies) in TBST-5%BSA, incubated with Santa Cruz luminal reagent, exposed
by Kodak MR film, and quantified by NIH imageJ.
Real-time quantitative RT-PCR. Total RNA was prepared from frozen kidney using
Trizol reagent according to manufacturer recommendation (Invitrogen, Carlsbad,
CA). cDNA was generated from five micrograms of total RNA using SuperScriptll RT
(Invitrogen). One hundred nanograms of cDNA were amplified in a 25 1 reaction
volume with predesigned primers (Applied Biosystems, Branchburg, New Jersey,
USA) and probes (TaqMan Gene Expression Assays) in an ABI Prism Sequence
Detection System 7700 (Applied Biosystems, Branchburg, New Jersey, USA) using
standard TaqMan protocols: IFN- y (Mm99999071_m1), IL-17 (Mm00439619_ml),
TNF-a (Mm99999068_ml), CCL2 (Mm00441243_gl), IL-10 (Mm00434228_m1),
CCL3 (Mm00441258_ml), CCL5 (Mm01302428_m1), CXCL1 (Mm00433859_m1),
CXCL2 (Mm00436450_m1), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Mm99999915_gl). Transcript levels were normalized to GAPDH, and
expressed as fold change relative to averaged sodium bicarbonate (vehicle control)
inoculated group, which were set at 1, using the Comparative Ct method (Applied
Biosystems, User Bulletin no. 2). Reactions were carried out in duplicate.
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B.5 Figures and Tables
Control
p-ERK1/2
12 hr 24 hr
*0-M 4..OO
ERK1/2
p-P38
P38
Figure B-1. Signal transduction in liver lysates of C. rodentium infected animals at 12
and 24 HPI
Signal transduction was evaluated by western analysis probing for STAT3, ERK, and p-38
phosphorylation at 12 and 24 HPI. Total ERK and p-38 are indicated.
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Figure B-2. qRT-PCR for acute phase and liver targets due to C. rodentium infection.
qRT-PCR (TAQMAN) for Serpine 1, Serum amyyloid A2, Cyp7al, and CXCL1 (KC) were
evaluated at 0, 12, 24, 48, 72, and 96 HPI using liver RNA. All targets were normalized to
GAPDH presented as Fold-change over the mean of controls (0 HPI). (Kruskal-Wallis with
Dunn's post test: * p <0.05, ** p<0.01, *** p<0.001). Lines indicate group means
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Figure B-3. C. rodentium induced systemic cytokines changes at early timepoints
Multiplex analysis using Bio-Rad cytokine/chemokine panels resulted in significant
serum elevations of IL-la/, IL-5, IL-6, G-CSF, and MIP-1b as early as 12-hrs post
inoculation. (One-way ANOVA with Bonferonni post test: * p <0.05, ** p<0.01, *
p<0.001). Lines indicate group means
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Figure B-4. Infection kinetics of DBS 9, DBS 120, and DBS255 in C57BL/6 mice
Bacterial load was assessed by fecal shedding by serial dilution at 12 and 24 HPI for DBS 9(E. coli), DBS 120 (WT C. rodentium), and DBS 255 (Intimin deficient C. rodentium).
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Figure B-5. STAT3 activation in livers of DBS9, DBS120, and DBS255 livers.
Signal transduction was evaluated by western analysis probing for phosphorylation of
STAT3 at 12 and 24 HPI for DBS9, DBS120, and DBS255 inoculated animals (n=3 livers were
used for each treatment group).
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Appendix C: Biomarkers of Inflammatory Bowel Disease
Knutson CG1, Raczynski AR1, Zeng Y', Iffrig EM1, Wishnok JS', Korzenik JR2 and
Tannenbaum SR1.
'Department of Biological Engineering, Massachusetts Institute of Technology,
Cambridge, MA 02138. 2Crohn's and Colitis Center, Gastrointestinal Unit,
Massachusetts General Hospital, Boston, MA 02114.
Sections of this chapter will be used for publication submission.
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C.1 Introduction
Ulcerative colitis (UC) and crohn's disease (CD) are two forms of inflammatory
bowel disease (IBD) that together affect approximately 2 million people in the
United States. Both conditions are multifactorial with unknown etiologies, but can
present in very similar fashions clinically, with intermittent and severe activation of
the mucosal immune system in the GI tract, promoting a chronic state of
inflammation [175]. While many immune regulators have been identified in human
analysis as well as animal models of IBD, their respective roles in disease
progression, usefulness as biomarkers, and potential for therapeutic intervention
remains an uncertainty [176, 177].
Currently, diagnostic evaluation uses erythrocyte sedimentation rate (ESR) and
serum C-reactive protein (CRP) levels as early indicators of disease for both forms of
IBD. CRP is an acute-phase protein produced in response to infection and
inflammation, which activates the classical complement system via c1q binding
phosphocholine expressed on the surface of dead or damaged cells (or bacteria),
which enhances macrophage phagocytosis. Such biomarkers are used in tandem to
evaluate disease severity coupled with symptoms presented by the patient upon
physical examination. Typically, patients undergo further evaluation in the form of
an endoscopy or colonoscopy as well as tissue biopsy to confirm pathology and
severity of disease. Such biomarkers, however, are non-specific; indicating generic
activation of inflammatory processes in an individual, providing minimal
information with respect to disease specificity, progression, or severity. For this
reason, there is growing interest in finding biomarkers more specific to IBD disease
subsets, potentially augmenting the current diagnostic process or optimally
decreasing the necessity to invasive practices without compromising proper
diagnosis.
Here we evaluated patient serum samples from 40 ulcerative colitis (20 active and
20 inactive), 40 crohn's (20 active and 20 inactive), assessing circulating serum
cytokines using multiplex cytokine/chemokine panels, coupled with circulating
inflammatory stress markers such as Cl-TYR, NO-TYR detected by LC/MS
methodology. Using principle components analysis (PCA) and partial least squares
regression (PLSR) techniques, we found targets that differentiated between active
and inactive individuals based on the clinical disease scores provided by the
clinician, yielding biomarkers for both UC and CD individuals that demonstrate high
specificity and selectivity for disease activity. Such biomarkers could prove helpful
in not only monitoring the disease progression and severity, but also gives insights
into potential new therapeutic approaches in controlling both CD and UC disease.
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C.2 Results
Details of human patient samples
Patient serum samples from UC, Crohn's, and normal patients were obtained from
Mass General Hospital (MGH) from the Gastroenterology department's repository.
A total of 40 ulcerative colitis patients (20 active, 20 inactive), 40 Crohn's patients
(20 active, 20 inactive), and 30 normal patients were used for analysis. Disease
score was provided for all UC and CD patients and based on disease scoring criteria.
General patients information was also provided (ex, gender, age, prescribed
pharmaceuticals).
OPLS analysis for disease score: active versus inactive
Quantitative data obtained from serum multiplex cytokine/chemokine analysis,
CRP, ESR, CL-TYR, and patient disease scores were combined from both study
cohorts and OPLS analysis was conducted to determine targets that co-varied best
with the clinically ascribed disease scores. UC and CD (four groups, n = 20 for each
grouping) patients' samples were combined for general IBD assessment and
individually to determine if certain variables were better able to differentiate
disease activity within the two disease types. Using orthogonormalized partial least
squares regression (OPLS) with disease score as the dependent "y" variable,
granulocyte colony- stimulating factor (G-CSF), chemokine ligand 10 (IP-10),
interleukin-8 (IL-8), IL-17, and IL-1 displayed covariance with the clinical disease
score (variable in projection scores (VIP) >1) when UC and CD data sets were
combined. When the data was limited to only CD and plotted variables using OPLS
(VIP >1) analysis the cytokine profile was unchanged. However, when OPLS (VIP
>1) analysis was limited to only UC variables, IL-6 displayed covariation with
disease score, but IP-10 and IL-17 did not, which suggests that these factors are less
predictive with UC disease score and more predictive of CD disease activity. Using
OPLS again, but focusing ony on active and inactive disease patients for each IBS
type, were able to obtain reasonable separation of patient samples (Figure C-1), and
determine the observed vs predicted performance of the model resuting in a R2 =
0.6231 (Figure C-2). The process was repeated for CD patients as well (Figure C-3
and C-4) resulting in reasonable separation of patients, however resulting in a
lower R2 = 0.3794.
Mann-Whitney analysis of targets obtained from OPLS
Targets determined to have a VIP score of greater than 1 were analyzed by Mann-
Whitne to determine if there were statistically significant differences between
circulating levels in active versus inactive (patients in remission) cohorts (Figure C-
6). We also evaluated CRP and ESR levels measured at the time of disease score
assessment and found them to be poor predictors of disease activity, both failing to
reach statistical significance in differentiating between groups (Figure C-5). From
this evaluation the statistical significance between groups demonstrates that
cytoines and chemokines are reasonable markers of disease activity.
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Total score and selectivity/specificity determination
Total scores were calculated by selecting the top 4 and 5 VIP scores for UC and CD,
respectively, normalizing the raw cytokine data to a base-10 spread, scaling by the
VIP factor, and summing the total. Patients' samples that resulted in scores above a
particular cutoff were designated as active and those below inactive. A
selectivity/sensitivity analysis was also conducted to determine the performance of
this discrimination.
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C.3 Discussion
Using multiplex analysis of serum cytokine/chemokine levels, inflammatory
markers of neutrophil activation (CL-Tyr), macrophage activation (NO-TYR), CRP,
ESR, and disease indexes collected from patients with active or inactive UC/CD, and
normal patients, we present potential biomarkers in the assessment of disease
activity for both CD and UC patient populations.
In the case of UC, we utilized OPLS analysis to determine the features that best
correlate with clinical disease score and discovered IL-8, CL-Tyr, G-CSF, and IL-6
were best the best performers of the targets measured. By creating a modified
disease score based on the four VIP scores and the normalized cytokine values
resulted in a total score with a corresponding specificity of 81.8% (Score >40) and
sensitivity of 84.2% (Score >40) for UC. For CD, OPLS analysis resulted in CL-TYR,
MIP-1b, IP-10, IL-6, and IL-1ra as the best correlates. Calculation of total score for
the CD model resulted in a specificity for CD = 87.5% (Score >47) and sensitivity =
75% (Score >47). These new biomarkers serve as potentially valuable
complementary tools to existing biomarkers to potentially differentiate between CD,
UC, but also monitor disease activity. Recently, disease severity in a mouse model of
IBS using C. rodentium infection in C57BL/6 mice resulted in the upregulation of
serum and colonic cytokines, many paralleling changes we observed in these two
forms of IBD (KC (mouse analog of human IL-8), G-CSF, CL-Tyr, and IL-6), indicating
a strong neutrophil component to disease severity [94].
UC and CD represent two major form of IBD that affects millions of patients in the
United States and abroad. While the current pharmacological inhibitors have been
tremendously helpful in managing both conditions, disease relapse and
development of resistance and treatment tolerance is a major issue. Here we
demonstrate that mediators of the innate immune system appear to be activated in
patients with disease activity, furthermore, find sets of biomarkers for both UC and
CD that perform quite well in their selectivity and specificity for disease activity.
These are markers that irrespective of patient gender age, or current
pharmaceutical intervention used, demonstrate a clear enrichment and correlation
with disease score and activity.
The current landscape of potentially new biomarkers for IBD has increased recently,
with many under clinical investigation [177]. The majorities of biomarkers
discovered are associative for either UC or CD and include anti-self antibodies for
perinuclear anti-neutrophil cytoplasmic antibodies (pANCA), bacterial products,
and glycans. Other general biomarkers of inflammation that have been applied in
the IBD settings include calprotectin and CRP [178, 179]. Continued exploration
into the role and function of the innate immune system during these disease
processes will hopefully lead to a greater understanding of disease etiology and
pathogenesis, with an eventual goal of better disease management and intervention.
C-133
CA Selected Methods
Cl-TYR and N-TYR detection
Nitrotyrosine and chlorotyrosine levels in human serum were measured by
negative-ion chemical ionization GC/MS. Briefly, serum (2 mg) was spiked with 1
pmol internal standards (L-3-chloro-[13C9, 15N]-tyrosine and L-3-nitro-[13C9,
15N]-tyrosine). Protein was digested by 1 mg Pronase E (Protease from
Streptomyces griseus) overnight at pH 7.4, followed by HPLC purification. The
purified residue was derivatized with ethyl perfluorobutyrate and N-methyl-N-(t-
butyldimethylsilyl) trifluoroacetamide + 1% trimethylchlorosilane (MtBSTFA, Regis
Technologies, Morton Grove, IL). The derivatized samples were analyzed by
negative-ion chemical ionization GC/MS. Separations were carried out on an Agilent
6890N GCMS system equipped with a 30 m HP-5MS capillary column (0.25 mm I.D.,
0.25 mm film thickness). The ions were monitored at m/z 489 and 499 for
chlorotyrosine and L-3-chloro- [13C9, 15N]-tyrosine, and at m/z 518 and 528 for
nitrotyrosine and L-3-nitro-[13C9, 15N]-tyrosine. Quantification of protein-bound
nitrotyrosine and chlorotyrosine were based on the calibration curves (5-points)
constructed over the range of 0.1-5.0 pmol for both nitrotyrosine and
chlorotyrosine. All analyses were carried out in triplicate.
Multiplex Detection of Serum Cytokines and Chemokines:
Human serum was obtained from Massachusetts General Hospital (MGH) and
analyzed using human 27-plex cytokine panels (Bio-Rad, Hercules, CA) as specified
by the manufacturer. Briefly, serum was diluted in human-specific sample diluent
(1:4) and SOuL of sample or premixed standards were incubated with pre-washed
target capture antibody-conjugated microspheres provided and incubated for 30
minutes with orbital shaking (300 rpm) in a 96-well plate. Upon washing, beads
were incubated with detection antibody (30 min), washed, and subsequently
incubated with streptavidin-PE (10 min). Beads were washed and resuspended
with 125uL assay buffer and read on the Luminex 200 suspension array system
using the low RP1 target setting (High PMT) for maximum sensitivity. Data analysis
was carried out with the Bio-Plex ManagerTM 5.0 software and cytokine or
chemokine concentrations calculated against an 8 point standard curve generated
by either 4PL or 5PL curve fitting.
Multivariate Data Analysis:
Principal components analysis (PCA) was used as a first-pass, unbiased assessment
of global variance in patient data set. To determine serum specific factors that best
differentiated normal, UC (active and inactive), CD (active and inactive) patients,
supervised multivariate methods were utilized using SIMCA-P software (Umetrics
Inc., Kinnelon, New Jersey). Projection to latent structure discriminate analysis
(PLS-DA) was conducted based on known classes. The information on class
membership allows optimal extraction of particular observations (e.g., serum
cytokine targets) that correlate best with disease state and activity. Orthogo-
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normalized Partial Least Squares regression (0-PLS) was subsequently used to
eliminate systematic variation unrelated to disease score, facilitating the
interpretation of disease activity specifically. In this case a cross-matrix correlation
between all serum targets (X) and the clinically determined disease score (Y) were
used as modeling parameters. Variable importance in the projection (VIP) were
computed from influence (weight) on disease score of every term in the model. The
average VIP equals 1, therefore VIPs >1 explain Y more than VIP<1. VIPs greater
than 1 were used in creating the total score.
Statistical Analysis:
Statistical significance in serum targets between patients groups that demonstrated
non-normal distributions or categorical in nature, were assessed by Kruskal-Wallis
non-parametric test with Dunn's multiple comparison test against controls unless
otherwise indicated. If only two groups were analyzed, Mann Whitney was utilized.
All analyses were done with GraphPad Prism software, version 4.0 and P values of
<0.05 were considered significant.
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C.5 Figures and Tables
Combined Studies
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Figure C-1. OPLS for disease score: Ulcerative colitis using active and inactive patients
(STUDY 1&2).
Cytokines, chemokines, CRP, ESF, and CL-TYR data ("x"-variables) from UC patients was
analyzed by OPLS using disease score as the dependent ("y") variable. Human controls
were not included for this analysis. Individual patients numbers are represented and
distinguished as either active (RED) or in remission (GREEN) based on clinical assessment.
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Figure C-2. Observed versus predicted disease score: Ulcerative colitis active and
inactive patients (STUDY 1&2)
Observed versus predicted disease score is plotted based on the OPLS analysis of active and
inactive patient data. A linear regression as to goodness of fit is shown (r2 = 0.6231).
Human controls were not included for this analysis. Individual patients numbers are
represented and distinguished as either active (RED) or in remission (GREEN) based on
clinical assessment.
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Figure C-3. OPLS for disease score: Crohn's using active and inactive patients (STUDY
1&2).
Log transformed cytokine, chemokine, CRP, ESF, and CL-TYR data ("x"-variables) from CD
patients was analyzed by OPLS using disease score as the dependent ("y") variable. Human
controls were not included for this analysis. Individual patients numbers are represented
and distinguished as either active (RED) or in remission (GREEN) based on clinical
assessment.
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Combined Studies
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Figure C-4. Observed versus predicted disease score: Crohn's active and inactive
patients (STUDY 1&2).
Observed versus predicted disease score is plotted based on the OPLS analysis of active and
inactive patient data. A linear regression as to goodness of fit is shown (r2 = 0.3794).
Human controls were not included for this analysis. Individual patients numbers are
represented and distinguished as either active (RED) or in remission (GREEN) based on
clinical assessment.
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Figure C-5. Mann-Whitney of ESR and CRP values for UC active and inactive patients.
ESR and CRP values analyzed from both active and inactive ulcerative colitis patients fail to
reach statistical significance for differentiation between groups: ESR (p = 0.2365), CRP(p=0.1556) (Mann-Whitney non-parametric test).
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Figure C-6. Potential biomarkers of disease activity obtained from OPLS analysis
Mann-Whitney non-parametric t-tests for the top variables obtained from VIP scores for CD
and UC patients comparing active and inactive disease populations. All variables were
statistically higher in serum of patients with active disease at compared to inactive, or
patients in remission (p<0.05).
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Figure C-7. Total scores for UC and CD patients based on VIP
OPLS.
scores obtained from
Calculation of Total Scores for UC and CD patients based on the top 4 UC VIP scores and the
top 5 CD VIP scores. Calculated specificity for UC = 81.8% (Score >40) and CD = 87.5%
(Score >47). Calculated sensitivity for UC = 84.2% (Score >40) and CD = 75% (Score >47).
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D.1 Introduction
Citrobacter rodentium (C. rodentium) is an enteric bacterial pathogen that results in
varying degrees of intestinal inflammation, acute colitis, hyperplasia, and edema in
numerous strains of mice [74, 75]. As a human homolog of enteropathogenic
Escherichia coli (E. coli) and enterohemorarrhagic E. coli (EPEC and EHEC
respectively), C. rodentium has become a highly utilized animal model of these
human infections, providing a reproducible, robust, and physiologically relevant
model of inflammation. However, only a subset of Shiga toxin (Stx)-producing E. coli
(STEC) are human pathogens, resulting in hemorrhagic colitis and hemolytic uremic
syndrome (HUS)[180]; a leading cause of acute renal failure in young children [181].
Currently the characteristics driving STEC pathogenicity are yet to be clearly
understood and appropriate animal models are lacking.
Here we evaluated intimin-deficient and Stx-expressing C. rodentium strains in
C57BL/6 mice. Animals were exposed to either sodium bicarbonate vehicle, DBS
807 (Trans Intimin 1), DBS 808 (Trans Intimin 2) DBS 806 (STX(+) strain), or DBS
771 (STX(-) control, non functional clone). Intimin is a virulence factor expressed
on the surface of bacterial cells and binds to its receptor Tir (translocated intimin
receptor) on colonic epithelial cells, an interaction that is critical for attaching and
effacing (A/E) lesions, central to the pathogenesis of EPEC and EHEC (EHEC)-
mediated diseases in humans and Citrobacter rodentium transmissible colonic
hyperplasia in mice [98, 173, 174]. The aim of this study is to determine if a Stx-
expressing strain of C. rodentium causes a pathogenic signature similar to that found
with the human equivalent shigatoxin-expression EPEC and EHEC by measuring
inflammatory markers in both circulating protein and kidney transcript levels.
D-143
D.2 Results
Luminex serum cytokine analysis
Serum samples collected 8 days post inoculation (DPI) for DBS 806 and DBS 771
(STX (+) and STX (-) strains) and 9 DPI for sodium bicarbonate, DBS 807 and DBS
808 (Intimin 1 and 2-deficeint strains of WT C. rodentium respectively) were
processed for Luminex multiplex detection of cytokine and chemokine levels. The
discrepancy in time-point was due to animals demonstrating dehydration and
severe body weight loss, particularly in the STX+ (DBS 806) cohort (data not
shown). Multiplex analysis of 23 cytokine and chemokine targets (23-PLEX mouse
panel, Bio-Rad) resulted in numerous targets demonstrating induction in the STX
(+) strain as compared to the STX (-) control (Figure D2-1). KC and IL-10 were
both elevated in STX (+) sera as compared to STX (-) controls (p < 0.05 and p < 0.01
respectively), while STX (-) animals demonstrated significantly higher levels of IL-
12 (p40) and IL-13 (p < 0.01 and p < 0.05 respectively). Both strains had
substantially higher levels of circulating granulocyte-stimulating factor (G-CSF) (p <
0.001) as compared to sodium bicarbonate controls and both demonstrated
elevated levels of IL-6, however; only the STX (+) group reached statistical
significance. IL-2 and MCP-1 also showed elevations in the STX (+) cohort but failed
to reach statistical significance. Intimin deficient strains (DBS 807 and DBS 808)
both failed to show statistically significant changes in systemic cytokine or
chemokine levels as compared to the sodium bicarbonate control group at 9 DPI.
Expression of pro-inflammatory and immunomodulatory genes in C57BL/6
kidneys
Quantitative RT-PCR was performed on RNA isolated from kidney tissue to evaluate
local expression of key pro-inflammatory (IL-1, IFN-y, TNF-a), immune modulatory
(IL-17), chemokines CCL2 (monocyte chemotactic protein-1: MCP-1), CCL3
(macrophage-inflammatory protein 1-alpha: MIP-la), CCL5 (regulated upon
activation, normal T-cell expressed, and secreted: RANTES) and cytokines CXCL1
(neutrophil activating protein: KC), CXCL2 (macrophage inflammatory protein 2-
alpha: MIP-2a) (Figure D2-2). Expression levels were assessed by one-way ANOVA
(p < 0.01) followed by Tukey's multiple comparison tests. The presence of Shiga
toxin resulted in significant elevations in kidney transcriptional levels for RANTES
(CCL5) (3.6-fold, p < 0.01 compared to sodium bicarbonate only), TNF-a (5.2-fold, p
< 0.01), KC (CXCL1)(122-fold, p < 0.01), and MIP-1a (CXCL2) (233-fold, p < 0.01).
Levels of IL-17 levels were induced in STX (-) and STX (+) strains as compared to
sodium bicarbonate controls (19 and 13.5-fold respectively), however, did not reach
statistical significance. STX (+) infection was also associated with the down-
regulation of IL-1p, IFN- y, and CCL3.
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D.3 Discussion
The aim of this study was to determine if a Stx-expressing strain of C. rodentium
causes a pathogenic signature similar to that found with the human equivalent
shigatoxin-expression EPEC and EHEC by measuring inflammatory markers in both
circulating protein and kidney transcript levels. Shiga toxin producing E. coli, such
as 0157:H7, have been found to induce hemorrhagic colits and hemolytic uremic
syndrome (HUS) in humans, the later characterized by systemic lysis of red blood
cells and resultant glomerular dysfunction and acute renal failure in approximately
10% of infected individuals. The interaction of shiga toxin with host endothelium in
brain, intestine, and kidney constitutes the majority of histological lesions observed
in HUS[182]. Specifically, Stx2-producing E. coli strains are more commonly
associated with HUS -associated pathology than Stx1-expressing strains [183].
HUS-like injury in C57BL/6 mice treated with STX-expressing C. rodentium was
evaluated by measuring circulating levels of inflammatory mediators as well as
kidney-specific transcriptional changes. Kidney mRNA were induced in STX (+)
strain treated C57BL/6 mice at 9DPI in RANTES (CCL5), KC (CXCL1), MIP-2 (CXCL2),
and TNF-a, indicating a pro-inflammatory state coupled with a local environment
enhanced for recruitment of lymphocytes and activation of both macrophages and
neutrophils. Kidney-specific changes were paralleled by serum elevations in KC;
however, RANTES and TNF-a did not show statistically significant elevations in mice
exposed to the STX (+) strain (circulating MIP-2a not measured). Treatment of
human endothelial cells with Stx alone results in increased mRNA levels and protein
expression of IL-8 (human analog of murine KC) [184, 185] and confirmed by
microarray experiments inhuman endothelial cells to elucidate responses in gene
regulation characteristic to both Stxl and 2 strains [186]. Most of the genes
regulated were for proteins associated with inflammatory responses such as
chemokines (IL-8) and cytokines (granulocyte-macrophage colony-stimulating
factor [GM-CSF]), findings in line with ours, indicating a contribution to HUS
pathogenesis via recruitment of inflammatory cells in the kidney.
In a clinical evaluation of eleven patients with HUS and 9 patients with hemorrhagic
colitis at the onset of E. coli 0157:H7, Yamamoto et al reported significant elevations
in serum IL-6 (p < 0.01), IL-8 (p < 0.05) (KC is the mouse homologue), IL-10 (p <
0.001), and endothelin (p < 0.001) in patients with HUS compared with those with
colitis alone [187]. Here we have complete concordance in results from this clinical
work. Inoculation of C57BL/6 mice with a Stx-expressing strain of C. rodentium
appears to be a potentially useful animal model that mimics the clinically relevant
parameters of HUS, furthermore, as a commonly used background for genetic
modification, allows for investigation into the molecular mechanisms driving this
major public health concern.
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D.4 Selected Methods
Culture Preparations and Animal Infections
Specific pathogen free C57BL/6 mice were (The Jackson Laboratory, Bar Harbor,
ME) were housed and maintained as described in Appendix A (General Methods).
Infections were induced by intragastric inoculation with -1 x 109 CFU of DBS 806
(STX(+)), DBS 771 (STX(-)), DBS 807 (intimin 1 deficient), or DBS 808 (intimin 2
deficient) in 3% sodium bicarbonate (in PBS, pH 7.4) using a 100uL volume. DBS
806 and DBS 771 mice were sacrificed 8 DPI for harvesting of tissues and blood for
serum collection. Control animals (sodium bicarbonate) and DBS 807 and DBS 808
were sacrificed 9 DPI animals and processed similarly to STX inoculated groups. All
animals were monitored for fecal shedding and body weight changes as indicated
and euthanized and necropsied at their respective timepoints as described in
Appendix A.
Multiplex Detection of Serum Cytokines and Chemokines:
Mouse serum collected at necropsy was processed using mouse 23-plex cytokine
panels (Bio-Rad, Hercules, CA) as specified by the manufacturer. Briefly, serum was
diluted in species-specific sample diluent (1:4) and 50uL of sample or premixed
standards were incubated with pre-washed target capture antibody-conjugated
microspheres provided and incubated for 30 minutes with orbital shaking (300
rpm) in a 96-well plate. Upon washing, beads were incubated with detection
antibody (30 min), washed, and subsequently incubated with streptavidin-PE (10
min). Beads were washed and resuspended with 125uL assay buffer and read on
the Luminex 200 suspension array system using the low RP1 target setting (High
PMT) for maximum sensitivity. Data analysis was carried out with the Bio-Plex
ManagerTM 5.0 software and cytokine or chemokine concentrations calculated
against an 8 point standard curve generated by either 4PL or 5PL curve fitting.
Real-time quantitative RT-PCR. Total RNA was prepared from frozen kidney using
Trizol reagent according to manufacturer recommendation (Invitrogen, Carlsbad,
CA). cDNA was generated from five micrograms of total RNA using SuperScriptIl RT
(Invitrogen). One hundred nanograms of cDNA were amplified in a 25 pl reaction
volume with predesigned primers (Applied Biosystems, Branchburg, New Jersey,
USA) and probes (TaqMan Gene Expression Assays) in an ABI Prism Sequence
Detection System 7700 (Applied Biosystems, Branchburg, New Jersey, USA) using
standard TaqMan protocols: IFN-g (Mm99999071_m1), IL-17 (Mm00439619_ml),
TNF-a (Mm99999068_m1), CCL2 (Mm00441243_gl), IL-1s (Mm00434228_ml),
CCL3 (Mm00441258_ml), CCL5 (Mm01302428_ml), CXCL1 (Mm00433859_ml),
CXCL2 (Mm00436450_m1), and glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (Mm99999915_gl). Transcript levels were normalized to GAPDH, and
expressed as fold change relative to averaged sodium bicarbonate (vehicle control)
inoculated group, which were set at 1, using the Comparative Ct method (Applied
Biosystems, User Bulletin no. 2). Reactions were carried out in duplicate.
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Figure D-1. Serum cytokine and chemokine changes in C57BL/6 mice exposed to
intimin-deficient and STX-expressing C. rodentium
Serum cytokine and chemokine detection by Luminex at 8 DPI (sodium bicarbonate,
DBS807, and DBS 808) and 9DPI (DBS 806 (STX+) and DBS 771 (STX-)). STX-expressing C.
rodentium had elevated KC, IL-6, and IL-10, while STX controls demonstrated elevations in
IL-12p40 and IL-13. Both STX(-) and STX(+) had significantly elevated circulating G-CSF (p
< 0.001 and p < 0.01) as compared to sodium bicarbonate controls. No changes were
observed with Intimin deficient strains DBS 807 and DBS 808. (One-way ANOVA with
Newman Kleus post test: * p <0.05, ** p<0.01, *** p<0.001).
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Figure D-2. Quantitative RT-PCR for expression of kidney cytokines and chemokines
transcript in C57BL/6 mice inoculated with STX-expressing C rodentiumntium
Kidneys from STX+ treated C57BL/6 mice at 9 DPI demonstrated significantly elevated
levels of TNF-a, CXCL1 (KC), and CXCL2 (MIP-2a), and depressed transcriptional levels of
IL-1$3, CCL3, and IFN-g as compared to sodium bicarbonate controls and STX (-) deficient
counterpart. Both STX(-) and STX(+) cohorts demonstrated elevations in IL-17 but failed to
reach significance (p < 0.01 level). Top of bars represent means Logio fold change in
expression relative to the average of sodium bicarbonate controls with standard error bars
present. One-way ANOVA followed by Tukey's Multiple Comparison Test (a = p < 0.01
compared to sodium bicarbonate, b = p < 0.01 compared to STX(-) control).
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Appendix E: Abbreviations
A/E: Attaching and effacing
APAP: Acetaminophen
ALP: Alkaline phosphatase
ALT: Alanine amino transferase
AST: Aspartate amino transferase
CD: Crohn's disease
CFU: Colony forming unit
CITRO: Citrobacter rodentium
CRP: C-reactive protein
DAMP: Damage-associated molecular pattern
DPI: Days post inoculation
E. coli Escherichia coli
EHEC: Enterohemorarrhagic Escherichia coli
EPEC: Enteropathogenic Escherichia coli
ESR: Erythrocyte sedimentation rate
G-CSF: Granulocyte stimulating factor
GM-CSF: Granulocyte-macrophage colony-stimulating factor
H&E: Hemotoxylin and eosin
IBD: Inflammatory bowel disease
IFN-g: Interferon gamma
LBP: LPS-binding protein
LPS: Lipopolysaccharide
MCP-1: Monocyte chemotactic protein-1
MGH: Massachusetts General Hospital
OPLS: Orthogonormalized partial least squares
PAMP: Pathogen-associated molecular pattern
PBS: Phosphate buffered saline
PCA: Principal components analysis
PLS-DA: Partial least squares discriminate analysis
PLSR: Partial least squares regression
RT-PCR: Real-time reverse-transcriptase polymerase chain reaction
STAT: Signal transducer and activator of transcription
STEC: Shiga toxin (Stx)-producing E. coli
STX: Shiga Toxin
Tir: Translocated intimin receptor
TLR: Toll-like receptor
TNF-a: Tumor necrosis factor alpha
UC: Ulcerative colitis
VIP: Variable in projection
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